

**BUKTI KORESPONDENSI  
JURNAL INTERNASIONAL BEREPUTASI**

Judul artikel : In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack

Jurnal : Tropical Journal of Natural Product Research (TJNPR)

Edisi : Tahun 2025, Vol 9 No 2, hal 545 – 553

Penerbit : Faculty of Pharmacy, University of Benin, Benin City, Nigeria

Penulis : Muhammad R. R. Rahardhian, Nurchasanah, Yasmiwar Susilawati, Sri A. Sumiwi, Dewi Ramonah, Chintiana N. Putri, Ririn Suharsanti

**Tabel Tahapan Publikasi Artikel**

No	Tahapan Publikasi	Tanggal
1	Submission of manuscript	10 November 2024
2	Editorial Decision “Accepts with major corrections”	17 November 2024
3	Follow-Up on manuscript revision request	1 Desember 2024
4	APC Payment request from TJNPR editorial	1 Desember 2024
5	APC payment report	2 Desember 2024
6	Editorial and Reviewers comments	8 Desember 2024
7	Submit first revised manuscript	19 Desember 2024
8	Editor's comments on first revised manuscripts	20 Desember 2024
9	Submit second revised manuscript	28 Desember 2024
10	Check Galley Proof	2 Februari 2025
11	Article Published Vol 9 issue 2 (28 Februari 2025) on Website <a href="http://www.tjnpr.org">www.tjnpr.org</a>	28 Februari 2025
12	TJNPR Published Information on Vol 9 issue 2 (28 Februari 2025)	17 Maret 2025

# 1. Submission of Manuscript

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email subject is 'Confirm co-authorship of submission to Tropical Journal of Natural Product Research'. The sender is 'editor.tjnpr@gmail.com' and the date is '10 Nov 2024, 06.29'. The email content includes a warning that the image is hidden, a translation button for Indonesian, and the following text:

The manuscript submitted to the Tropical Journal of Natural Product Research <https://www.scopus.com/sourceid/21100933230> SCOPUS\_Q3 Ranking by the corresponding author is undergoing the peer-review process.

Title: *In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from Peronema canescens Jack.*

Journal: Tropical Journal of Natural Product Research [www.tjnpr.org](http://www.tjnpr.org) SCOPUS/SCIMAGO Q3

Corresponding Author: Ririn Suharsanti

# 2. Editorial Decision

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email subject is 'Trop J Nat Prod Res Editorial Decision'. The sender is 'Editor-in-Chief Tjnpr <editor.tjnpr@gmail.com>' and the date is 'Min, 17 Nov 2024, 18.44'. The email content includes a translation button for Indonesian and the following text:

Dear Dr. Ririn Suharsanti,

The manuscript submitted to the Tropical Journal of Natural Product Research [www.tjnpr.org](http://www.tjnpr.org) Q3 <https://www.scopus.com/sourceid/21100933230> has been carefully reviewed by competent experts.

Find attached the details of the decision.

Please send your response urgently to the Editor-in-Chief, to enable us to process your manuscript for the next issue **Vol 8 issue 11, 2024**. Kindly acknowledge the receipt of the mail.

Title: *In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from Peronema canescens Jack.*

Authors: Muhammad Ryan Radix Rahardhian, Nurchasanah, Yasmiwar Susilawati, Sri Adi Sumiwi, Dewi Ramonah, Chintiana Nindya Putri, Ririn Suharsanti\*

**TJNPR Editorial Decision: Accepts with major corrections**

Congratulations.

### 3. Follow-Up on manuscript revision request

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email being viewed is titled "Follow-Up on Manuscript Revision Request" and is categorized as "Kotak Masuk". The sender is "ririn santi" (ririnsuharsanti@gmail.com) and the recipient is "editor.tjnpr@gmail.com". The email is dated "Min, 1 Des 2024, 08.38".

The email content is as follows:

Dear Prof. Falodun,

I hope this message finds you well.

I am writing as the corresponding author of the manuscript titled "In Vitro and In Silico Analysis of Antipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack" (Manuscript ID: **TJNPR** MH559RN), which we submitted to your esteemed journal.

On 17th November 2024, I received an email informing us that the manuscript requires revisions. However, we have not yet received the specific revision instructions or reviewer comments necessary to proceed with the requested updates to our submission.

Could you kindly provide guidance or resend the revision details so that we may address the feedback and improve our manuscript in accordance with the journal's standards?

Thank you for your attention to this matter, and I apologize for any inconvenience caused. I look forward to your response and am committed to revising the manuscript promptly upon receiving your directions.

Warm regards,

Dr. Ririn Suharsanti  
Corresponding Author

### 4. APC Payment request from TJNPR editorial

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email being viewed is from "Editor-in-Chief Tjnpr" (editor.tjnpr@gmail.com) to "saya" (me). The email is dated "1 Des 2024, 14.11".

The email content is as follows:

Corresponding Author  
Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang

**Editor-in-Chief Tjnpr** <editor.tjnpr@gmail.com>  
kepada saya

Terjemahkan ke Indonesia

Please send your APC payment to enable us send the review comments

Best regards  
Abiodun

**Professor Abiodun Falodun**, PhD; FAAS, FISPON  
Editor-in-Chief:  
Tropical Journal of Natural Product Research (**TJNPR**)  
Head, Natural Product Research Group, University of Benin  
Email: [editor.tjnpr@gmail.com](mailto:editor.tjnpr@gmail.com)  
[www.tjnpr.org](http://www.tjnpr.org) SCOPUS, SCImago SJR Q3

## 5. APC payment report

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email is from 'ririn santi' (ririnsuharsanti@gmail.com) to the Editor-in-Chief, dated December 2, 2024, at 12:58. The subject is 'Dear editor, i have paid for aur APC article'. The email body includes 'Dear editor, i have paid for aur APC article' and 'regards, Ririn'. There are two attachments: a PDF file named 'file\_88880204718...' and another PDF named '888802047183703...'. The left sidebar shows various mail folders like 'Kotak Masuk' (4,789), 'Berbintang', 'Ditunda', 'Penting', 'Ter kirim', 'Draf' (213), 'Kategori', 'Sosial' (1,332), 'Info Terbaru' (3,330), 'Forum', 'Promosi' (2,719), and 'Selengkapnya'.

## 6. Editorial and Reviewers comments

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The email is from 'Editor-in-Chief Tjnpr' (editor.tjnpr@gmail.com) to the sender, dated December 8, 2024, at 00:38. The subject is 'Editorial and Reviewers comments'. The email body contains editorial comments for a manuscript titled 'In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from Peronema canescens Jack.'. The comments include instructions on title formatting, abstract length (250 words), combining results and discussion, moving figures and tables, and using italics for botanical and zoological names. There are five attachments: three Word documents (1-TJNPR-2024-M..., 2-TJNPR-2024-M..., 5-TJNPR-2024-M...) and two PDFs (3-TJNPR-2024-M..., 4-Editorial comm...). The left sidebar shows various mail folders like 'Kotak Masuk' (4,789), 'Berbintang', 'Ditunda', 'Penting', 'Ter kirim', 'Draf' (213), 'Kategori', 'Sosial' (1,332), 'Info Terbaru' (3,330), 'Forum', 'Promosi' (2,719), and 'Selengkapnya'.

## 7. Submit first (1<sup>st</sup>) revised manuscript

The screenshot shows an email from Rin Suharsanti (ririnsuharsanti@gmail.com) to the Editor-in-Chief of TJNPR, dated December 19, 2024. The email content is as follows:

Dear editor in chief Prof Abiodun

Previously, we have added 2 articles from **TJNPR** to the manuscript (yellow highlight)

Next we have added references courtesy of Okolie NP, Falodun A, Davids O. (yellow highlight)

we have also readjusted it to the provisions of the **TJNPR** text.

Hopefully our improvements have been appropriate

Rewards,  
Ririn Suharsanti

\*\*\*

Satu lampiran • Dipindai dengan Gmail

The email includes a scanned attachment, likely the revised manuscript.

## 8. Editor's comments on first revised manuscripts

The screenshot shows an email from the Editor-in-Chief of TJNPR (editor.tjnpr@gmail.com) to the author, dated December 20, 2024. The email content is as follows:

Terjemahkan ke Indonesia

The authors should carefully revise and correct the manuscript to avoid a possible rejection

Best regards  
Abiodun

**Professor Abiodun Falodun, PhD; FAAS, FISPON**  
Editor-in-Chief:  
Tropical Journal of Natural Product Research (**TJNPR**)  
Head, Natural Product Research Group, University of Benin  
Email: [editor.tjnpr@gmail.com](mailto:editor.tjnpr@gmail.com)  
[www.tjnpr.org](http://www.tjnpr.org) SCOPUS, SCImago SJR Q3

Professor of Pharmaceutical Chemistry, FAAS  
Fellow, Fulbright (USA)  
Deputy Vice-Chancellor (Academic) 2014-2016

## 9. Submit second (2<sup>nd</sup>) revised manuscript

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The main email is from 'ririn santi' to 'Editor-in-Chief'. The email body contains the following text:

We have tried to adhere strictly to the Journal's style of including references. Abbreviate all journal names, and replace 'et al' with the names of all contributing authors and has changed the format of table 3 as previously commented by the editor. we have also added 3 relevant articles from **TJNPR**.

f there are still errors in writing, we are ready to correct them again, We hope that we will still be given the opportunity to be published in **TJNPR**

Thank You

regards,  
ririn

\*\*\*

4 Lampiran • Dipindai dengan Gmail

The attachments are:

- TJNPR (2024) (M...)
- 6-TJNPR (2024) (...)
- Grammarty report...
- Turnitin TJNPR (1)...

Editor-in-Chief Tjnpr <editor.tjnpr@gmail.com> 28 Des 2024, 17:23

## 10. Check Galley Proof

The screenshot shows a Gmail interface with a search bar containing 'tjnpr'. The main email is from 'Editorial Team' to 'Editor-in-Chief'. The email body contains the following text:

Check Galley Proof

Dear Author,

See the attached galley proof manuscript with title " **In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack** " for authors perusal

Please, read through the galley proof, and submit your observations/corrections (not later than 48 hours) Also, respond to the comment(s) where indicated.

Carefully review the formatting of names, affiliations, figures, tables, citations and entire text.

**Note:**  
Failure to address all comments raised would cause the manuscript to be dropped from publication in this issue.

Failure to return the revised version of the galley proof (at the given period) would cause the manuscript to be dropped from publication in this issue.

All corrections/changes made in the manuscript should be highlighted in yellow ink when submitting the revised manuscript.

## 11. Article Published Vol 9 issue 2 (28 Februari 2025) on Website

tjnpr.org/index.php/home/article/view/5833

**Tropical Journal of Natural Product Research**  
Official Journal of Natural Product Research Group


ISSN: 2616-0684 (Print)  
ISSN: 2616-0692 (Online)

The Publisher ririnsuharsanti

Home About For Authors For Reviewers Issues Copyright Policy Payment Repository Contact Us

Home / Archives / Vol. 9 No. 2 (2025): Tropical Journal of Natural Product Research (TJNPR) / Articles

### In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack



**Muhammad R. R. Rahardhian**  
Department of Pharmaceutical Biology, Sekolah Tinggi Ilmu Farmasi Yayasan Farmasi Semarang, Indonesia.

**Nurchasanah**  
Department of Pharmaceutical Biology, Sekolah Tinggi Ilmu Farmasi Yayasan Farmasi Semarang, Indonesia.

**Yasmiwati Susilawati**  
Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Radjasa, Indonesia.

Google Scholar



## 12. TJNPR Published Information (vol 9 no 2)

mail.google.com/mail/u/0/#search/tjnpr/FMfcgZQTgXBCLhqWkrLRMDVHvcxSjWM

Gmail

tjnpr

2 dari 22

### TJNPR Published Vol 9 issue 2

Editor-in-Chief Tjnpr <editortjnpr@gmail.com>  
kepada bcc: saya

Sen, 17 Mar, 00.42

Dear Colleagues,  
Your articles published in Vol 9 issue 2 Tropical Journal of Natural Product research.  
Congratulations

**Tropical Journal of Natural Product Research** [www.tjnpr.org](http://www.tjnpr.org) Volume 9 Issue 2 March 2025 PUBLISHED online

<https://www.scimagojr.com/journalsearch.php?q=21100933230&tip=sid>

Please, enjoy free access to the exciting articles (52)

Dear Dr Ririn Suharsanti,

### **Provisional Acceptance letter for Article Manuscript Number TJNPR MH559ARN**

**Title:** *In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from Peronema canescens Jack.*

**Authors:** Muhammad Ryan Radix Rahardhian, Nurchasanah, Yasmiwar Susilawati, Sri Adi Sumiwi, Dewi Ramonah, Chintiana Nindya Putri, Ririn Suharsanti\*

I am pleased to inform you that your manuscript sent to the Tropical Journal of Natural Product Research has been reviewed and recommended for publication as a research article. However, before the issues raised by the Reviewers are forwarded, to enable you correct your manuscript, accordingly, please pay a publication charge of **\$ USD280**. The actual publication of the paper will be in the upcoming issue (**Vol 8 issue 11, 2024**). **Authors are responsible for all bank charges.** Please, the manuscript number (**TJNPR MH559RN**) should be included in the bank transfer.

Congratulations.

The money should be remitted in favour of:

**Name of account:** Abiodun FALODUN

**Bank Name:** Access Bank Plc


**Account Number:**1456136521.

**Sort Code:** 044040699


**Swift code:** ABNGNGLA

**Address of Bank:** Ransome Kuti Road, University of Benin, Benin City, Edo State, Nigeria

Sincerely,



**Professor A. Falodun, PhD, FAAS**  
**Editor-in-Chief**



1 **In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule**  
2 **Effervescent from *Peronema canescens* Jack.**

3  
4  
5  
6

7 **Abstract**

8 Obesity results from prolonged energy imbalance, with antiobesity treatment targeting  
9 pancreatic lipase inhibition. *Peronema canescens* Jack. (PC) known as sungkai, has  
10 traditionally been used to treat various ailments. This study aimed to assess PC's antioxidant  
11 and antilipase activities and optimize effervescent granule formulations. Phytochemical  
12 screening and TLC were performed, followed by antioxidant analysis via the DPPH method  
13 and pancreatic antilipase activity using the p-NPB substrate. The ethanol fraction of PC  
14 demonstrated potent antioxidant activity ( $IC_{50} = 47.27 \mu\text{g/mL}$ ), while the insoluble fraction  
15 showed the highest pancreatic antilipase activity (67.65%). GC-MS identified active  
16 compounds, including dimethyl tetracycline, 2-methoxy-5H-indolo[2,3-b]quinoxaline, and  
17 trilaurin, with molecular docking indicating dimethyl tetracycline as the best antilipase  
18 candidate via binding to the pancreatic receptor (PDB ID: 1LPB). This compound also met  
19 Lipinski's Rule of Five and ADMET criteria, indicating favorable pharmacokinetics and  
20 safety. Evaluation of effervescent granules included angle of repose, bulk density, and tapped  
21 density, with tartaric and citric acid concentration optimization through Design Expert 13  
22 yielding two optimal formulas: Formula 1 with 13.16% tartaric acid and 0.84% citric acid,  
23 and Formula 2 with 13.21% tartaric acid and 0.80% citric acid.

24

25 **Keywords:** *Peronema Canescens* Jack., antioxidant, effervescent granules, molecular  
26 docking, pancreatic antilipase.

27

28 

## Introduction

29         The increasing prevalence of degenerative diseases in Indonesia, alongside infectious  
30 diseases, indicates changing health challenges, with obesity emerging as a major concern.  
31 RISKESDAS data reveal a rise in obesity rates from 14.8% in 2013 to 21% in 2018<sup>1</sup>. Factors  
32 that contribute to obesity encompass environmental factors, urban living, and eating patterns.  
33 Diets high in fats and sugars but low in fiber cause an energy imbalance, and when combined  
34 with triglyceride buildup, this imbalance triggers oxidative stress and inflammatory responses  
35 within the body <sup>2</sup> . This ongoing inflammation, fat accumulation, and suppression of fat  
36 breakdown causes adipocyte apoptosis, producing Reactive Oxygen Species (ROS) that harm  
37 cells and tissues, thereby raising the risk of degenerative diseases<sup>3</sup>. Antioxidants are essential  
38 for neutralizing ROS, helping to reduce the risk of degenerative diseases linked to oxidative  
39 stress <sup>4</sup>.

40         In the context of medical treatments, FDA-approved drugs for obesity aim to either  
41 decrease calorie absorption or control appetite. Central nervous system (CNS) suppressants,  
42 including lorcaserin, liraglutide, phentermine-topiramate, and naltrexone/bupropion, work by  
43 targeting appetite-regulating receptors such as 5HT<sub>2c</sub>, GLP-1, and TAAR-1. On the other  
44 hand, Orlistat acts as a lipase inhibitor, reducing the absorption of dietary fats by  
45 approximately 30%<sup>5</sup>.

46         People in Indonesia prefer using herbal medicine due to its natural properties, which  
47 are perceived as safer and less likely to cause unwanted side effects. In general, herbal  
48 medicines are more affordable than synthetic drugs. They also contain a variety of plant-  
49 based ingredients. Herbal medicine is considered effective for targeting multiple health issues.  
50 Conversely, Orlistat is a therapeutic agent for obesity that works by reducing calorie  
51 absorption in the intestinal tract<sup>5</sup>. Nevertheless, the effectiveness of Orlistat is constrained by

52 side effects such as gastrointestinal problems, including oily stools, flatulence, and rectal  
53 discharge <sup>6</sup> . These limitations highlight the importance of seeking complementary or  
54 alternative treatments, especially natural ones with fewer side effects and potential long-term  
55 benefits.

56 Herbal medicine presents a promising alternative to synthetic drugs for managing  
57 obesity, thanks to its safety, availability, and ability to target multiple mechanisms. *Peronema*  
58 *canescens* Jack. (PC), locally known as sungkai, has attracted attention for its potential  
59 therapeutic benefits. Traditionally utilized in Indonesian medicine, the leaves of PC contain  
60 secondary metabolites like phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and  
61 saponins, which have been reported to exhibit anti-inflammatory, antioxidant, antidiabetic,  
62 and immune-boosting properties<sup>7</sup>. The bioactive compounds in PC position it as a promising  
63 candidate for antiobesity treatments, primarily by inhibiting pancreatic lipase, which helps  
64 reduce lipid absorption.

65 Combining in vitro and in silico approaches provides a strong strategy for validating  
66 the antiobesity potential of PC. For example, in silico modeling allows for structural  
67 predictions and identifying binding sites, enhancing target interaction in drug development<sup>8</sup>.  
68 Moreover, effervescent granules offer a convenient dosage form by combining acidic and  
69 alkaline compounds that release CO<sub>2</sub> upon dissolution. These granules provide high solubility,  
70 ease of use, and rapid absorption, making them an ideal delivery system for antioxidants and  
71 antilipase agents <sup>9</sup>. Given the therapeutic potential of PC, developing a granule formulation  
72 can enhance the accessibility and effectiveness of its bioactive components.

73 While traditional treatments like GLP-1 receptor agonists have proven effective in  
74 managing obesity, they are especially beneficial for patients with comorbidities such as type  
75 2 diabetes. Other plant-based studies indicate that appetite suppression may occur by  
76 activating the 5-HT<sub>2C</sub> receptor <sup>10</sup> . Additionally, TAAR1 agonists present the potential to  
77 address maladaptive eating behaviors associated with metabolic disorders <sup>11</sup> . Inhibitors

78 targeting the lipase enzyme, such as those aimed at PDB proteins 1LPB and 5ZUN, further  
79 reinforce the potential of lipase inhibition as a therapeutic target for antiobesity drugs<sup>12</sup>.

80 This study is the first comprehensive PC analysis as an antiobesity agent through  
81 pancreatic lipase inhibition, integrating in vitro antilipase and antioxidant assays with in silico  
82 molecular docking, pharmacokinetic, and toxicity predictions. By focusing on pancreatic  
83 lipase inhibition as a mechanism for combating obesity, the study provides insights into the  
84 bioactive compounds of PC identified via GC-MS. It evaluates the most promising candidates  
85 based on Lipinski's Rule of Five for oral bioavailability. This holistic approach highlights the  
86 potential of PC as a safe, accessible, and effective therapy for obesity.

87

## 88 Materials

89 Rotary evaporator (Heidolph-G3), Silica Gel F254 plates, UV lamps (254 nm and 366  
90 nm, Evaco GL 220V 50Hz T8 15W), micropipettes (Socorex & Dragon Lab), vortex mixers,  
91 UV-Vis spectrophotometer (Shimadzu UV-1780, Serial no. A119161), ELISA reader  
92 (Synergy-HTX multi-mode, 96-well plates), GC-MS (QP 2010). *Peronema canescens* Jack  
93 (PC), ethanol, n-hexane, ethyl acetate, FeCl<sub>3</sub>, MgSO<sub>4</sub>, hydrochloric-ethanolic acid mixture  
94 (1:1), hydrochloric acid, Liebermann-Burchard reagent, DPPH (Sigma), quercetin, p.a.  
95 methanol, crude porcine pancreatic lipase (PPL), p-nitrophenyl butyrate (p-NPB), phosphate  
96 buffer (pH 7.2), DMSO, and orlistat standard.

## 97 Hardware and Software

98 Some of the software used, including the receptors for the test, can be downloaded  
99 from the RCSB PDB website (<https://www.rcsb.org/>). The ligands used in the test are  
100 available for download from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). Test  
101 ligands and receptors were created using ChemDraw Professional 15.0, Chem3D 15.0, Biovia  
102 Discovery Studio 2021, Command Prompt, and AutoDock Tools 1.5.6. Docking



### 117 Sample preparation, extraction, and fractionation

118 The sample used in this study was *Peronema canescens*, Jack (PC), sourced from  
119 Kayutanam in Padang Pariaman District, West Sumatra, harvested between May and July  
120 2021 from trees measuring 6-7 meters in height. The maceration process was conducted for 3  
121 days (3x24 hours), with occasional stirring and repeated solvent changes using 96% ethanol.  
122 The resulting macerate was then filtered and concentrated using a rotary vacuum evaporator,  
123 followed by thickening in a water bath at approximately 40°C<sup>13</sup>

124 Twenty grams of the PC ethanol extract were placed in a beaker with a stir bar and  
125 magnetic stirrer. The fractionation process began by adding 100 mL of n-hexane, followed by  
126 stirring to separate the liquid from the insoluble extract. This step was repeated 5-6 times,  
127 adding 100 mL of n-hexane each time until a clear n-hexane fraction was obtained. Next, 100  
128 mL of ethyl acetate was added to the insoluble n-hexane extract, and the fractionation was  
129 repeated until a distinct ethyl acetate fraction was obtained. Subsequently, 100 mL of ethanol  
130 solution was used to fractionate the insoluble ethyl acetate extract, repeating the process 5-6  
131 times until a precise ethanol fraction was obtained. The remaining insoluble fraction, treated  
132 with ethanol, was designated as the insoluble fraction. The fractions were concentrated using  
133 a rotary vacuum evaporator, and the final thickening was performed in a water bath at  
134 approximately 50°C to yield a viscous fraction<sup>13</sup>.

### 135 Antioxidant Activity

136 The PC fraction was dissolved in methanol and prepared at different concentrations of  
137 10, 20, 30, 40, 50, and 60 µg/mL<sup>14</sup>. The antioxidant activity was determined by adding 1.0  
138 mL of the PC fraction solution to a test tube containing 4.0 mL of 0.1 mM DPPH for each  
139 concentration. The mixture was homogenized using a vortex for 1 minute and allowed to  
140 stand for the designated time for each test solution. The absorbance of the solution was then

141 measured at the maximum wavelength. The same procedure was followed to measure the  
142 absorbance of the quercetin standard series.

#### 143 Pancreatic Antilipase Activity

144 The pancreatic antilipase inhibition activity of the n-hexane, ethyl acetate, ethanol, and  
145 insoluble fractions was assessed using 96-well plates and an ELISA reader. The enzyme  
146 stock concentration was approximately 0.1  $\mu\text{g/mL}$ , prepared by dissolving 1 mg of solid  
147 porcine pancreatic lipase (PPL) powder in 1 mL of buffer solution (a). The fraction was  
148 prepared at a concentration of 500  $\mu\text{g/mL}$  (b), and p-NPB was dissolved in 1% DMSO (c)  
149 and subsequently diluted with a 50 mM phosphate buffer (pH 7.2, 0.5%) to a final  
150 concentration of 2.5 mM in 100  $\mu\text{L}$  (d). Solutions (a), (b), and (d) were mixed and incubated  
151 at 37°C for 10 minutes. Each sample was tested in triplicate. Orlistat was used as a positive  
152 control, and 1% DMSO was the negative control without inhibitors. One unit of activity is  
153 defined as the reaction rate that generates 1  $\mu\text{mol}$  of p-nitrophenyl butyrate at 37°C. Lipase  
154 activity inhibition was expressed as the percentage reduction in activity when PPL was  
155 incubated with the test compound<sup>15</sup>.

#### 156 Identification of compounds in the active fraction of PC using GC-MS.

157 GC-MS analysis was conducted at the integrated laboratory of Universitas Islam  
158 Indonesia. The active fraction, prepared at a concentration of 500  $\mu\text{g/mL}$ , was injected in a  
159 volume of 1.0  $\mu\text{L}$  for analysis using Gas Chromatography coupled with a Flame Ionization  
160 Detector (FID) and Mass Spectrometry (MS). The mobile phase consisted of chloroform:  
161 ethanol mixture (1:1), and the analysis was performed using an Rtx-5 MS column (5%  
162 diphenyl / 95% dimethyl polysiloxane) with specifications of 0.25  $\mu\text{m}$  thickness, 30.0 m  
163 length, and 0.25 mm inner diameter. The instrument settings included an initial temperature  
164 of 80°C, an injection temperature of 300°C, and an ion source temperature of 250°C. The

165 oven temperature was gradually increased to 330°C at 6°C per minute. The column flow rate  
166 was set to 0.74 mL/min with a pressure of 42.3 kPa<sup>16</sup>.

### 167 Molecular Docking

168 The receptors used in this study were obtained from the Protein Data Bank in 3D  
169 structure format or were drawn using ChemDraw software. These receptors, which are  
170 protein macromolecules, were isolated from any irrelevant molecules along with the ligands.  
171 The isolation process was performed using Discovery Studio 2021, and the files were saved  
172 in pdb format. Optimization involved adding hydrogen atoms, merging nonpolar hydrogens,  
173 and calculating Gasteiger charges using AutodockTools 1.5.6. The resulting file was saved in  
174 pdbqt format. For ligand preparation, 2D and 3D structures of the selected ligands were  
175 created to determine their molecular structure. This was done using ChemDraw Pro 12.0  
176 software. The ligands were then prepared using AutoDockTools 1.5.6, where the compound  
177 structures were corrected, and Gasteiger charges were added. The prepared ligands were  
178 saved in \*pdbqt format <sup>8,12</sup>.

### 179 Evaluation of Drug Likelihood and ADMET

180 Assessing the drug-likeness of compounds is based on Lipinski's Rule of Five, which  
181 utilizes both experimental and computational approaches to evaluate solubility and  
182 permeability in drug discovery and development <sup>17</sup>. The Rule of Five suggests that poor  
183 absorption and permeability are likely when the molecular weight exceeds 500, the number of  
184 hydrogen bond acceptors is greater than 10, the number of hydrogen bond donors exceeds 5,  
185 and the calculated log P (ClogP) is higher than 5 (or MlogP > 4.15). ADMET predictions  
186 encompass absorption (CaCO<sub>2</sub> permeability), distribution (BBB permeability), metabolism  
187 (CYP2D6 substrate), excretion (total clearance), and toxicity (AMES toxicity) <sup>8</sup>.

188 Effervescent formulation

189 The effervescent formula consists of five different formulations. Each ingredient is  
 190 weighed and sifted through mesh 30. After sifting, the ingredients are added, extracted, and  
 191 homogenized. The homogeneous mixture is gradually combined with 95% ethanol until  
 192 granules are formed. The granules are then sifted through mesh 20/30 and dried. The  
 193 effervescent formula containing PC extract is presented in Table 1.

194 **Table 1.** Formulation of Effervescent Granules from PC Extract.

Ingredient	Formula				
	A	B	C	D	E
PC Extract	10%	10%	10%	10%	10%
Tartaric Acid	12,72%	12,30%	13,58%	14%	13,15%
Citric Acid	1,58%	2%	0,72%	0,30%	1,15%
Na. Bicarbonate	14,30%	14,30%	14,30%	14,30%	14,30%
Sucrose	60,40%	60,40%	60,40%	60,40%	60,40%
PVP	1%	1%	1%	1%	1%

195

196 Results And Discussion

197 Antioxidant Activity (DPPH)

198 The antioxidant activity was determined using the DPPH method, with the results  
 199 expressed as the Inhibition Concentration 50 (IC<sub>50</sub>). According to <sup>18</sup>, a compound is classified  
 200 as a powerful antioxidant if its IC<sub>50</sub> is less than 50 µg/mL, strong if IC<sub>50</sub> is less than 100  
 201 µg/mL, medium if IC<sub>50</sub> is less than 150 µg/mL, weak if IC<sub>50</sub> is less than 200 µg/mL, and very  
 202 weak if IC<sub>50</sub> is greater than 200 µg/mL. The IC<sub>50</sub> values obtained in this study for the PC  
 203 fractions are shown in Table 2. As indicated in Table 2, the ethanol fraction exhibits stronger

204 antioxidant activity than the other samples, with the order being Ethanol fraction > ethanol  
 205 extract > insoluble fraction > ethyl acetate fraction > n-hexane fraction. Polar molecules such  
 206 as flavonoids, phenolics, and glycosides are known for their antioxidant properties. The  
 207 Ethanol fraction, having the lowest IC<sub>50</sub> value, shows a significant difference, as denoted by  
 208 four stars, when compared to the ethyl acetate and n-hexane fractions.

209 Polar fractions, such as the ethanol and insoluble fractions, contain a higher number of  
 210 substances capable of donating hydrogen atoms, leading to the formation of a reduced  
 211 (nonradical) form, which is indicated by the loss of the purple color, as described in  
 212 reference <sup>18</sup>, This process converts DPPH into a stable hydrazine form, DPP. The DPPH  
 213 antioxidant activity of the PC fractions is presented in Table 2.

214 **Table 2.** Antioxidant activity of PC fractions measured by DPPH assay.

Sample	IC <sub>50</sub> ± SD	Types of Antioxidants
Quercetin Standard	23.77 µg/mL	Very strong
N-hexane Fraction	685.70 ±32.15 µg/mL	Very weak
Ethyl Acetate Fraction	201.89 ±20.08 µg/mL	Very weak
Ethanol Fraction	47.27 ±1.90 µg/mL	Very strong
Insoluble Fraction	86.09 ±7.94 µg/mL	Strong

215

#### 216 [In vitro Pancreatic Antilipase Activity](#)

217 The inhibition of pancreatic lipase involves the interaction between lipase enzymes and  
 218 their substrates. This test uses PNPB (P-nitrophenyl butyrate) as the substrate and Porcine  
 219 Pancreatic Lipase (PPL) as the enzyme. The inhibitory effect is assessed by measuring the  
 220 hydrolysis of P-nitrophenyl butyrate to P-nitrophenol at a wavelength of 405 nm using an  
 221 ELISA reader. Pancreatic lipase inhibition by PC was tested at a concentration of 200 µg/mL,  
 222 with PPL solution in phosphate buffer (pH 7.2) and PNPB solution. One unit of activity is

223 defined as the reaction rate that produces 1  $\mu\text{mol}$  of p-nitrophenol in 10 minutes at 37°C. The  
 224 inhibition of lipase activity is expressed as the percentage reduction in activity when PPL is  
 225 incubated with the test compound. PPL was chosen as the enzyme model due to its  
 226 similarities with human pancreatic lipase (HPL), exhibiting comparable kinetics and enzyme  
 227 characteristics <sup>19</sup>. According to <sup>15</sup>, antilipase activity is considered robust when the inhibition  
 228 percentage exceeds 50%. The results of the PC fraction at a concentration of 200  $\mu\text{g/mL}$  are  
 229 shown in Table 3.


230 **Table 3.** Pancreatic antilipase activity of the PC fraction.

Sample	% inhibition of $\pm\text{SD}$	Types of Antilipase
Orlistat Standard	61.64% $\pm$ 9.11%	Strong
N-hexane fraction	18.66% $\pm$ 5.21%	Weak
Ethyl Acetate Fraction	67.65% $\pm$ 8.04%	Strong
Ethanol Fraction	14.22% $\pm$ 4.69%	Weak
Insoluble fraction	6.45% $\pm$ 1.13%	Weak

231

### 232 [In silico Pancreatic Antilipase Activity](#)

233 Molecular docking validation is performed by redocking, where the native ligand is  
 234 removed from the protein's active site and then re-docked. A good RMSD score is considered  
 235 to be  $<2$ . The redocking results of the native ligands are shown in Figure 2. The most active  
 236 fraction is identified as the ethyl acetate fraction. Identification is done using the GC-MS  
 237 instrument, which reveals three peaks in the ethyl acetate fraction of PC. These peaks  
 238 correspond to three compounds, which are further tested in silico to determine which ones  
 239 have the potential to act as inhibitors of the pancreatic lipase enzyme.




240





241 **Figure 2.** 3D structure of the pancreatic lipase enzyme (PDB ID 1LPB) showing an overlay  
 242 of the blue (before) and red (after) molecular docking of the native ligand.

243

244 The GC-MS identification revealed that the primary compound in the active fraction  
 245 was Trilaurin, accounting for 54.83% of the area and a similarity index of 59%. The three  
 246 compounds identified by GC-MS were then prepared for further in silico molecular docking  
 247 tests. Molecular docking of the quercetin standard, Orlistat, and the three GC-MS compounds  
 248 was performed to compare the compounds obtained from pancreatic antilipase testing with  
 249 the standards known to exhibit pancreatic antilipase activity, as reported in previous studies.  
 250 The results of the molecular docking are presented in Table 4.

251 **Table 4.** Binding energy and amino acid residues of Orlistat, quercetin, and PC's ethyl  
 252 acetate fraction compound.

No	Structure Name	Structure Drawings	Binding Energy	Amino Acid Bonds
1	Orlistat		-6,62	Gly 76, Phe 77, Ile 78, Asp 79, Tyr 114, His 151, <b>Ser 152</b> , Leu 153, Ala 178, Glu 179, Pro 180, Ile 209, Phe 215, Arg 256, Ala 259, His 263, Leu 264

2	Quercetin		-8.28 (run 83)	His B:75, Gly B:76, Phe B:77, of Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Ala B:178, Glu B:179, Pro B:180, Ile B:209, Phe B:215, Gly B:216, Arg B:256, His B:263.
3	Dimethyl Tetracycline		-7.78 (run 14)	Gly B:76, Phe B:77, Ile B:78, of Asp B:79, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Phe B:215, Arg B:256, Asp B:257, Ala B:259, Ala B:260, His B:263, Leu B:264.
4	2-methoxy-5H-indole[2,3-b]quinoxaline		-7.25 (run 77)	His B:75, Gly B:76, Phe B:77, of Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Phe B:215, His B:263, Leu B:264.
5	Trilaurin		-3.52 (Run of 7)	Ile B:78, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B: 209, Leu B:213, Phe B:215, Trp B:252, Thr B:255, Arg B:256, Ala B:259, Ala B:260, His

---

 B:263, Leu B:264.
 

---

253

254 The most promising compound is Dimethyl Tetracycline, which exhibits the lowest  
 255 binding energy and inhibition coefficient values compared to the Orlistat standard. This  
 256 suggests that Dimethyl Tetracycline has antilipase activity similar to Orlistat. In addition to  
 257 the binding energy and inhibition coefficient, pancreatic antilipase activity is evaluated based  
 258 on its interaction with the amino acid serine 152. After analyzing the GC-MS-identified  
 259 compounds through in silico tests, any compounds that bind to amino acid residues can  
 260 potentially serve as alternative ligands to replace Orlistat. The next step is to assess whether  
 261 these compounds can be used as oral drugs by evaluating them according to Lipinski's Rule  
 262 of Five, as shown in Table 5.

263 **Table 5.** Predicted Lipinski's Rule of Five for the Ligands.

No	Molecular Name	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar Voltage Activity (PSA)
1	Quercetin	302,238	1,988	5	7	122,108
2	Dimethyl Tetracycline	430,413	-0,5451	6	9	176,064
3	2-methoxy-5H-indolo[2,3-b]quinoxaline	249,273	3,2729	1	3	108,603
4	Trilaurin	639,015	11,7473	0	6	278,432

264

265 The indicates that the natural ligand candidates suitable for use are Quercetin,  
 266 Dimethyl Tetracycline, and 2-methoxy-5H-indolo[2,3-b]quinoxaline. These compounds meet  
 267 Lipinski's Rule of Five, with molecular weights under 500 Da, hydrogen bond donors not  
 268 exceeding 5, hydrogen bond acceptors not exceeding 10, partition coefficients (log P) under 5,

269 and polar surface areas (PSA) under 1025 Å<sup>2</sup>, making them suitable for oral administration.  
 270 In addition to adhering to Lipinski's Rule, candidate compounds must also pass  
 271 pharmacokinetic and toxicity assessments conducted using pkCSM software. The results of  
 272 drug-likeness analysis, along with absorption, distribution, metabolism, excretion, and  
 273 toxicity (ADMET) predictions, are presented in Table 6.

274 **Table 6.** DMET Prediction for Compounds from the Ethyl Acetate Fraction of PC

No	Molecular Name	Absorption	Distribution	Metabolism	Excretion	AMES	Hepatotoxicity	Skin Sensitization
		(log Papp in 10 <sup>-6</sup> cm/sec) (CaCO <sub>2</sub> Permeability) (log (human (CYP2D6))) (log (YES/NO)) (L/kg)	(log (VDss in L/kg)) (log (YES/NO)) (L/kg)	(log (CYP2D6)) (log (YES/NO)) (L/kg)	(log (Total clearance ml/min/kg)) (log (YES/NO)) (L/kg)	(log (YES/NO)) (L/kg)	(log (YES/NO)) (L/kg)	(log (YES/NO)) (L/kg)
1	Orlistat	0,396	-1,017	No	1,679	No	Yes	No
2	Quercetin	-0,277	0,057	No	0,457	No	No	No
3	Dimethyl tetracycline	-0,01	0,605	No	0,354	No	No	No
4	2-methoxy-5H-indolo[2,3-b]quinoxaline	1,301	-0,011	No	0,773	Yes	Yes	No
5	Trilaurin	0,141	-0,821	No	2,232	No	No	No

276 A compound is considered to have blood-brain barrier (BBB) permeability if its log  
 277 BB value in the distribution phase is greater than 0.3. Molecules with a log BB value below  
 278 0.1 are not effectively distributed in the brain. CYP2D6 metabolic parameters predict whether  
 279 cytochrome P450 will likely metabolize a given molecule. The total clearance (CL<sub>tot</sub>)  
 280 parameter indicates excretion rates in log (ml/min/kg). Drug clearance primarily occurs  
 281 through renal and hepatic clearance (kidney excretion) (liver metabolism and bile excretion).  
 282 Ames toxicity testing is a commonly used method to evaluate the mutagenic potential of  
 283 compounds through bacterial assays. Among the candidates, Dimethyl Tetracycline meets  
 284 both Lipinski's rule of five and ADMET prediction criteria.

285 The Evaluation of granule preparations includes tests for flow rate, angle of repose,  
 286 bulk density, tapped density, Carr's compressibility index, and Hausner ratios<sup>20</sup>. In this study,  
 287 optimization using design experts focuses on flow rate, angle of repose, and Carr's index.  
 288 Good flow characteristics are defined by the ability of particles to flow independently without  
 289 clumping, influenced by gravitational force <sup>21</sup>. The flow rate test indicates that all the  
 290 effervescent granules produced exhibit excellent flow, with a suitable flow time greater than  
 291 10 grams per second.

292 Table 7. Flow rate, angle of repose, and bulk density of the effervescent granules from PC.

	<b>Flow</b>	<b>Angle of</b>	<b>Bulk</b>	<b>Tapped</b>	<b>Hausner</b>	<b>Carr's</b>
<b>Formula</b>	<b>rate</b>	<b>repose</b>	<b>density</b>	<b>density</b>	<b>ratios</b>	<b>compressibility</b>
			<b>(g/ml)</b>	<b>(g/ml)</b>		<b>index (%)</b>
A	18,66	25,05	0,5205	0,5552	1,0667	6,25
B	20,43	25,85	0,5263	0,5497	1,0445	4,26
C	20,79	27,16	0,5278	0,5638	1,0682	6,38
D	20,63	24,09	0,4957	0,5632	1,1362	11,98
E	18,74	26,03	0,4942	0,5257	1,0637	5,99

293

294 The flow rate results of the effervescent granules for each formula are presented in  
295 Table 7. Based on the observations for Formula 3 and Formula 4 in Table 7, these formulas  
296 exhibit a faster flow time due to a higher tartaric acid content than Formula 1 and Formula 2.  
297 Tartaric acid has a higher density than citric acid, which allows granules with a greater  
298 tartaric acid content to flow more rapidly because of the increased gravitational force<sup>21</sup>. The  
299 angle of repose is the stable angle formed between a pile of cone-shaped particles and a  
300 horizontal plane. If the angle is less than 30°, the material is considered to flow easily.

301 Conversely, if the angle is 40° or greater, the material will likely be difficult to flow.  
302 The shape of the granules can influence the value of the angle of repose<sup>22</sup>. Table 7 presents  
303 the results of the stationary angle test for formulas 1-5, all of which are below 30°. A  
304 stationary angle of no more than 30° indicates excellent flow properties, meaning all the  
305 formulas demonstrate good flow behavior. The granules flow more quickly and easily with  
306 less friction and tensile force between them. Furthermore, smaller granule sizes tend to  
307 increase cohesiveness, reducing the flow velocity and resulting in a higher stationary angle<sup>23</sup>.


308 Determining bulk density includes measuring the actual weight, compressive weight,  
309 Hausner factor, and percent compressibility. The Hausner factor is used to compare the actual  
310 and compressive weights, helping to assess the flow or free-flowing properties of the powder.  
311 All seven formulas meet the qualification of having a Hausner factor of less than 1.25,  
312 indicating good flow characteristics. Granule compressibility refers to the ability of the  
313 granules to maintain compactness under pressure. Factors such as porosity, type density,  
314 particle shape, and moisture content can affect the flow properties of the granules. Good flow  
315 properties ensure easier molding of the granules and help maintain uniform weight. The  
316 results for the Hausner factor and compressibility are shown in Table 7. The percent  
317 compressibility results indicated that Carr's index ranged from 4.26% to 14.59%, which  
318 aligns with the literature stating that granules with a Carr's index value below 15%  
319 demonstrate good flowability.

320 The optimal formula using Design Expert is intended to generate the most efficient  
 321 formula based on the response data from the prepared parameters. The response data,  
 322 analyzed through ANOVA in Design Expert, is processed to identify the optimal formula<sup>9</sup>.  
 323 The ideal formula is the one with a desirability value closest to 1. Using the simplex lattice  
 324 design method in the Design Expert software, the optimal formula was determined to have  
 325 65.8126 mg of tartaric acid and 4.1874 mg of citric acid, with a desirability value of 0.862.  
 326 Before finalizing, the optimal formula requires verification. The results of the formula  
 327 optimization are shown in Figure 1, with the formula test results from the design expert  
 328 optimization provided in Table 8.

329 Table 8. Results of the formula test from Design Expert Optimization.


	<b>Flow</b>	<b>Angle of</b>	<b>Bulk</b>	<b>Tapped</b>	<b>Hausner</b>	<b>Carr's</b>
<b>Formula</b>	<b>rate</b>	<b>repose</b>	<b>density</b>	<b>density</b>	<b>ratios</b>	<b>compressibility</b>
			<b>(g/ml)</b>	<b>(g/ml)</b>		<b>index (%)</b>
1	20,5	27,61	0,5156	0,6037	1,1709	14,59
2	17,96	24,1	0,5386	0,5898	1,0951	8,68

330



331

332 **Figure 3.** Formula Solution (A) 1 from Design Expert optimization (2) 2 from Design Expert  
333 optimization



334

335 Note: ns = not Significant ( $p > 0,05$ ), \* ( $p < 0,05$ ), F1 DE (Formula 1 Design Expert), F2 DE  
336 (Formula 2 Design Expert), F1 Test (Formula 1 test), F2 Test (Formula 2 test)

337 **Figure 4.** Formula optimization using Design expert vs test

338

339 Based on the GraphPad statistical analysis, the flow rate and angle of repose values  
340 from Formula 1 and Formula 2 in both the Design Expert optimization and the actual test  
341 results showed no significant difference, indicating that the optimization and laboratory test  
342 produced similar outcomes. However, Carr's index test revealed a discrepancy between the  
343 Design Expert optimization and the test results, as effervescent granules are highly sensitive  
344 to room temperature, which may have influenced the test outcomes.

345

346 Additional research is needed to isolate compounds from PC based on the results of the  
347 in silico data. An integrated study of network pharmacology and component analysis should  
be conducted to explore the molecular mechanisms of PC extract in treating obesity<sup>24</sup>. In

348 silico antiobesity activity should be explored using additional receptor targets, as the  
349 antiobesity mechanism extends beyond pancreatic lipase. Central nervous system  
350 mechanisms can be investigated, targeting receptors such as GLP-1 (liraglutide), 5-HT<sub>2c</sub>  
351 (lorcaserin), and TAAR-1 (phentermine). Further research is needed to explore other  
352 antiobesity strategies beyond the pancreatic lipase inhibition pathway or in vivo methods.

353

### 354 Conclusion

355 The antioxidant activity of the PC fraction, evaluated using the DPPH method,  
356 revealed the ethanol fraction as the most potent, with an IC<sub>50</sub> of 47.2712 µg/mL. The ethyl  
357 acetate fraction showed the highest pancreatic antilipase activity, with a 67.65% inhibition  
358 rate. GC-MS analysis identified three active compounds in the PC fraction:  
359 Demethyltetracycline, 2-methoxy-5H-indolo[2,3-b]quinoxaline, and Trilaurin, all of which  
360 demonstrated pancreatic antilipase activity in silico, with Dimethyl Tetracycline showing the  
361 most potential. Formula optimization using the Design Expert software resulted in two  
362 formulas. The flow rate and angle of repose values from the design expert and the laboratory  
363 tests did not show significant differences, indicating that the optimization and experimental  
364 results aligned. However, differences were observed in the Carr's Index test between the  
365 design expert optimization and the lab results.

366

### 367 Conflict of Interest

368 The authors declare no conflict of interest.

369

### 370 Authors' Declaration

371 The authors affirm that the work presented in this article is original, and they accept full  
372 responsibility for any claims related to the content of the article.

373

## 374 Acknowledgement

375 Acknowledgment Hibah Penelitian Dan Pengabdian Kepada Masyarakat Akademik  
 376 Pendidikan Tinggi Vokasi supports this work. Contract Number:  
 377 103/SPK/D.D4/PPK.01.APTV/III/2024. Derivative Contract Number 018 /LL6/PPM-  
 378 V/AL.04/2024.

379

380 **References**

- 381 Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementerian Kesehatan RI  
 382 2018;53(9):1689–1699.
- 383 Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomedicine and*  
 384 *Pharmacotherapy* 2020;128(November 2019).
- 385 Ladeska V, Elya B, Hanafi M, Kusmardi, Rohmat SS. Pharmacognostic Evaluation and  
 386 Antioxidant Activities of *Tetracera indica* (Christm. and Panz.) Merr. *Hayati* 2024;31(5):836–  
 387 853.
- 388 Romiti GF, Corica B, Raparelli V, Basili S, Cangemi R. The interplay between antioxidants  
 389 and the immune system: A promising field, still looking for answers. *Nutrients*  
 390 2020;12(6):10–13.
- 391 Li S, Pan J, Hu X, Zhang Y, Gong D, Zhang G. Kaempferol inhibits pancreatic lipase activity  
 392 and its synergistic effect with Orlistat. *J Funct Foods* [homepage on the Internet]  
 393 2020;72(March):104041. Available from: <https://doi.org/10.1016/j.jff.2020.104041>
- 394 Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver  
 395 injury: Self controlled case series study in UK Clinical Practice Research Datalink. *BMJ*  
 396 (Online) 2013;346(7906):1–9.
- 397 Rahardhian MRR, Susilawati Y, Sumiwi A, Muktiwardoyo M, Muchtaridi M, Sumiwi SA. A  
 398 Review Of Sungkai (*Peronema Canescens*): Traditional Usage, Phytoconstituent, And  
 399 Pharmacological Activities. *International Journal of Applied Pharmaceutics* 2022;14(Special  
 400 issue 5):15–23.
- 401 Rahardhian MRR, Susilawati Y, Musfiroh I, Febriyanti RM, Muchtaridi, Sumiwi SA. In  
 402 Silico Study of Bioactive Compounds From Sungkai (*Peronema Canescens*) As  
 403 Immunomodulator. *International Journal of Applied Pharmaceutics* 2022;14(Special Issue  
 404 4):135–141.
- 405 Indriastuti M, Astuti AF, Anna L Yusuf, Akbar F, Kurnia R R. Optimization of Formula  
 406 Preparation of Effervescent Granules of Moringa Leaf Extract (*Moringa oleifera* L.). *Medical*  
 407 *Sains : Jurnal Ilmiah Kefarmasian* 2023;8(2):519–528.
- 408 Yang HY, Tae J, Seo YW, et al. Novel pyrimidoazepine analogs as serotonin 5-HT<sub>2A</sub> and 5-  
 409 HT<sub>2C</sub> receptor ligands for the treatment of obesity. *Eur J Med Chem* 2013;63:558–569.
- 410 Dedic N, Wang L, Hajos-Korcsok E, et al. TAAR1 agonists improve glycemic control,  
 411 reduce body weight and modulate neurocircuits governing energy balance and feeding. *Mol*  
 412 *Metab* [homepage on the Internet] 2024;80(January):101883. Available from:  
 413 <https://doi.org/10.1016/j.molmet.2024.101883>

- 414 Suharsanti R, Wahyuono S, Yuniarti N, Astuti P. Molecular Docking of Lipase Inhibitory  
415 Activities , Pharmacokinetics and Toxicity Prediction of Chemical Constituents from  
416 *Curcuma aeruginosa* Roxb Rhizome. 2024;9(2):162–174.
- 417 Rahardhian MRR, Suharsanti R, Sugihartini N, Lukitaningsih E. In vitro assessment of total  
418 phenolic, total flavonoid and sunscreen activities of crude ethanolic extract of belimbing  
419 wuluh (*Averrhoa bilimbi*) fruits and leaves. *Journal of Global Pharma Technology*  
420 2019;11(4):308–313.
- 421 Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Potency Of Belimbing  
422 Wuluh (*Averrhoa Bilimbi*) As Antioxidat And Tyrosinase Inhibitor For Skin Whitening  
423 Product. *Journal of Pharma Research* 2019;8(4):151–154.
- 424 Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomedicine and  
425 Pharmacotherapy* 2020;128(November 2019).
- 426 Hotmian E, Suoth E, Fatimawali, Tallei T. GC-MS (Gas Chromatography - Mass  
427 Spectrometry) Analysis of Nut Grass Tuber (*Cyperus rotundus* L.) Methanolic Extract.  
428 *Pharmacon* 2021;10(2):849–856.
- 429 Puspitasari YE, Alfikri MA, Sitanggang R, Tambunan JE, Hardoko H. In Silico Analysis of  
430 Phenolic Compounds from *Ceriops decandra* Griff. Leaves and Molecular Interaction as Anti  
431 Diabetes. *Science and Technology Indonesia* 2023;8(4):542–553.
- 432 Molyneux P. The Use of the Stable Free Radical Diphenylpicryl-hydrazyl (DPPH) for  
433 Estimating Antioxidant Activity. *Songklanakarin Journal of Science and Technology*  
434 2004;26(December 2003):211–219.
- 435 Abd Rahman RNZR. Antiobesity Potential of Selected Tropical Plants via Pancreatic Lipase  
436 Inhibition. *Adv Obes Weight Manag Control* 2017;6(4).
- 437 Shah RB, Tawakkul MA, Khan MA. Comparative Evaluation of flow for pharmaceutical  
438 powders and granules. *AAPS PharmSciTech* 2008;9(1):250–258.
- 439 Rani KC, Parfati N, Muarofah D, Sacharia SN. Formulasi Granul Effervescent Herba  
440 Meniran (*Phyllanthus niruri* L.) dengan Variasi Suspending Agent Xanthan Gum, CMC-Na,  
441 dan Kombinasi CMC-Na-Mikrokristalin Selulosa RC- 591. *Jurnal Sains Farmasi & Klinis*  
442 2020;7(1):39.
- 443 Aulton M. *Pharmaceutics: the Science of Dosage Form Design*. 2nd ed. Edinburgh: Churchill  
444 Livingstone, 2002;
- 445 Lee, R. E. *Effervescent Tablets : Key Facts About A Unique, Effective Dossage Form*. CSC  
446 Publishing, 2004;
- 447 Mutiah R, Briliana MSD, Ahmad ARA, Fauziyah B, Janaloka NA, Suryadinata A. Network  
448 Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular  
449 Mechanisms of *Lansium parasiticum* Bark Extract in Colon Cancer Treatment. *Science and  
450 Technology Indonesia* 2024;9(2):314–324.
- 451  
452  
453

## BUKTI KORESPONDENSI EDITORIAL COMMENTS TO AUTHORS

### Editorial comments to authors

**Title: Names (First and Last name in full, middle name as initials) and affiliations of authors should be written correctly. Correspondence authors' contact address (email and telephone number) should also be stated.**

**Abstract:** format to accommodate to the required word (250) limit. Format to a single paragraph and avoid subheadings. Begin with a brief background, the aim of study should be clearly stated, methodology, results and conclusion.

Combine the results and discussion into a single section.

Move all figures and tables under the reference section.

**All botanical and zoological names should be *italicized including those in reference section***

**For non-integers, use periods/decimal point NOT commas.**

**Write all page number in full. E.g 12345 – 12359 and not 12345 – 59**

**Remove italics and abbreviate journal title in reference section**

**Remove et al. and list all authors in the reference section**

**In-text references should be in superscript numerals without square brackets, and placed after commas or full-stop.**

**References:** Cite relevant and related references from the published articles of TJNPR [www.tjnpr.org](http://www.tjnpr.org)

**Adhere strictly to the Journal's style for listing references.** Abbreviate all journal names, and replace 'et al' with names of all contributing authors;

Falodun A, Siraj R, Choudhary MI. GC-MS Insecticidal Leaf essential oil of *P. staudtii* Hutch and Dalz (Icacinaceae). Trop J. Pharm Res. 2009; 82:139-143.

Okolie NP, Falodun A, Oluseyi D. Evaluation of the antioxidant activity of root extract of pepper fruit (*Dennetia tripetala*), and its potential for the inhibition of Lipid peroxidation. Afr J. Trad Compl and Altern Med. 2014; 11(3):221-227. Doi: 10.4314/ajtcam.v11i3.31

**Conflict of interest** session should be included, and if there is no conflict of interest, this should be stated clearly as follows; **The authors declare no conflict of interest.**

**A declaration of the liability** of the authors for claims relating to the content of this article should also be included when submitting the revised manuscript. This should be stated as follows;

**Authors' Declaration**

The authors hereby declare that the work presented in this article are original and that any liability for claims relating to the content of this article will be borne by them.

**All comments/corrections made by reviewers should be completely addressed, point by point, and make appropriate changes in the manuscript, or provide a suitable rebuttal to any specific request for change that has not been made.**

**All corrections/changes** made in the manuscript should be **highlighted in yellow colour** when submitting the manuscript in the revised form.

**Please keep the revised manuscript code format as “TJNPR-(Year)-(Code). Do not Rename the document.**

**All corrections/changes** made in the manuscript should be **highlighted in yellow colour** when submitting the manuscript in the **revised form on 11<sup>th</sup> December 2024**

**BUKTI KORESPONDENSI**  
**CATATAN REVIEWER**

1 **In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule**  
2 **Effervescent from *Peronema canescens* Jack.**

3  
4  
5  
6  
7 **Abstract**

8 Obesity results from prolonged energy imbalance, with antiobesity treatment targeting  
9 pancreatic lipase inhibition. *Peronema canescens* Jack. (PC) known as sungkai, has  
10 traditionally been used to treat various ailments. This study aimed to assess PC's antioxidant  
11 and antilipase activities and optimize effervescent granule formulations. Phytochemical  
12 screening and TLC were performed, followed by antioxidant analysis via the DPPH method  
13 and pancreatic antilipase activity using the p-NPB substrate. The ethanol fraction of PC  
14 demonstrated potent antioxidant activity ( $IC_{50} = 47.27 \mu\text{g/mL}$ ), while the insoluble fraction  
15 showed the highest pancreatic antilipase activity (67.65%). GC-MS identified active  
16 compounds, including dimethyl tetracycline, 2-methoxy-5H-indolo[2,3-b]quinoxaline, and  
17 trilaurin, with molecular docking indicating dimethyl tetracycline as the best antilipase  
18 candidate via binding to the pancreatic receptor (PDB ID: 1LPB). This compound also met  
19 Lipinski's Rule of Five and ADMET criteria, indicating favorable pharmacokinetics and  
20 safety. Evaluation of effervescent granules included angle of repose, bulk density, and tapped  
21 density, with tartaric and citric acid concentration optimization through Design Expert 13  
22 yielding two optimal formulas: Formula 1 with 13.16% tartaric acid and 0.84% citric acid,  
23 and Formula 2 with 13.21% tartaric acid and 0.80% citric acid.

24

25 **Keywords:** *Peronema Canescens* Jack., antioxidant, effervescent granules, molecular  
26 docking, pancreatic antilipase.

27

28 Introduction

29 The increasing prevalence of degenerative diseases in Indonesia, alongside infectious  
30 diseases, indicates changing health challenges, with obesity emerging as a major concern.  
31 RISKESDAS data reveal a rise in obesity rates from 14.8% in 2013 to 21% in 2018<sup>1</sup>. Factors  
32 that contribute to obesity encompass environmental factors, urban living, and eating patterns.  
33 Diets high in fats and sugars but low in fiber cause an energy imbalance, and when combined  
34 with triglyceride buildup, this imbalance triggers oxidative stress and inflammatory responses  
35 within the body<sup>2</sup>. This ongoing inflammation, fat accumulation, and suppression of fat  
36 breakdown causes adipocyte apoptosis, producing Reactive Oxygen Species (ROS) that harm  
37 cells and tissues, thereby raising the risk of degenerative diseases<sup>3</sup>. Antioxidants are essential  
38 for neutralizing ROS, helping to reduce the risk of degenerative diseases linked to oxidative  
39 stress<sup>4</sup>.

40 In the context of medical treatments, FDA-approved drugs for obesity aim to either  
41 decrease calorie absorption or control appetite. Central nervous system (CNS) suppressants,  
42 including lorcaserin, liraglutide, phentermine-topiramate, and naltrexone/bupropion, work by  
43 targeting appetite-regulating receptors such as 5HT<sub>2c</sub>, GLP-1, and TAAR-1. On the other  
44 hand, Orlistat acts as a lipase inhibitor, reducing the absorption of dietary fats by  
45 approximately 30%<sup>5</sup>.

46 People in Indonesia prefer using herbal medicine due to its natural properties, which  
47 are perceived as safer and less likely to cause unwanted side effects. In general, herbal  
48 medicines are more affordable than synthetic drugs. They also contain a variety of plant-

49 based ingredients. Herbal medicine is considered effective for targeting multiple health issues.  
50 Conversely, Orlistat is a therapeutic agent for obesity that works by reducing calorie  
51 absorption in the intestinal tract<sup>5</sup>. Nevertheless, the effectiveness of Orlistat is constrained by  
52 side effects such as gastrointestinal problems, including oily stools, flatulence, and rectal  
53 discharge <sup>6</sup> . These limitations highlight the importance of seeking complementary or  
54 alternative treatments, especially natural ones with fewer side effects and potential long-term  
55 benefits.

56 Herbal medicine presents a promising alternative to synthetic drugs for managing  
57 obesity, thanks to its safety, availability, and ability to target multiple mechanisms. *Peronema*  
58 *canescens* Jack. (PC), locally known as sungkai, has attracted attention for its potential  
59 therapeutic benefits. Traditionally utilized in Indonesian medicine, the leaves of PC contain  
60 secondary metabolites like phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and  
61 saponins, which have been reported to exhibit anti-inflammatory, antioxidant, antidiabetic,  
62 and immune-boosting properties<sup>7</sup>. The bioactive compounds in PC position it as a promising  
63 candidate for antiobesity treatments, primarily by inhibiting pancreatic lipase, which helps  
64 reduce lipid absorption.

65 Combining in vitro and in silico approaches provides a strong strategy for validating  
66 the antiobesity potential of PC. For example, in silico modeling allows for structural  
67 predictions and identifying binding sites, enhancing target interaction in drug development<sup>8</sup>.  
68 Moreover, effervescent granules offer a convenient dosage form by combining acidic and  
69 alkaline compounds that release CO<sub>2</sub> upon dissolution. These granules provide high solubility,  
70 ease of use, and rapid absorption, making them an ideal delivery system for antioxidants and  
71 antilipase agents <sup>9</sup>. Given the therapeutic potential of PC, developing a granule formulation  
72 can enhance the accessibility and effectiveness of its bioactive components.

73 While traditional treatments like GLP-1 receptor agonists have proven effective in  
74 managing obesity, they are especially beneficial for patients with comorbidities such as type

75 2 diabetes. Other plant-based studies indicate that appetite suppression may occur by  
76 activating the 5-HT<sub>2C</sub> receptor<sup>10</sup>. Additionally, TAAR1 agonists present the potential to  
77 address maladaptive eating behaviors associated with metabolic disorders<sup>11</sup>. Inhibitors  
78 targeting the lipase enzyme, such as those aimed at PDB proteins 1LPB and 5ZUN, further  
79 reinforce the potential of lipase inhibition as a therapeutic target for antiobesity drugs<sup>12</sup>.

80 This study is the first comprehensive PC analysis as an antiobesity agent through  
81 pancreatic lipase inhibition, integrating in vitro antilipase and antioxidant assays with in silico  
82 molecular docking, pharmacokinetic, and toxicity predictions. By focusing on pancreatic  
83 lipase inhibition as a mechanism for combating obesity, the study provides insights into the  
84 bioactive compounds of PC identified via GC-MS. It evaluates the most promising candidates  
85 based on Lipinski's Rule of Five for oral bioavailability. This holistic approach highlights the  
86 potential of PC as a safe, accessible, and effective therapy for obesity.

87

#### 88 Materials

89 Rotary evaporator (Heidolph-G3), Silica Gel F254 plates, UV lamps (254 nm and 366  
90 nm, Evaco GL 220V 50Hz T8 15W), micropipettes (Socorex & Dragon Lab), vortex mixers,  
91 UV-Vis spectrophotometer (Shimadzu UV-1780, Serial no. A119161), ELISA reader  
92 (Synergy-HTX multi-mode, 96-well plates), GC-MS (QP 2010). *Peronema canescens* Jack  
93 (PC), ethanol, n-hexane, ethyl acetate, FeCl<sub>3</sub>, MgSO<sub>4</sub>, hydrochloric-ethanolic acid mixture  
94 (1:1), hydrochloric acid, Liebermann-Burchard reagent, DPPH (Sigma), quercetin, p.a.  
95 methanol, crude porcine pancreatic lipase (PPL), p-nitrophenyl butyrate (p-NPB), phosphate  
96 buffer (pH 7.2), DMSO, and orlistat standard.

#### 97 Hardware and Software


98 Some of the software used, including the receptors for the test, can be downloaded  
99 from the RCSB PDB website (<https://www.rcsb.org/>). The ligands used in the test are

100 available for download from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). Test  
 101 ligands and receptors were created using ChemDraw Professional 15.0, Chem3D 15.0, Biovia  
 102 Discovery Studio 2021, Command Prompt, and AutoDock Tools 1.5.6. Docking  
 103 visualizations were performed using Biovia Discovery Studio 2021. Lipinski's Rule of Five  
 104 testing was conducted using the Lipinski rules available at ([http://www.scfbio-  
 106 iitd.res.in/software/drugdesign/lipinski.jsp](http://www.scfbio-<br/>
  105 iitd.res.in/software/drugdesign/lipinski.jsp)). Pharmacokinetics and toxicology testing were  
 107 performed using the pk-CSM website (<https://biosig.lab.uq.edu.au/pkcs/>). Molecular  
 108 docking simulations were conducted on a laptop (Acer Aspire A314-35, LAPTOP-  
 109 ML0EUN2).

109

## 110 Methods

111 The general research methods for the in vitro and in silico analysis of antilipase,  
 112 antioxidants, and optimization of effervescent granules from PC are outlined in Figure 1.



113

114 **Figure 1.** Research methods for in vitro and in silico analysis of antilipase, antioxidants, and  
 115 optimization of effervescent granules from PC.

116

#### 117 Sample preparation, extraction, and fractionation

118 The sample used in this study was *Peronema canescens*, Jack (PC), sourced from  
119 Kayutanam in Padang Pariaman District, West Sumatra, harvested between May and July  
120 2021 from trees measuring 6-7 meters in height. The maceration process was conducted for 3  
121 days (3x24 hours), with occasional stirring and repeated solvent changes using 96% ethanol.  
122 The resulting macerate was then filtered and concentrated using a rotary vacuum evaporator,  
123 followed by thickening in a water bath at approximately 40°C<sup>13</sup>

Comment[111]: Include GPS location

124 Twenty grams of the PC ethanol extract were placed in a beaker with a stir bar and  
125 magnetic stirrer. The fractionation process began by adding 100 mL of n-hexane, followed by  
126 stirring to separate the liquid from the insoluble extract. This step was repeated 5-6 times,  
127 adding 100 mL of n-hexane each time until a clear n-hexane fraction was obtained. Next, 100  
128 mL of ethyl acetate was added to the insoluble n-hexane extract, and the fractionation was  
129 repeated until a distinct ethyl acetate fraction was obtained. Subsequently, 100 mL of ethanol  
130 solution was used to fractionate the insoluble ethyl acetate extract, repeating the process 5-6  
131 times until a precise ethanol fraction was obtained. The remaining insoluble fraction, treated  
132 with ethanol, was designated as the insoluble fraction. The fractions were concentrated using  
133 a rotary vacuum evaporator, and the final thickening was performed in a water bath at  
134 approximately 50°C to yield a viscous fraction<sup>13</sup>.

#### 135 Antioxidant Activity

136 The PC fraction was dissolved in methanol and prepared at different concentrations of  
137 10, 20, 30, 40, 50, and 60 µg/mL<sup>14</sup>. The antioxidant activity was determined by adding 1.0  
138 mL of the PC fraction solution to a test tube containing 4.0 mL of 0.1 mM DPPH for each  
139 concentration. The mixture was homogenized using a vortex for 1 minute and allowed to  
140 stand for the designated time for each test solution. The absorbance of the solution was then

141 measured at the maximum wavelength. The same procedure was followed to measure the  
142 absorbance of the quercetin standard series.

Comment[I12]: Specify the wavelength

Reply[I13]: Mention instrument used alongside the model,  
manufacturer and country

#### 143 Pancreatic Antilipase Activity

144 The pancreatic antilipase inhibition activity of the n-hexane, ethyl acetate, ethanol, and  
145 insoluble fractions was assessed using 96-well plates and an ELISA reader. The enzyme  
146 stock concentration was approximately 0.1  $\mu\text{g/mL}$ , prepared by dissolving 1 mg of solid  
147 porcine pancreatic lipase (PPL) powder in 1 mL of buffer solution (a). The fraction was  
148 prepared at a concentration of 500  $\mu\text{g/mL}$  (b), and p-NPB was dissolved in 1% DMSO (c)  
149 and subsequently diluted with a 50 mM phosphate buffer (pH 7.2, 0.5%) to a final  
150 concentration of 2.5 mM in 100  $\mu\text{L}$  (d). Solutions (a), (b), and (d) were mixed and incubated  
151 at 37°C for 10 minutes. Each sample was tested in triplicate. Orlistat was used as a positive  
152 control, and 1% DMSO was the negative control without inhibitors. One unit of activity is  
153 defined as the reaction rate that generates 1  $\mu\text{mol}$  of p-nitrophenyl butyrate at 37°C. Lipase  
154 activity inhibition was expressed as the percentage reduction in activity when PPL was  
155 incubated with the test compound<sup>15</sup>.

Comment[I14]: Mention instrument used alongside the model,  
manufacturer and country

#### 156 Identification of compounds in the active fraction of PC using GC-MS.

157 GC-MS analysis was conducted at the integrated laboratory of Universitas Islam  
158 Indonesia. The active fraction, prepared at a concentration of 500  $\mu\text{g/mL}$ , was injected in a  
159 volume of 1.0  $\mu\text{L}$  for analysis using Gas Chromatography coupled with a Flame Ionization  
160 Detector (FID) and Mass Spectrometry (MS). The mobile phase consisted of chloroform:  
161 ethanol mixture (1:1), and the analysis was performed using an Rtx-5 MS column (5%  
162 diphenyl / 95% dimethyl polysiloxane) with specifications of 0.25  $\mu\text{m}$  thickness, 30.0 m  
163 length, and 0.25 mm inner diameter. The instrument settings included an initial temperature  
164 of 80°C, an injection temperature of 300°C, and an ion source temperature of 250°C. The

Comment[I15]: Mention instrument used alongside the model,  
manufacturer and country

165 oven temperature was gradually increased to 330°C at 6°C per minute. The column flow rate  
166 was set to 0.74 mL/min with a pressure of 42.3 kPa<sup>16</sup>.

### 167 Molecular Docking

168 The receptors used in this study were obtained from the Protein Data Bank in 3D  
169 structure format or were drawn using ChemDraw software. These receptors, which are  
170 protein macromolecules, were isolated from any irrelevant molecules along with the ligands.  
171 The isolation process was performed using Discovery Studio 2021, and the files were saved  
172 in pdb format. Optimization involved adding hydrogen atoms, merging nonpolar hydrogens,  
173 and calculating Gasteiger charges using AutodockTools 1.5.6. The resulting file was saved in  
174 pdbqt format. For ligand preparation, 2D and 3D structures of the selected ligands were  
175 created to determine their molecular structure. This was done using ChemDraw Pro 12.0  
176 software. The ligands were then prepared using AutoDockTools 1.5.6, where the compound  
177 structures were corrected, and Gasteiger charges were added. The prepared ligands were  
178 saved in ~~pd~~ pdbqt format<sup>8,12</sup>.

Comment[116]: remove

### 179 Evaluation of Drug Likelihood and ADMET

180 Assessing the drug-likeness of compounds is based on Lipinski's Rule of Five, which  
181 utilizes both experimental and computational approaches to evaluate solubility and  
182 permeability in drug discovery and development<sup>17</sup>. The Rule of Five suggests that poor  
183 absorption and permeability are likely when the molecular weight exceeds 500, the number of  
184 hydrogen bond acceptors is greater than 10, the number of hydrogen bond donors exceeds 5,  
185 and the calculated log P (ClogP) is higher than 5 (or MlogP > 4.15). ADMET predictions  
186 encompass absorption (CaCO<sub>2</sub> permeability), distribution (BBB permeability), metabolism  
187 (CYP2D6 substrate), excretion (total clearance), and toxicity (AMES toxicity)<sup>8</sup>.

## 188 Effervescent formulation

189 The effervescent formula consists of five different formulations. Each ingredient is  
 190 weighed and sifted through mesh 30. After sifting, the ingredients are added, extracted, and  
 191 homogenized. The homogeneous mixture is gradually combined with 95% ethanol until  
 192 granules are formed. The granules are then sifted through mesh 20/30 and dried. The  
 193 effervescent formula containing PC extract is presented in Table 1.

194 **Table 1.** Formulation of Effervescent Granules from PC Extract.

Ingredient	Formula				
	A	B	C	D	E
PC Extract	10%	10%	10%	10%	10%
Tartaric Acid	12,72%	12,30%	13,58%	14%	13,15%
Citric Acid	1,58%	2%	0,72%	0,30%	1,15%
Na. Bicarbonate	14,30%	14,30%	14,30%	14,30%	14,30%
Sucrose	60,40%	60,40%	60,40%	60,40%	60,40%
PVP	1%	1%	1%	1%	1%

195

## 196 Results And Discussion

## 197 Antioxidant Activity (DPPH)

198 The antioxidant activity was determined using the DPPH method, with the results  
 199 expressed as the Inhibition Concentration 50 (IC<sub>50</sub>). According to <sup>18</sup>, a compound is classified  
 200 as a powerful antioxidant if its IC<sub>50</sub> is less than 50 µg/mL, strong if IC<sub>50</sub> is less than 100  
 201 µg/mL, medium if IC<sub>50</sub> is less than 150 µg/mL, weak if IC<sub>50</sub> is less than 200 µg/mL, and very  
 202 weak if IC<sub>50</sub> is greater than 200 µg/mL. The IC<sub>50</sub> values obtained in this study for the PC  
 203 fractions are shown in Table 2. As indicated in Table 2, the ethanol fraction exhibits stronger

204 antioxidant activity than the other samples, with the order being Ethanol fraction > ethanol  
 205 extract > insoluble fraction > ethyl acetate fraction > n-hexane fraction. Polar molecules such  
 206 as flavonoids, phenolics, and glycosides are known for their antioxidant properties. The  
 207 Ethanol fraction, having the lowest IC<sub>50</sub> value, shows a significant difference, as denoted by  
 208 four stars, when compared to the ethyl acetate and n-hexane fractions.

209 Polar fractions, such as the ethanol and insoluble fractions, contain a higher number of  
 210 substances capable of donating hydrogen atoms, leading to the formation of a reduced  
 211 (nonradical) form, which is indicated by the loss of the purple color, as described in  
 212 reference <sup>18</sup>, This process converts DPPH into a stable hydrazine form, DPPH. The DPPH  
 213 antioxidant activity of the PC fractions is presented in Table 2.

Comment[I17]: in full prior to abbreviations

214 **Table 2.** Antioxidant activity of PC fractions measured by DPPH assay.

Sample	IC <sub>50</sub> ± SD	Types of Antioxidants
Quercetin Standard	23.77 µg/mL	Very strong
N-hexane Fraction	685.70 ± 32.15 µg/mL	Very weak
Ethyl Acetate Fraction	201.89 ± 20.08 µg/mL	Very weak
Ethanol Fraction	47.27 ± 1.90 µg/mL	Very strong
Insoluble Fraction	86.09 ± 7.94 µg/mL	Strong

Comment[I18]: include reference – citation needed

215

Comment[I19]: this result should be presented as graph used in the estimation of the IC<sub>50</sub> with their corresponding error bars

#### 216 [In vitro Pancreatic Antilipase Activity](#)

217 The inhibition of pancreatic lipase involves the interaction between lipase enzymes and  
 218 their substrates. This test uses PNPB (P-nitrophenyl butyrate) as the substrate and Porcine  
 219 Pancreatic Lipase (PPL) as the enzyme. The inhibitory effect is assessed by measuring the  
 220 hydrolysis of P-nitrophenyl butyrate to P-nitrophenol at a wavelength of 405 nm using an  
 221 ELISA reader. Pancreatic lipase inhibition by PC was tested at a concentration of 200 µg/mL,  
 222 with PPL solution in phosphate buffer (pH 7.2) and PNPB solution. One unit of activity is

223 defined as the reaction rate that produces 1  $\mu\text{mol}$  of p-nitrophenol in 10 minutes at 37°C. The  
 224 inhibition of lipase activity is expressed as the percentage reduction in activity when PPL is  
 225 incubated with the test compound. PPL was chosen as the enzyme model due to its  
 226 similarities with human pancreatic lipase (HPL), exhibiting comparable kinetics and enzyme  
 227 characteristics<sup>19</sup>. According to<sup>15</sup>, antilipase activity is considered robust when the inhibition  
 228 percentage exceeds 50%. The results of the PC fraction at a concentration of 200  $\mu\text{g/mL}$  are  
 229 shown in Table 3.

230 **Table 3.** Pancreatic antilipase activity of the PC fraction.


Sample	% inhibition of $\pm$ SD	Types of Antilipase
Orlistat Standard	61.64% $\pm$ 9.11%	Strong
N-hexane fraction	18.66% $\pm$ 5.21%	Weak
Ethyl Acetate Fraction	67.65% $\pm$ 8.04%	Strong
Ethanol Fraction	14.22% $\pm$ 4.69%	Weak
Insoluble fraction	6.45% $\pm$ 1.13%	Weak

Comment[I110]: include reference – citation

231

#### 232 [In silico Pancreatic Antilipase Activity](#)

233 Molecular docking validation is performed by redocking, where the native ligand is  
 234 removed from the protein's active site and then re-docked. A good RMSD score is considered  
 235 to be  $<2$ . The redocking results of the native ligands are shown in Figure 2. The most active  
 236 fraction is identified as the ethyl acetate fraction. Identification is done using the GC-MS  
 237 instrument, which reveals three peaks in the ethyl acetate fraction of PC. These peaks  
 238 correspond to three compounds, which are further tested in silico to determine which ones  
 239 have the potential to act as inhibitors of the pancreatic lipase enzyme.




240





241 **Figure 2.** 3D structure of the pancreatic lipase enzyme (PDB ID 1LPB) showing an overlay  
242 of the blue (before) and red (after) molecular docking of the native ligand.

243

244 The GC-MS identification revealed that the primary compound in the active fraction  
245 was Trilaurin, accounting for 54.83% of the area and a similarity index of 59%. The three  
246 compounds identified by GC-MS were then prepared for further in silico molecular docking  
247 tests. Molecular docking of the quercetin standard, Orlistat, and the three GC-MS compounds  
248 was performed to compare the compounds obtained from pancreatic antilipase testing with  
249 the standards known to exhibit pancreatic antilipase activity, as reported in previous studies.  
250 The results of the molecular docking are presented in Table 4.

251 **Table 4.** Binding energy and amino acid residues of Orlistat, quercetin, and PC's ethyl  
252 acetate fraction compound.

Structure No	Structure Name	Structure Drawings	Binding Energy	Amino Acid Bonds
1	Orlistat		-6,62	Gly 76, Phe 77, Ile 78, Asp 79, Tyr 114, His 151, <b>Ser 152</b> , Leu 153, Ala 178, Glu 179, Pro 180, Ile 209, Phe 215, Arg 256, Ala 259, His 263, Leu 264

2	Quercetin		-8.28 (run 83)	His B:75, Gly B:76, Phe B:77, of Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Ala B:178, Glu B:179, Pro B:180, Ile B:209, Phe B:215, Gly B:216, Arg B:256, His B:263.
3	Dimethyl Tetracycline		-7.78 (run 14)	Gly B:76, Phe B:77, Ile B:78, of Asp B:79, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Phe B:215, Arg B:256, Asp B:257, Ala B:259, Ala B:260, His B:263, Leu B:264.
4	2-methoxy-5H-indole[2,3-b]quinoxaline		-7.25 (run 77)	His B:75, Gly B:76, Phe B:77, of Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Phe B:215, His B:263, Leu B:264.
5	Trilaurin		-3.52 (Run of 7)	Ile B:78, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B: 209, Leu B:213, Phe B:215, Trp B:252, Thr B:255, Arg B:256, Ala B:259, Ala B:260, His

B:263, Leu B:264.

253

254 The most promising compound is Dimethyl Tetracycline, which exhibits the lowest  
 255 binding energy and inhibition coefficient values compared to the Orlistat standard. This  
 256 suggests that Dimethyl Tetracycline has antilipase activity similar to Orlistat. In addition to  
 257 the binding energy and inhibition coefficient, pancreatic antilipase activity is evaluated based  
 258 on its interaction with the amino acid serine 152. After analyzing the GC-MS-identified  
 259 compounds through in silico tests, any compounds that bind to amino acid residues can  
 260 potentially serve as alternative ligands to replace Orlistat. The next step is to assess whether  
 261 these compounds can be used as oral drugs by evaluating them according to Lipinski's Rule  
 262 of Five, as shown in Table 5.

263 **Table 5.** Predicted Lipinski's Rule of Five for the Ligands.

No	Molecular Name	Molecular Weight	Log P	Hydrogen	Hydrogen	Polar
				Bond Donor (HBD)	Bond Acceptor (HBA)	Voltage Activity (PSA)
1	Quercetin	302,238	1,988	5	7	122,108
2	Dimethyl Tetracycline	430,413	-0,5451	6	9	176,064
3	2-methoxy-5H-indolo[2,3-b]quinoxaline	249,273	3,2729	1	3	108,603
4	Trilaurin	639,015	11,7473	0	6	278,432

264

Comment[111]: do not use commas as a decimal point rather use periods

265 The [Lipinski-table](#) indicates that the natural ligand candidates suitable for use are  
 266 Quercetin, Dimethyl Tetracycline, and 2-methoxy-5H-indolo[2,3-b]quinoxaline. These  
 267 compounds meet Lipinski's Rule of Five, with molecular weights under 500 Da, hydrogen  
 268 bond donors not exceeding 5, hydrogen bond acceptors not exceeding 10, partition

Inserted[11]: t Table 5

269 coefficients (log P) under 5, and polar surface areas (PSA) under 1025 Å<sup>2</sup>, making them  
 270 suitable for oral administration. In addition to adhering to Lipinski's Rule, candidate  
 271 compounds must also pass pharmacokinetic and toxicity assessments conducted using  
 272 pkCSM software. The results of drug-likeness analysis, along with absorption, distribution,  
 273 metabolism, excretion, and toxicity (ADMET) predictions, are presented in Table 6.

274 **Table 6.** DMET Prediction for Compounds from the Ethyl Acetate Fraction of PC

No	Molecular Name	Absorption (CaCO <sub>2</sub> Permeability) (log Papp in 10 <sup>-6</sup> cm/sec)	Distribution (VDss (L/kg))	Metabolism (human CYP2D6) (log (YES/NO))	Excretion (Total clearance) (ml/min/kg)	AMES Toxicity (YES/NO)	Hepatotoxicity (YES/NO)	Skin Sensitization (YES/NO)
1	Orlistat	0,396	-1,017	No	1,679	No	Yes	No
2	Quercetin	-0,277	0,057	No	0,457	No	No	No
3	Dimethyl tetracycline	-0,01	0,605	No	0,354	No	No	No
4	2-methoxy-5H-indolo[2,3-b]quinoxaline	1,301	-0,011	No	0,773	Yes	Yes	No
5	Trilaurin	0,141	-0,821	No	2,232	No	No	No

Comment[1112]: do not use commas as a decimal point rather use periods

276 A compound is considered to have blood-brain barrier (BBB) permeability if its log  
 277 BB value in the distribution phase is greater than 0.3. Molecules with a log BB value below  
 278 0.1 are not effectively distributed in the brain. CYP2D6 metabolic parameters predict whether  
 279 cytochrome P450 will likely metabolize a given molecule. The total clearance (CL<sub>tot</sub>)  
 280 parameter indicates excretion rates in log (ml/min/kg). Drug clearance primarily occurs  
 281 through renal and hepatic clearance (kidney excretion) (liver metabolism and bile excretion).  
 282 Ames toxicity testing is a commonly used method to evaluate the mutagenic potential of  
 283 compounds through bacterial assays. Among the candidates, Dimethyl Tetracycline meets  
 284 both Lipinski's rule of five and ADMET prediction criteria.

285 The Evaluation of granule preparations includes tests for flow rate, angle of repose,  
 286 bulk density, tapped density, Carr's compressibility index, and Hausner ratios<sup>20</sup>. In this study,  
 287 optimization using design experts focuses on flow rate, angle of repose, and Carr's index.  
 288 Good flow characteristics are defined by the ability of particles to flow independently without  
 289 clumping, influenced by gravitational force<sup>21</sup>. The flow rate test indicates that all the  
 290 effervescent granules produced exhibit excellent flow, with a suitable flow time greater than  
 291 10 grams per second.

292 Table 7. Flow rate, angle of repose, and bulk density of the effervescent granules from PC.

	<b>Flow</b>	<b>Angle of</b>	<b>Bulk</b>	<b>Tapped</b>	<b>Hausner</b>	<b>Carr's</b>
<b>Formula</b>	<b>rate</b>	<b>repose</b>	<b>density</b>	<b>density</b>	<b>ratios</b>	<b>compressibility</b>
			<b>(g/ml)</b>	<b>(g/ml)</b>		<b>index (%)</b>
A	18,66	25,05	0,5205	0,5552	1,0667	6,25
B	20,43	25,85	0,5263	0,5497	1,0445	4,26
C	20,79	27,16	0,5278	0,5638	1,0682	6,38
D	20,63	24,09	0,4957	0,5632	1,1362	11,98
E	18,74	26,03	0,4942	0,5257	1,0637	5,99

Comment[1113]: do not use commas as a decimal point rather use periods

293

294 The flow rate results of the effervescent granules for each formula are presented in  
295 Table 7. Based on the observations for Formula 3 and Formula 4 in Table 7, these formulas  
296 exhibit a faster flow time due to a higher tartaric acid content than Formula 1 and Formula 2.  
297 Tartaric acid has a higher density than citric acid, which allows granules with a greater  
298 tartaric acid content to flow more rapidly because of the increased gravitational force<sup>21</sup>. The  
299 angle of repose is the stable angle formed between a pile of cone-shaped particles and a  
300 horizontal plane. If the angle is less than 30°, the material is considered to flow easily.

301 Conversely, if the angle is 40° or greater, the material will likely be difficult to flow.  
302 The shape of the granules can influence the value of the angle of repose<sup>22</sup>. Table 7 presents  
303 the results of the stationary angle test for formulas 1-5, all of which are below 30°. A  
304 stationary angle of no more than 30° indicates excellent flow properties, meaning all the  
305 formulas demonstrate good flow behavior. The granules flow more quickly and easily with  
306 less friction and tensile force between them. Furthermore, smaller granule sizes tend to  
307 increase cohesiveness, reducing the flow velocity and resulting in a higher stationary angle<sup>23</sup>.

308 Determining bulk density includes measuring the actual weight, compressive weight,  
309 Hausner factor, and percent compressibility. The Hausner factor is used to compare the actual  
310 and compressive weights, helping to assess the flow or free-flowing properties of the powder.  
311 All seven formulas meet the qualification of having a Hausner factor of less than 1.25,  
312 indicating good flow characteristics. Granule compressibility refers to the ability of the  
313 granules to maintain compactness under pressure. Factors such as porosity, type density,  
314 particle shape, and moisture content can affect the flow properties of the granules. Good flow  
315 properties ensure easier molding of the granules and help maintain uniform weight. The  
316 results for the Hausner factor and compressibility are shown in Table 7. The percent  
317 compressibility results indicated that Carr's index ranged from 4.26% to 14.59%, which  
318 aligns with the literature stating that granules with a Carr's index value below 15%  
319 demonstrate good flowability.

320 The optimal formula using Design Expert is intended to generate the most efficient  
 321 formula based on the response data from the prepared parameters. The response data,  
 322 analyzed through ANOVA in Design Expert, is processed to identify the optimal formula<sup>9</sup>.  
 323 The ideal formula is the one with a desirability value closest to 1. Using the simplex lattice  
 324 design method in the Design Expert software, the optimal formula was determined to have  
 325 65.8126 mg of tartaric acid and 4.1874 mg of citric acid, with a desirability value of 0.862.  
 326 Before finalizing, the optimal formula requires verification. The results of the formula  
 327 optimization are shown in Figure 1, with the formula test results from the design expert  
 328 optimization provided in Table 8.


Comment[I114]: ?

329 Table 8. Results of the formula test from Design Expert Optimization.

<b>Formula</b>	<b>Flow rate</b>	<b>Angle of repose</b>	<b>Bulk density (g/ml)</b>	<b>Tapped density (g/ml)</b>	<b>Hausner ratios</b>	<b>Carr's compressibility index (%)</b>
1	20,5	27,61	0,5156	0,6037	1,1709	14,59
2	17,96	24,1	0,5386	0,5898	1,0951	8,68

Comment[I115]: do not use commas as a decimal point rather use periods

330




Comment[I116]: all images should be clear and readable – at least 300dpi

331

332 **Figure 3.** Formula Solution (A) 1 from Design Expert optimization (2) 2 from Design Expert

333 optimization



334

335 Note: ns = not Significant ( $p > 0.05$ ),  $*(p < 0.05)$ , F1 DE (Formula 1 Design Expert), F2 DE

336 (Formula 2 Design Expert), F1 Test (Formula 1 test), F2 Test (Formula 2 test)

337 **Figure 4.** Formula optimization using Design expert vs test

338

339 Based on the GraphPad statistical analysis, the flow rate and angle of repose values  
 340 from Formula 1 and Formula 2 in both the Design Expert optimization and the actual test  
 341 results showed no significant difference, indicating that the optimization and laboratory test  
 342 produced similar outcomes. However, Carr's index test revealed a discrepancy between the  
 343 Design Expert optimization and the test results, as effervescent granules are highly sensitive  
 344 to room temperature, which may have influenced the test outcomes.

345 Additional research is needed to isolate compounds from PC based on the results of the  
 346 in silico data. An integrated study of network pharmacology and component analysis should  
 347 be conducted to explore the molecular mechanisms of PC extract in treating obesity<sup>24</sup>. In

348 silico antiobesity activity should be explored using additional receptor targets, as the  
349 antiobesity mechanism extends beyond pancreatic lipase. Central nervous system  
350 mechanisms can be investigated, targeting receptors such as GLP-1 (liraglutide), 5-HT2c  
351 (lorcaserin), and TAAR-1 (phentermine). Further research is needed to explore other  
352 antiobesity strategies beyond the pancreatic lipase inhibition pathway or in vivo methods.

353

#### 354 Conclusion

355 The antioxidant activity of the PC fraction, evaluated using the DPPH method,  
356 revealed the ethanol fraction as the most potent, with an IC<sub>50</sub> of 47.2712 µg/mL. The ethyl  
357 acetate fraction showed the highest pancreatic antilipase activity, with a 67.65% inhibition  
358 rate. GC-MS analysis identified three active compounds in the PC fraction:  
359 Demethyltetracycline, 2-methoxy-5H-indolo[2,3-b]quinoxaline, and Trilaurin, all of which  
360 demonstrated pancreatic antilipase activity in silico, with Dimethyl Tetracycline showing the  
361 most potential. Formula optimization using the Design Expert software resulted in two  
362 formulas. The flow rate and angle of repose values from the design expert and the laboratory  
363 tests did not show significant differences, indicating that the optimization and experimental  
364 results aligned. However, differences were observed in the Carr's Index test between the  
365 design expert optimization and the lab results.

366

#### 367 Conflict of Interest

368 The authors declare no conflict of interest.

369

#### 370 Authors' Declaration

371 The authors affirm that the work presented in this article is original, and they accept full  
372 responsibility for any claims related to the content of the article.

373

374 **Acknowledgement**

375 Acknowledgment Hibah Penelitian Dan Pengabdian Kepada Masyarakat Akademik  
 376 Pendidikan Tinggi Vokasi supports this work. Contract Number:  
 377 103/SPK/D.D4/PPK.01.APTV/III/2024. Derivative Contract Number 018 /LL6/PPM-  
 378 V/AL.04/2024.

379

380 **References**

- 381 Kemenkes RI. Hasil Riset Kesehatan Dasar Tahun 2018. Kementerian Kesehatan RI  
 382 2018;53(9):1689–1699.
- 383 Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomedicine and  
 384 Pharmacotherapy* 2020;128(November 2019).
- 385 Ladeska V, Elya B, Hanafi M, Kusmardi, Rohmat SS. Pharmacognostic Evaluation and  
 386 Antioxidant Activities of *Tetracera indica* (Christm. and Panz.) Merr. *Hayati* 2024;31(5):836–  
 387 853.
- 388 Romiti GF, Corica B, Raparelli V, Basili S, Cangemi R. The interplay between antioxidants  
 389 and the immune system: A promising field, still looking for answers. *Nutrients*  
 390 2020;12(6):10–13.
- 391 Li S, Pan J, Hu X, Zhang Y, Gong D, Zhang G. Kaempferol inhibits pancreatic lipase activity  
 392 and its synergistic effect with Orlistat. *J Funct Foods* [homepage on the Internet]  
 393 2020;72(March):104041. Available from: <https://doi.org/10.1016/j.jff.2020.104041>
- 394 Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver  
 395 injury: Self controlled case series study in UK Clinical Practice Research Datalink. *BMJ*  
 396 (Online) 2013;346(7906):1–9.
- 397 Rahardhian MRR, Susilawati Y, Sumiwi A, Muktiwardoyo M, Muchtaridi M, Sumiwi SA. A  
 398 Review Of Sungkai (*Peronema Canescens*): Traditional Usage, Phytoconstituent, And  
 399 Pharmacological Activities. *International Journal of Applied Pharmaceutics* 2022;14(Special  
 400 issue 5):15–23.
- 401 Rahardhian MRR, Susilawati Y, Musfiroh I, Febriyanti RM, Muchtaridi, Sumiwi SA. In  
 402 Silico Study of Bioactive Compounds From Sungkai (*Peronema Canescens*) As  
 403 Immunomodulator. *International Journal of Applied Pharmaceutics* 2022;14(Special Issue  
 404 4):135–141.
- 405 Indriastuti M, Astuti AF, Anna L Yusuf, Akbar F, Kurnia R R. Optimization of Formula  
 406 Preparation of Effervescent Granules of Moringa Leaf Extract (*Moringa oleifera* L.). *Medical  
 407 Sains : Jurnal Ilmiah Kefarmasian* 2023;8(2):519–528.
- 408 Yang HY, Tae J, Seo YW, et al. Novel pyrimidoazepine analogs as serotonin 5-HT<sub>2A</sub> and 5-  
 409 HT<sub>2C</sub> receptor ligands for the treatment of obesity. *Eur J Med Chem* 2013;63:558–569.
- 410 Dedic N, Wang L, Hajos-Korcsok E, et al. TAAR1 agonists improve glycemic control,  
 411 reduce body weight and modulate neurocircuits governing energy balance and feeding. *Mol  
 412 Metab* [homepage on the Internet] 2024;80(January):101883. Available from:  
 413 <https://doi.org/10.1016/j.molmet.2024.101883>

Comment[EF17]: Cite two related published articles from  
 TJNPR

- 414 Suharsanti R, Wahyuono S, Yuniarti N, Astuti P. Molecular Docking of Lipase Inhibitory  
415 Activities , Pharmacokinetics and Toxicity Prediction of Chemical Constituents from  
416 *Curcuma aeruginosa* Roxb Rhizome. 2024;9(2):162–174.
- 417 Rahardhian MRR, Suharsanti R, Sugihartini N, Lukitaningsih E. In vitro assessment of total  
418 phenolic, total flavonoid and sunscreen activities of crude ethanolic extract of belimbing  
419 wuluh (*Averrhoa bilimbi*) fruits and leaves. *Journal of Global Pharma Technology*  
420 2019;11(4):308–313.
- 421 Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Potency Of Belimbing  
422 Wuluh (*Averrhoa Bilimbi*) As Antioxidat And Tyrosinase Inhibitor For Skin Whitening  
423 Product. *Journal of Pharma Research* 2019;8(4):151–154.
- 424 Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomedicine and*  
425 *Pharmacotherapy* 2020;128(November 2019).
- 426 Hotmian E, Suoth E, Fatimawali, Tallei T. GC-MS (Gas Chromatography - Mass  
427 Spectrometry) Analysis of Nut Grass Tuber (*Cyperus rotundus* L.) Methanolic Extract.  
428 *Pharmacon* 2021;10(2):849–856.
- 429 Puspitasari YE, Alfikri MA, Sitanggang R, Tambunan JE, Hardoko H. In Silico Analysis of  
430 Phenolic Compounds from *Ceriops decandra* Griff. Leaves and Molecular Interaction as Anti  
431 Diabetes. *Science and Technology Indonesia* 2023;8(4):542–553.
- 432 Molyneux P. The Use of the Stable Free Radical Diphenylpicryl-hydrazyl (DPPH) for  
433 Estimating Antioxidant Activity. *Songklanakarin Journal of Science and Technology*  
434 2004;26(December 2003):211–219.
- 435 Abd Rahman RNZR. Antiobesity Potential of Selected Tropical Plants via Pancreatic Lipase  
436 Inhibition. *Adv Obes Weight Manag Control* 2017;6(4).
- 437 Shah RB, Tawakkul MA, Khan MA. Comparative Evaluation of flow for pharmaceutical  
438 powders and granules. *AAPS PharmSciTech* 2008;9(1):250–258.
- 439 Rani KC, Parfati N, Muarofah D, Sacharia SN. Formulasi Granul Effervescent Herba  
440 Meniran (*Phyllanthus niruri* L.) dengan Variasi Suspending Agent Xanthan Gum, CMC-Na,  
441 dan Kombinasi CMC-Na-Mikrokristalin Selulosa RC- 591. *Jurnal Sains Farmasi & Klinis*  
442 2020;7(1):39.
- 443 Aulton M. *Pharmaceutics: the Science of Dosage Form Design*. 2nd ed. Edinburgh: Churchill  
444 Livingstone, 2002;
- 445 Lee, R. E. *Effervescent Tablets : Key Facts About A Unique, Effective Dossage Form*. CSC  
446 Publishing, 2004;
- 447 Mutiah R, Briliana MSD, Ahmad ARA, Fauziyah B, Janaloka NA, Suryadinata A. Network  
448 Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular  
449 Mechanisms of *Lansium parasiticum* Bark Extract in Colon Cancer Treatment. *Science and*  
450 *Technology Indonesia* 2024;9(2):314–324.
- 451
- 452
- 453

## REVIEW FORM

The Editorial Team of the Tropical Journal of Natural Product Research kindly request you to review the enclosed article. Please complete the form and return to the Editor-in-Chief, [editor.tjnpr@gmail.com](mailto:editor.tjnpr@gmail.com)

### A. MANUSCRIPT

Journal	<b>Tropical Journal of Natural Product Research</b>
Manuscript Number	TJNPR MH559AR
Type of paper	Research article
Title of paper	In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from <i>Peronema canescens</i> Jack.
Name of Authors	

### B. REVIEWER'S SPECIFIC COMMENTS PER SECTION OF MANUSCRIPT

Title	The title is mostly appropriate
Abstract	<p>The abstract word count is &lt; 250. The authors should correct all grammatical, spellings and punctuation errors.</p> <ul style="list-style-type: none"> <li>The abstract should be revised as recommended</li> </ul>
Keywords	Keywords are okay
Introduction	<p>The aim and objectives of the research are obvious. The authors should include a statement of research novelty. Authors should briefly discuss the relevance of the research methods to the research. All grammatical, spellings and punctuation errors should be corrected. The literature review should mostly be contextual. Use recent citations. Abbreviated words should be mentioned in full prior to abbreviations.</p> <ul style="list-style-type: none"> <li>The introduction should be improved as recommended</li> </ul>
Methodology	<p><b>Include methods for the statistical analysis. Mention the software used in the statistical analysis alongside the manufacturer, version and release year. Include the number of replicate measurements.</b> All chemicals and reagents used should be mentioned alongside the manufacturer, % purity, conc., grade and specificities. <b>All equipment and instrument used should be mentioned alongside their model, manufacturer and country.</b> Authors should specify instruments/equipment used for each experiment. All methods used should be validated with relevant citations. All grammatical, spellings and punctuation errors should be corrected. Authors should include the GPS location of the sample collection site.</p> <ul style="list-style-type: none"> <li>Methods used are mostly appropriate for the research</li> </ul>
Results	<p>All results should be presented based on the journal guideline. Images should be of a very high quality/resolution (300 dpi) – some images were not clear and readable. Authors should forward all supplementary data (input and output files) associated with the research to the journal management for validations and authentications. Use footnotes were necessary to define terms. Crosscheck the methodologies to ensure that results obtained tally with methods used. <b>The results of the IC50 (antioxidant assay) should be presented as graphs used in the estimation of the IC50. Authors should include the GCMS spectra obtained from the analysis.</b> Authors shouldn't use commas as decimal points.</p> <ul style="list-style-type: none"> <li>The results obtained are mostly appropriate for the methods used.</li> </ul>

Discussion	The discussions should be mostly statistically comparative. Authors should discuss mainly the significant findings in details. Authors should use recent citations in discussing their findings. All grammatical, spellings and punctuation errors should be corrected. <ul style="list-style-type: none"> <li>The discussion should be improved</li> </ul>
Conclusion	Authors should capture the future prospects of the research.
References	Authors should ensure that all the references follow the journal guideline. The number of cited references must tally with those at the references sections
Figures	All figures should be presented based on the journal guideline. All figures should be of a very high quality/resolution. <b>Figures 3 and 4 captured were not discussed in the manuscript.</b>
Tables	All tables should be presented based on the journal guideline. Table captured was discussed in the manuscript.

**Note: Further corrections are contained in the reviewed manuscript**

### C. REVIEWER'S GENERAL COMMENTS AND REMARKS

The authors studied "In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack.". The abstract should be revised as recommended. The introduction should be improved as recommended. Methods used are mostly appropriate for the research. The results obtained are mostly appropriate for the methods used. The discussion should be improved. Authors should capture the future prospects of the research. Authors should ensure that all the references follow the journal guideline. The number of cited references must tally with those at the references sections.

Authors should Include methods for the statistical analysis.

Mention the software used in the statistical analysis alongside the manufacturer, version and release year.

Authors should Include the number of replicate measurements.

The results of the IC50 (antioxidant assay) should be presented as graphs used in the estimation of the IC50.

Authors should include the GCMS spectra obtained from the analysis.

Some images were not clear and readable

The manuscript should be formatted based on the journal guideline

The manuscript should be grammar edited by a professional English language editor – **very important**

The manuscript should be checked for plagiarism

Authors should forward all supplementary data (input and output files) associated with the research to the journal management for validations and authentications.

Accept with major corrections

### D. REVIEWER'S RECOMMENDATION

Please mark with "X" one of the options.

You state the article should:

Publish As is	
---------------	--

Accept with minor revisions (editor will check), specific comments to the editor below	
Accept with moderate revisions as recommended by reviewer	
Accept with major corrections (the article should be thoroughly changed)	<b>X</b>
Article not suitable for publication in Trop J Nat Prod Res	
Reject for reasons noted by the reviewer (please be specific)	

## REVIEW FORM

The Editorial Team of the Tropical Journal of Natural Product Research kindly request you to review the enclosed article. Please complete the form and return to the Editor-in-Chief, [editor.tjnpr@gmail.com](mailto:editor.tjnpr@gmail.com)

### A. MANUSCRIPT

Journal	<b>Tropical Journal of Natural Product Research</b>
Manuscript Number	TJNPR MH559AR
Type of paper	Full article/Original Article
Title of paper	<i>In Vitro</i> and <i>In Silico</i> Analysis of Anti-lipase, Antioxidant, and Optimization of Granule Effervescent from <i>Peronema canescens</i> Jack.
Name of Authors	-

### B. REVIEWER'S SPECIFIC COMMENTS PER SECTION OF MANUSCRIPT

Abstract	A brief conclusion should be added at the end of abstract.
Introduction	Many grammatical errors and typos appear in the text such as anti-lipase, anti-obesity, <i>in vitro</i> , <i>in silico</i> , etc. It is suggested that the authors revisit and improve the English quality of the manuscript.
Methodology	In Figure 4, statistical analysis was applied to examine the granule characteristics. Which statistical method was used here? The statistical analysis should be mentioned in the Methods section in detail.
Results	-
Discussion	<ol style="list-style-type: none"> <li>1. The IC50 of ethanol fraction is higher than that of quercetin standard showing the better antioxidant activity of the standard as compared to the PC fraction. How did the authors explain this result?</li> <li>2. What is the correlation of antioxidant activity and anti-lipase potency of the PC towards the anti-obesity as the primary claim of this study?</li> <li>3. Ethanol fraction was revealed as the most potent anti-oxidant agent, while ethyl acetate showed the highest pancreatic anti-lipase activity. Why do these two assays demonstrate different findings? Which type of fraction was finally used in the effervescent formula? And why? Authors are suggested to discuss it more profoundly in the Results and Discussion Section.</li> <li>4. Why is the optimized effervescent granule formula not continued with the tablet formulation?</li> <li>5. Authors need to enrich the Discussion with more relevant references</li> </ol>
Conclusion	-
References	All references should have a consistent style and format according to the journal guidelines.
Figures, Tables	Figure legends in Figure 3 are too small.

### C. REVIEWER'S GENERAL COMMENTS AND REMARKS

Comments may be continued onto another sheet if necessary.

In this manuscript (TJNPR MH559AR), *in vitro* and *in silico* approaches were applied to assess the antioxidant and anti-lipase activities of *Peronema canescens* Jack. and further optimize effervescent granule formulations. In general, this work is well-organized and of current interest for the obesity phytotherapy community. However, some issues need to be addressed before being accepted in the TJNPR journal.

1. The title is not precise and can be changed to "*In Vitro* and *In Silico* Evaluation of Phytochemical Compounds from *Peronema canescens* Jack. and Optimization towards Effervescent Granules"
2. Many grammatical errors and typos appear in the text such as anti-lipase, anti-obesity, *in vitro*, *in silico*, etc. It is suggested that the authors revisit and improve the English quality of the manuscript.
3. Figure legends in Figure 3 are too small.
4. The IC50 of ethanol fraction is higher than that of quercetin standard showing the better antioxidant activity of the standard as compared to the PC fraction. How did the authors explain this result?
5. In Figure 4, statistical analysis was applied to examine the granule characteristics. Which statistical method was used here? The statistical analysis should be mentioned in the Methods section in detail.
6. What is the correlation of antioxidant activity and anti-lipase potency of the PC towards the anti-obesity as the primary claim of this study?
7. Ethanol fraction was revealed as the most potent anti-oxidant agent, while ethyl acetate showed the highest pancreatic anti-lipase activity. Why do these two assays demonstrate different findings? Which type of fraction was finally used in the effervescent formula? And why? Authors are suggested to discuss it more profoundly in the Results and Discussion Section.
8. Why is the optimized effervescent granule formula not continued with the tablet formulation?
9. Authors need to enrich the Discussion with more relevant references.
10. All references should have a consistent style and format according to the journal guidelines.

### D. REVIEWER'S RECOMMENDATION

Please mark with "X" one of the options.

You state the article should:

Publish as it is	
Accept with minor revisions (editor will check), specific comments to the editor below	
Accept with moderate revisions as recommended by reviewer	<b>X</b>
Accept with major corrections (the article should be thoroughly changed)	
<b>Full article</b>	<b>X</b>
<b>Short communication</b>	
Reject for reasons noted by the reviewer (please be specific)	

### E. REVIEWER'S INFORMATION

Name	
Official title	
Affiliation	
Specialization	
Country	
E-mail	

Phone	
Signature	

## REVIEW FORM

The Editorial Team of the Tropical Journal of Natural Product Research kindly request you to review the enclosed article. Please complete the form and return to the Editor-in-Chief, [editor.tjnpr@gmail.com](mailto:editor.tjnpr@gmail.com)

### A. MANUSCRIPT

Journal	<b>Tropical Journal of Natural Product Research</b>
Manuscript Number	MH559AR
Type of paper	Research article
Title of paper	<b>In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from <i>Peronema canescens</i> Jack.</b>
Name of Authors	

### B. REVIEWER'S SPECIFIC COMMENTS PER SECTION OF MANUSCRIPT

Abstract	Line 9 sungkai, change to Sungkai Line 12 DPPH, describe DPPH Line 19 ADMET, describe admet
Introduction	Line 31 RISKESDAS, describe RISKESDAS Line 55-56 add reference Line 63 add reference
Methodology	Line 140 add reference
Results	Every data change comma to dot and consistently 2 digits behind the dot
Discussion	
Conclusion	Add a closing statement that emphasizes the contribution of the research to scientific development or its applications.
References	IC50 change comma to dot and consistently 2 digits behind the dot
Figures, Tables	Every table change comma to dot and consistently 2 digits behind the dot

### C. REVIEWER'S GENERAL COMMENTS AND REMARKS

Comments may be continued onto another sheet if necessary.

The manuscript demonstrates a solid research approach and valuable findings, but several areas could benefit from further clarification and consistency to improve its clarity and readability. Specifically, terminology and acronyms should be fully described upon their first mention, such as DPPH, ADMET, and RISKESDAS, to ensure the audience is clear on their meaning. Additionally, referencing should be more consistent, with key statements backed by appropriate citations where needed

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27

**In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack.**

**Muhammad R. R. Rahardhian<sup>1</sup>, Nurchasanah<sup>1</sup>, Yasmiwar Susilawati<sup>2</sup>, Sri A. Sumiwi<sup>3</sup>, Dewi Ramonah<sup>1</sup>, Chintiana N. Putri<sup>4</sup>, Ririn Suharsanti<sup>1\*</sup>**

<sup>1</sup>*Department of Pharmaceutical Biology, Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, Indonesia.*

<sup>2</sup>*Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.*

<sup>3</sup>*Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.*

<sup>4</sup>*Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Islam Sultan Agung, Semarang, Indonesia.*

**\*Corresponding author: Ririn Suharsanti, email : [ririnsuharsanti@gmail.com](mailto:ririnsuharsanti@gmail.com),  
Phone Number : [+62 821 3692 3586](tel:+6282136923586)**

28

29 **Abstract** : Obesity results from prolonged energy imbalance, with anti-obesity treatment  
30 targeting pancreatic lipase inhibition. *Peronema canescens* Jack. (PC) known as **Sungkai**, has  
31 traditionally been used to treat various ailments. **This study aimed to assess PC antioxidant**  
32 **and antilipase activities** and optimize effervescent granule formulations. Phytochemical  
33 screening and **thin-layer chromatography (TLC)** were performed, followed by antioxidant  
34 analysis **using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and pancreatic antilipase activity, using**  
35 **the p-NPB substrate, were employed.** The ethanol fraction of PC demonstrated potent  
36 antioxidant activity ( $IC_{50} = 47.27 \mu\text{g/mL}$ ), while the insoluble fraction showed the highest  
37 pancreatic antilipase activity (67.65%). **Gas chromatography-mass spectrometry (GC-MS)**  
38 identified active compounds, **including** dimethyl tetracycline, 2-methoxy-5H-indolo[2,3-b]  
39 quinoxaline, and trilaurin, with molecular docking **study** indicating dimethyl tetracycline **was**  
40 **the most effective antilipase candidate,** binding to the pancreatic receptor (PDB ID: 1LPB).  
41 This compound also met Lipinski's Rule of Five and ADMET (**Absorption, Distribution,**  
42 **Metabolism, Excretion, and Toxicity**), **suggesting** favorable pharmacokinetics and safety.  
43 Evaluation of effervescent granules included angle of repose, bulk density, and tapped  
44 density. **Optimization of** tartaric and citric acid concentration **using** Design Expert 13  
45 yielding two optimal formulas: Formula 1 with 13.16% tartaric acid and 0.84% citric acid,  
46 and Formula 2 with 13.21% tartaric acid and 0.80% citric acid. **PC leaves have the potential**  
47 **to be an antioxidant and anti-obesity and can be developed into effervescent formula.**

48

49 **Keywords:** *Peronema Canescens* Jack., antioxidant, effervescent granules, molecular  
50 docking, pancreatic antilipase.

51

52

53

54 **Introduction**

55 The increasing prevalence of degenerative diseases in Indonesia, alongside infectious  
56 diseases, indicates changing health challenges, with obesity emerging as a major concern.  
57 RISKESDAS (Indonesia's basic health research) data reveal a rise in obesity rates from  
58 14.8% in 2013 to 21% in 2018.<sup>1</sup> Factors that contribute to obesity encompass environmental  
59 factors, urban living, and eating patterns. Diets high in fats and sugars but low in fiber cause  
60 an energy imbalance, which, when combined with triglyceride buildup, this imbalance  
61 triggers oxidative stress and inflammatory responses within the body.<sup>2</sup> This ongoing  
62 inflammation, fat accumulation, and suppression of fat breakdown causes adipocyte apoptosis,  
63 producing Reactive Oxygen Species (ROS) that harm cells and tissues, raising the risk of  
64 degenerative diseases.<sup>3</sup> Antioxidants are essential for neutralizing ROS, helping to reduce the  
65 risk of degenerative diseases linked to oxidative stress.<sup>4</sup>

66 In the context of medical treatments, FDA-approved drugs for obesity aim to either  
67 decrease calorie absorption or control appetite. Central nervous system (CNS) suppressants,  
68 including lorcaserin, liraglutide, phentermine-topiramate, and naltrexone/bupropion, work by  
69 targeting appetite-regulating receptors such as 5HT<sub>2c</sub>, GLP-1, and TAAR-1. On the other  
70 hand, Orlistat acts as a lipase inhibitor, reducing the absorption of dietary fats by  
71 approximately 30%.<sup>5</sup>

72 People in Indonesia prefer using herbal medicine due to its natural properties, which are  
73 perceived as safer and less likely to cause unwanted side effects. In general, herbal medicines  
74 are more affordable than synthetic drugs. They also contain a variety of plant-based  
75 ingredients. Herbal medicine is considered effective for targeting multiple health issues.  
76 Conversely, Orlistat is a therapeutic agent for obesity that reduces calorie absorption in the  
77 intestinal tract.<sup>5</sup> Nevertheless, the effectiveness of Orlistat is constrained by side effects such

78 as gastrointestinal problems, including oily stools, flatulence, and rectal discharge.<sup>6</sup> These  
79 limitations highlight the importance of seeking complementary or alternative treatments,  
80 especially natural ones with fewer side effects and potential long-term benefits.

81 Herbal medicine presents a promising alternative to synthetic drugs for managing  
82 obesity, thanks to its safety, availability, and ability to target multiple mechanisms. *Peronema*  
83 *canescens* Jack. (PC), locally known as Sungkai, has attracted attention for its potential  
84 therapeutic benefits. Traditionally utilized in Indonesian medicine, the leaves of PC contain  
85 secondary metabolites like phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and  
86 saponins, which have been reported to exhibit anti-inflammatory, antioxidant, antidiabetic,  
87 and immune-boosting properties.<sup>7</sup> The bioactive compounds in PC position it as a promising  
88 candidate for anti-obesity treatments, primarily by inhibiting pancreatic lipase, which helps  
89 reduce lipid absorption.

90 **Recent studies have highlighted the potential of plant-based compounds for pancreatic**  
91 **lipase inhibition, particularly in treating obesity.**<sup>8</sup> For example, in silico modeling allows for  
92 structural predictions and identifying binding sites, enhancing target interaction in drug  
93 development.<sup>9</sup> Moreover, effervescent granules offer a convenient dosage form by combining  
94 acidic and alkaline compounds that release CO<sub>2</sub> upon dissolution. These granules provide  
95 high solubility, ease of use, and rapid absorption, making them an ideal delivery system for  
96 antioxidants and antilipase agents.<sup>10</sup> Given the therapeutic potential of PC, developing a  
97 granule formulation can enhance the accessibility and effectiveness of its bioactive  
98 components.

99 While traditional treatments like GLP-1 receptor agonists have proven effective in  
100 managing obesity, they are especially beneficial for patients with comorbidities such as type  
101 2 diabetes. Other plant-based studies indicate that appetite suppression may occur by  
102 activating the 5-HT<sub>2C</sub> receptor.<sup>11</sup> Additionally, TAAR1 agonists present the potential to

103 address maladaptive eating behaviors associated with metabolic disorders.<sup>12</sup> Inhibitors  
104 targeting the lipase enzyme, such as those aimed at PDB proteins 1LPB and 5ZUN, further  
105 reinforce the potential of lipase inhibition as a therapeutic target for anti-obesity drugs.<sup>13</sup>

106 The methods employed in this study, including phytochemical screening, DPPH  
107 antioxidant assay, pancreatic antilipase activity testing, and molecular docking, are  
108 specifically chosen to assess the bioactive compounds in PC and their potential for obesity  
109 treatment. These approaches are highly relevant as they combine experimental and  
110 computational techniques to identify promising antilipase candidates. This is the first study to  
111 comprehensively evaluate PC antioxidant and antilipase activities while optimizing  
112 effervescent granule formulations. The integration of in vitro and in silico approaches in this  
113 study provides a novel insight into the potential therapeutic uses of PC in combating obesity.  
114 This holistic approach highlights the potential of PC as a safe, accessible, and effective  
115 therapy for obesity.

116

## 117 **Materials and Methods**

### 118 *Materials*

119 Rotary evaporator (Heidolph-G3), Silica Gel F254 plates, UV lamps (254 nm and 366  
120 nm, Evaco GL 220V 50Hz T8 15W), micropipettes (Socorex & Dragon Lab), vortex mixers,  
121 UV-Vis Spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation, Japan), ELISA  
122 reader (Synergy HTX, Agilent, USA), GC-MS (Shimadzu QP 2010 SE, Shimadzu  
123 Corporation, Japan). *Peronema canescens* Jack (PC), ethanol, n-hexane, ethyl acetate, FeCl<sub>3</sub>,  
124 MgSO<sub>4</sub>, hydrochloric-ethanolic acid mixture (1:1), hydrochloric acid, Liebermann-Burchard  
125 reagent, 2,2-diphenyl-1-picrylhydrazyl (DPPH, Sigma-Aldrich, USA, 97% purity, analytical  
126 grade) was used for antioxidant assays, quercetin, p.a. methanol, crude porcine pancreatic  
127 lipase (PPL), P-nitrophenyl butyrate (p-NPB, Sigma-Aldrich, USA, 98% purity, analytical

128 grade) was used for pancreatic antilipase activity, phosphate buffer (pH 7.2), DMSO, and  
129 orlistat standard.

### 130 *Hardware and Software*

131 Some of the software used, including the receptors for the test, can be downloaded  
132 from the RCSB PDB website (<https://www.rcsb.org/>). The ligands used in the test are  
133 available for download from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). Test  
134 ligands and receptors were created using ChemDraw Professional 15.0, Chem3D 15.0, Biovia  
135 Discovery Studio 2021, Command Prompt, and AutoDock Tools 1.5.6. Docking  
136 visualizations were performed using Biovia Discovery Studio 2021. Lipinski's Rule of Five  
137 testing was conducted using the Lipinski rules available at ([http://www.scfbio-](http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp)  
138 [iitd.res.in/software/drugdesign/lipinski.jsp](http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp)). Pharmacokinetics and toxicology testing were  
139 performed using the pk-CSM website (<https://biosig.lab.uq.edu.au/pkcsml/>). Molecular  
140 docking simulations were conducted on a laptop (Acer Aspire A314-35, Laptop-ML0EUN2).

### 141 *Methods*

142 The general research methods for the in vitro and in silico analysis of antilipase,  
143 antioxidants, and optimization of effervescent granules from PC are outlined in Figure 1.

### 144 *Sample preparation, extraction, and fractionation*

145 The sample used in this study was *Peronema canescens*, Jack (PC), sourced from  
146 Kayutanam in Padang Pariaman District, West Sumatra, Latitude : 0°29'46.8312", Longitude :  
147 100°20'7.638", Altitude: Located at an altitude of between 100 to 1000 meters above sea  
148 level. Harvested between May and July 2021 from trees measuring 6-7 meters in height. The  
149 maceration process was conducted for 3 days (3x24 hours), with occasional stirring and  
150 repeated solvent changes using 96% ethanol. The resulting macerate was then filtered and  
151 concentrated using a rotary vacuum evaporator, followed by thickening in a water bath at  
152 approximately 40°C.<sup>14-16</sup>

153 Twenty grams of the PC ethanol extract were placed in a beaker with a stir bar and  
154 magnetic stirrer. The fractionation process began by adding 100 mL of n-hexane, followed by  
155 stirring to separate the liquid from the insoluble extract. This step was repeated 5-6 times,  
156 adding 100 mL of n-hexane each time until a clear n-hexane fraction was obtained. Next, 100  
157 mL of ethyl acetate was added to the insoluble n-hexane extract, and the fractionation was  
158 repeated until a distinct ethyl acetate fraction was obtained. Subsequently, 100 mL of ethanol  
159 solution was used to fractionate the insoluble ethyl acetate extract, repeating the process 5-6  
160 times until a precise ethanol fraction was obtained. The remaining insoluble fraction, treated  
161 with ethanol, was designated as the insoluble fraction. The fractions were concentrated using  
162 a rotary vacuum evaporator, and the final thickening was performed in a water bath at  
163 approximately 50°C to yield a viscous fraction.<sup>14</sup>

#### 164 *Antioxidant Activity*

165 The PC fraction was dissolved in methanol and prepared at 10, 20, 30, 40, 50, and 60  
166 µg/mL.<sup>17</sup> The antioxidant activity was determined by adding 1.0 mL of the PC fraction  
167 solution to a test tube containing 4.0 mL of 0.1 mM DPPH for each concentration. The  
168 mixture was homogenized using a vortex for 1 minute and allowed to stand for the designated  
169 time for each test solution. The absorbance of the solution was then measured wavelength at  
170 516.0 nm using a UV-Vis spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation,  
171 Japan). The same procedure was followed to measure the absorbance of the quercetin  
172 standard series.

#### 173 *Pancreatic Antilipase Activity*

174 The pancreatic antilipase inhibition activity of the n-hexane, ethyl acetate, ethanol, and  
175 insoluble fractions was assessed using 96-well plates and an ELISA reader (Synergy HTX,  
176 Agilent, USA). The enzyme stock concentration was approximately 0.1 µg/mL, prepared by  
177 dissolving 1 mg of solid porcine pancreatic lipase (PPL) powder in 1 mL of buffer solution

178 (a). The fraction was prepared at a concentration of 500  $\mu\text{g/mL}$  (b), and p-NPB was dissolved  
179 in 1% DMSO (c) and subsequently diluted with a 50 mM phosphate buffer (pH 7.2, 0.5%) to  
180 a final concentration of 2.5 mM in 100  $\mu\text{L}$  (d). Solutions (a), (b), and (d) were mixed and  
181 incubated at 37°C for 10 minutes. Each sample was tested in triplicate. Orlistat was used as a  
182 positive control, and 1% DMSO was the negative control without inhibitors. One unit of  
183 activity is defined as the reaction rate that generates 1  $\mu\text{mol}$  of p-nitrophenyl butyrate at 37°C.  
184 Lipase activity inhibition was expressed as the percentage reduction in activity when PPL  
185 was incubated with the test compound.<sup>18</sup>

#### 186 *Identification of compounds in the active fraction of PC using GC-MS.*

187 GC-MS analysis was conducted at the integrated laboratory of Universitas Islam  
188 Indonesia. The active fraction, prepared at a concentration of 500  $\mu\text{g/mL}$ , was injected in a  
189 volume of 1.0  $\mu\text{L}$  for analysis using Gas Chromatography coupled with a Flame Ionization  
190 Detector (FID) and Mass Spectrometry (MS) (Shimadzu QP 2010 SE, Shimadzu Corporation,  
191 Japan). The mobile phase consisted of chloroform: ethanol mixture (1:1), and the analysis  
192 was performed using an Rtx-5 MS column (5% diphenyl / 95% dimethyl polysiloxane) with  
193 specifications of 0.25  $\mu\text{m}$  thickness, 30.0 m length, and 0.25 mm inner diameter. The  
194 instrument settings included an initial temperature of 80°C, an injection temperature of 300°C,  
195 and an ion source temperature of 250°C. The oven temperature was gradually increased to  
196 330°C at 6°C per minute. The column flow rate was set to 0.74 mL/min with a pressure of  
197 42.3 kPa.<sup>19</sup>

#### 198 *Molecular Docking*

199 The receptors used in this study were obtained from the Protein Data Bank in 3D  
200 structure format or were drawn using ChemDraw software. These receptors, which are  
201 protein macromolecules, were isolated from any irrelevant molecules along with the ligands.  
202 The isolation process was performed using Discovery Studio 2021, and the files were saved

203 in pdb format. Optimization involved adding hydrogen atoms, merging nonpolar hydrogens,  
204 and calculating Gasteiger charges using AutodockTools 1.5.6. The resulting file was saved in  
205 pdbqt format. For ligand preparation, 2D and 3D structures of the selected ligands were  
206 created to determine their molecular structure using ChemDraw Pro 12.0 software. The  
207 ligands were then prepared using AutoDockTools 1.5.6, where the compound structures were  
208 corrected, and Gasteiger charges were added. **The prepared ligands were saved and ready for**  
209 **docking**.<sup>9,13</sup>

### 210 *Evaluation of Drug Likelihood and ADMET*

211 Assessing the drug-likeness of compounds is based on Lipinski's Rule of Five, which  
212 utilizes both experimental and computational approaches to evaluate solubility and  
213 permeability in drug discovery and *development*.<sup>20</sup> The Rule of Five suggests that poor  
214 absorption and permeability are likely when the molecular weight exceeds 500, the number of  
215 hydrogen bond acceptors is greater than 10, the number of hydrogen bond donors exceeds 5,  
216 and the calculated log P (ClogP) is higher than 5 (or MlogP > 4.15). ADMET predictions  
217 encompass absorption (CaCO<sub>2</sub> permeability), distribution (BBB permeability), metabolism  
218 (CYP2D6 substrate), excretion (total clearance), and toxicity (AMES toxicity).<sup>9</sup>

### 219 *Effervescent formulation*

220 The effervescent formula consists of five different formulations. Each ingredient is  
221 weighed and sifted through mesh 30. After sifting, the ingredients are added, extracted, and  
222 homogenized. The homogeneous mixture is gradually combined with 95% ethanol until  
223 granules are formed. The granules are then sifted through mesh 20/30 and dried. The  
224 effervescent formula containing PC extract is presented in Table 1.

### 225 **Data Analysis**

226 **The data were expressed as the mean ± standard deviation (SD) of experiments in**  
227 **triplicate. This statistical analysis in this study was carried out with one-way anova using a**

228 GraphPad Prism (Version 9.5.1 (528), 2023. Graph Pad Inc. software San Diego, CA, USA).  
229  $IC_{50}$  value represented the concentration of the test sample causing 50% inhibition, in which  
230 the value  $<0.05$  was considered significant.

231

## 232 **Results And Discussion**

### 233 *Antioxidant Activity (DPPH)*

234 The antioxidant activity was determined using the DPPH method, with the results  
235 expressed as the Inhibition Concentration 50 ( $IC_{50}$ ). According to,<sup>21</sup> a compound is classified  
236 as a powerful antioxidant if its  $IC_{50}$  is less than 50  $\mu\text{g/mL}$ , strong if  $IC_{50}$  is less than 100  
237  $\mu\text{g/mL}$ , medium if  $IC_{50}$  is less than 150  $\mu\text{g/mL}$ , weak if  $IC_{50}$  is less than 200  $\mu\text{g/mL}$ , and very  
238 weak if  $IC_{50}$  is greater than 200  $\mu\text{g/mL}$ . The  $IC_{50}$  values obtained in this study for the PC  
239 fractions are shown in Figure 2. Quercetin as a positive control had the highest antioxidant  
240 activity with an  $IC_{50}$  value of 23.77  $\mu\text{g/mL}$ , which is classified as very strong according to the  
241 criteria established by,<sup>21</sup> and the ethanol fraction with  $IC_{50}$  of  $47.27 \pm 1.90$   $\mu\text{g/mL}$ , which is  
242 categorized as very strong exhibits stronger antioxidant activity than the other fraction. In  
243 contrast, the ethyl acetate fraction exhibited a much weaker antioxidant potential with an  $IC_{50}$   
244 of  $201.89 \pm 20.08$   $\mu\text{g/mL}$ , classified as very weak. The N-hexane fraction showed the highest  
245  $IC_{50}$  value at  $685.70 \pm 32.15$   $\mu\text{g/mL}$ , indicating very weak antioxidant activity. The insoluble  
246 fraction had an  $IC_{50}$  value of  $86.09 \pm 7.94$   $\mu\text{g/mL}$ , falling under the strong category for  
247 antioxidant activity. with the order being Ethanol fraction > ethanol extract > insoluble  
248 fraction > ethyl acetate fraction > n-hexane fraction. The OH group on quercetin can function  
249 as a hydrogen donor. Quercetin can donate hydrogen atoms to neutralize free radicals,  
250 reducing the potential for cell oxidative damage.<sup>21</sup> Polar molecules such as flavonoids,  
251 phenolics, and glycosides are known for their antioxidant properties. The Ethanol fraction,

252 having the lowest IC<sub>50</sub> value, shows a significant difference, as denoted by four stars, when  
253 compared to the ethyl acetate and n-hexane fractions.

254 Polar fractions, such as the ethanol and insoluble fractions, contain a higher number of  
255 substances capable of donating hydrogen atoms, leading to the formation of a reduced  
256 (nonradical) form, which is indicated by the loss of the purple color, as described in  
257 reference,<sup>21</sup> This process reduces 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals into a stable  
258 nonradical hydrazine derivative, resulting in a color change. The DPPH antioxidant activity  
259 of the PC fractions is presented in Figure 2.

### 260 *In vitro Pancreatic Antilipase Activity*

261 The inhibition of pancreatic lipase involves the interaction between lipase enzymes and  
262 their substrates. This test uses PNPB (P-nitrophenyl butyrate) as the substrate and Porcine  
263 Pancreatic Lipase (PPL) as the enzyme. The inhibitory effect is assessed by measuring the  
264 hydrolysis of P-nitrophenyl butyrate to P-nitrophenol at a wavelength of 405 nm using an  
265 ELISA reader. Pancreatic lipase inhibition by PC was tested at a concentration of 200 µg/mL,  
266 with PPL solution in phosphate buffer (pH 7.2) and PNPB solution. One unit of activity is  
267 defined as the reaction rate that produces 1 µmol of p-nitrophenol in 10 minutes at 37°C. The  
268 inhibition of lipase activity is expressed as the percentage reduction in activity when PPL is  
269 incubated with the test compound. PPL was chosen as the enzyme model due to its  
270 similarities with human pancreatic lipase (HPL), exhibiting comparable kinetics and enzyme  
271 characteristics.<sup>22</sup> According to,<sup>18</sup> antilipase activity is robust when the inhibition percentage  
272 exceeds 50%. The results of the PC fraction at a concentration of 200 µg/mL are shown in  
273 Table 2. Similar to our findings, a recent study demonstrated that flavonoid-rich plant  
274 extracts exhibit strong antioxidant and antilipase activities, making them potential candidates  
275 for anti-obesity therapy.<sup>5</sup>

276 Obesity triggers inflammatory processes in excess lipogenesis, inhibits lipolysis, and  
277 increases adipocyte apoptosis. This matter increases the release of Reactive Oxygen Species  
278 (ROS) and will cause oxidative stress. Oxidative stress caused by obesity can result in  
279 damage to cells and tissues and trigger the emergence of degenerative diseases.<sup>23</sup>  
280 Antioxidants help neutralize radicals and reduce the risk of complications from degenerative  
281 diseases. Therefore, supplementation with antioxidants will reduce the risk of obesity-related  
282 complications and oxidative stress.<sup>24</sup>

283 The ethanol fraction proved the most potent antioxidant agent, while ethyl acetate  
284 showed pancreatic antilipase activity. Differences in the compounds that guide these two  
285 activities. These results follow research on other materials that show that the ethyl acetate  
286 fraction has higher anti-obesity activity than the ethanol fraction. The ethanol fraction has  
287 stronger antioxidant activity than the ethyl acetate fraction. Regarding compound content, the  
288 ethanol fraction has higher total phenolic content and total flavonoid content than the ethyl  
289 acetate fraction.<sup>25</sup> It is necessary to prove the levels of PC leaf extracts and fractions  
290 regarding the levels of compounds, not only phenolics and flavonoids but also other groups  
291 of compounds. So, to support both activities, an effervescent preparation will be made from  
292 PC leaves extract. Effervescent granules are preferred because they are easy to use, dissolve  
293 easily in water, and taste better. Compared to tablet preparations, effervescent granules  
294 reduce stomach irritation, which sometimes occurs when tablet preparations are swallowed  
295 directly, and reduce the risk of blockage in the esophagus because they are completely  
296 dissolved in liquid before consumption.

### 297 *In silico Pancreatic Antilipase Activity*

298 Molecular docking validation is performed by redocking. The redocking results of the  
299 native ligands are shown in Figure 3. The blue structure represents the initial conformation of  
300 the enzyme-ligand complex before molecular docking. In contrast, the red structure shows the

301 optimized docking pose of the native ligand after computational refinement. The close  
302 alignment between the pre-and post-docking structures, indicated by a root mean square  
303 deviation (RMSD) value below 2 Å, confirms the reliability and accuracy of the docking  
304 method used in this study.

305 The GC-MS identification revealed that the primary compound in the active fraction  
306 was Trilaurin, accounting for 54.83% of the area and a similarity index of 59%. The three  
307 compounds identified by GC-MS were then prepared for further in silico molecular docking  
308 tests. Molecular docking of the quercetin standard, Orlistat, and the three GC-MS compounds  
309 was performed to compare the compounds obtained from pancreatic antilipase testing with  
310 the standards known to exhibit pancreatic antilipase activity, as reported in previous studies.  
311 The results of the molecular docking are presented in Table 3.

312 The most promising compound is Dimethyl Tetracycline, which exhibits the lowest  
313 binding energy and inhibition coefficient values compared to the Orlistat standard. The  
314 Dimethyl Tetracycline has antilipase activity similar to Orlistat. In addition to the binding  
315 energy and inhibition coefficient, pancreatic antilipase activity is evaluated based on its  
316 interaction with the amino acid serine 152. After analyzing the GC-MS-identified compounds  
317 through in silico tests, any compounds that bind to amino acid residues can potentially serve  
318 as alternative ligands to replace Orlistat. The next step is to assess whether these compounds  
319 can be used as oral drugs by evaluating them according to Lipinski's Rule of Five, as shown  
320 in Table 4.

321 Table 4 indicates that the natural ligand candidates suitable for use are Quercetin,  
322 Dimethyl Tetracycline, and 2-methoxy-5H-indolo[2,3-b]quinoxaline. These compounds meet  
323 Lipinski's Rule of Five, with molecular weights under 500 Da, hydrogen bond donors not  
324 exceeding 5, hydrogen bond acceptors not exceeding 10, partition coefficients (log P) under 5,  
325 and polar surface areas (PSA) under 1025 Å<sup>2</sup>, making them suitable for oral administration.

326 In addition to adhering to Lipinski's Rule, candidate compounds must also pass  
327 pharmacokinetic and toxicity assessments conducted using pkCSM software. The results of  
328 drug-likeness analysis, along with absorption, distribution, metabolism, excretion, and  
329 toxicity (ADMET) predictions, are presented in Table 5.

330 A compound is considered to have blood-brain barrier (BBB) permeability if its log BB  
331 value in the distribution phase is greater than 0.3. Molecules with a log BB value below 0.1  
332 are not effectively distributed in the brain. CYP2D6 metabolic parameters predict whether  
333 cytochrome P450 will likely metabolize a given molecule. The total clearance (CL<sub>tot</sub>)  
334 parameter indicates excretion rates in log (ml/min/kg). Drug clearance primarily occurs  
335 through renal and hepatic clearance (kidney excretion) (liver metabolism and bile excretion).  
336 Ames toxicity testing is a commonly used method to evaluate the mutagenic potential of  
337 compounds through bacterial assays. Among the candidates, Dimethyl Tetracycline meets  
338 both Lipinski's rule of five and ADMET prediction criteria.

339 The Evaluation of granule preparations includes tests for flow rate, angle of repose,  
340 bulk density, tapped density, Carr's compressibility index, and Hausner ratios.<sup>26</sup> In this study,  
341 optimization using design experts focuses on flow rate, angle of repose, and Carr's index.  
342 Good flow characteristics are defined by the ability of particles to flow independently without  
343 clumping, influenced by gravitational force.<sup>27</sup> The flow rate test indicates that all the  
344 effervescent granules produced exhibit excellent flow, with a suitable flow time greater than  
345 10 grams per second.

346 The flow rate results of the effervescent granules for each formula are presented in  
347 Table 6. Based on the observations for Formula 3 and Formula 4 in Table 6, these formulas  
348 exhibit a faster flow time due to a higher tartaric acid content than Formula 1 and Formula 2.  
349 Tartaric acid has a higher density than citric acid, which allows granules with a greater  
350 tartaric acid content to flow more rapidly because of the increased gravitational force.<sup>27</sup> The

351 angle of repose is the stable angle formed between a pile of cone-shaped particles and a  
352 horizontal plane. If the angle is less than  $30^\circ$ , the material is considered to flow easily.

353         Conversely, if the angle is  $40^\circ$  or greater, the material will likely be difficult to flow.  
354 The shape of the granules can influence the value of the angle of repose.<sup>28</sup> Table 6 presents  
355 the results of the stationary angle test for formulas 1-5, all of which are below  $30^\circ$ . A  
356 stationary angle of no more than  $30^\circ$  indicates excellent flow properties, meaning all the  
357 formulas demonstrate good flow behavior. The granules flow more quickly and easily with  
358 less friction and tensile force between them. Furthermore, smaller granule sizes increase  
359 cohesiveness, reducing the flow velocity and resulting in a higher stationary angle.<sup>29</sup>

360         Determining bulk density includes measuring the actual weight, compressive weight,  
361 Hausner factor, and percent compressibility. The Hausner factor is used to compare the actual  
362 and compressive weights, helping to assess the flow or free-flowing properties of the powder.  
363 All seven formulas meet the qualification of having a Hausner factor of less than 1.25,  
364 indicating good flow characteristics. Granule compressibility refers to the ability of the  
365 granules to maintain compactness under pressure. Factors such as porosity, type density,  
366 particle shape, and moisture content can affect the flow properties of the granules. Good flow  
367 properties ensure easier molding of the granules and help maintain uniform weight. The  
368 results for the Hausner factor and compressibility are shown in Table 6. The percent  
369 compressibility results indicated that Carr's index ranged from 4.26% to 14.59%, which  
370 aligns with the literature stating that granules with a Carr's index value below 15%  
371 demonstrate good flowability.

372 The optimal formula using Design Expert is intended to generate the most efficient formula  
373 based on the response data from the prepared parameters. The response data, analyzed  
374 through ANOVA in Design Expert, is processed to identify the optimal formula.<sup>10</sup> The ideal  
375 formula is the one with a desirability value closest to 1. Using the simplex lattice design

376 method in the Design Expert software, the optimal formula was determined to have 65.81 mg  
377 of tartaric acid and 4.19 mg of citric acid, with a desirability value of 0.86. Before finalizing,  
378 the optimal formula requires verification. The results of design expert optimization formula 1  
379 solution and formula 2 solution are shown in Figure 4, with the formula test results from the  
380 design expert optimization provided in Table 7.

381 This study utilized a Design Expert to optimize the effervescent granule formulation  
382 containing PC extract Figure 4. This software allows integrated analysis to evaluate  
383 interactions between formulation variables and determine the optimal combination of  
384 ingredients used. The optimization of the effervescent granule formulation resulted in two  
385 optimal formulas. Formula 1: 13.16% tartaric acid and 0.84% citric acid. Formula 2: 13.21%  
386 tartaric acid and 0.80% citric acid. The desirability score for both formulas was 0.862,  
387 indicating a high optimization level. The flow rate and angle of repose parameters from the  
388 optimized formulas showed no significant differences compared to laboratory experimental  
389 results ( $p > 0.05$ ), suggesting the predictive model's accuracy in Figure 5.

390 Based on the GraphPad Version 9.5.1 (528), 2023 statistical analysis Figure 5, the  
391 flow rate and angle of repose values from Formula 1 and Formula 2 in both the Design  
392 Expert optimization and the actual test results showed no significant difference, indicating  
393 that the optimization and laboratory test produced similar outcomes. However, Carr's index  
394 test revealed a discrepancy between the Design Expert optimization and the test results, as  
395 effervescent granules are highly sensitive to room temperature, which may have influenced  
396 the test outcomes.

397 Additional research is needed to isolate compounds from PC based on the results of the  
398 in silico data. An integrated study of network pharmacology and component analysis should  
399 be conducted to explore the molecular mechanisms of PC extract in treating obesity.<sup>30</sup> In  
400 silico anti-obesity activity should be explored using additional receptor targets, as the anti-

401 obesity mechanism extends beyond pancreatic lipase. Central nervous system mechanisms  
402 can be investigated, targeting receptors such as GLP-1 (liraglutide), 5-HT<sub>2c</sub> (lorcaserin), and  
403 TAAR-1 (phentermine). In vivo, testing is also recommended to validate the efficacy and  
404 safety of these compounds in animal models and clinical settings. Furthermore, advanced  
405 formulations, such as nanocarrier systems, could be developed to enhance PC-based products'  
406 bioavailability and therapeutic potential. Future studies should focus on the antioxidant  
407 properties of the sample using comprehensive methods.<sup>31</sup> These include determination of  
408 hydrogen peroxide scavenging capacity, determination of ferric reducing power,  
409 determination of nitric oxide (NO) scavenging activity, determination of ascorbic acid,  
410 determination of vitamin e, and assessment of lipid peroxidation inhibition. These assays will  
411 provide a deeper understanding of the antioxidant potential and the mechanisms by which the  
412 sample mitigates oxidative stress.

413

#### 414 **Conclusion**

415 The antioxidant activity of the PC fraction, evaluated using the DPPH method, revealed  
416 that the ethanol fraction exhibited significantly stronger antioxidant activity ( $IC_{50} = 47.27 \pm$   
417  $1.90 \mu\text{g/mL}$ ) compared to the ethyl acetate fraction ( $IC_{50} = 201.89 \pm 20.08 \mu\text{g/mL}$ ,  $p < 0.05$ ).  
418 This difference highlights the greater presence of polar compounds, such as flavonoids and  
419 phenolics, in the ethanol fraction. Among the identified compounds, dimethyl tetracycline  
420 showed the lowest binding energy ( $-7.78 \text{ kcal/mol}$ ) in molecular docking studies, suggesting  
421 its potential as a strong pancreatic lipase inhibitor. This was further supported by its  
422 adherence to Lipinski's Rule of Five, indicating good oral bioavailability. Formula  
423 optimization using the Design Expert software resulted in two formulas. The flow rate and  
424 angle of repose values from the design expert and the laboratory tests did not show  
425 significant differences, indicating that the optimization and experimental results aligned.

426 However, differences were observed in the Carr's Index test between the design expert  
427 optimization and the lab results.

428

#### 429 **Conflict of Interest**

430 The authors declare no conflict of interest.

431

#### 432 **Authors' Declaration**

433 The authors affirm that the work presented in this article is original, and they accept full  
434 responsibility for any claims related to the **article's content**.

435

#### 436 **Acknowledgments**

437 Acknowledgment Hibah Penelitian Dan Pengabdian Kepada Masyarakat Akademik  
438 Pendidikan Tinggi Vokasi supports this work. Contract Number:  
439 103/SPK/D.D4/PPK.01.APTV/III/2024. Derivative Contract Number 018 /LL6/PPM-  
440 V/AL.04/2024.

441

#### 442 **References**


- 443 1. Ministry of Health RI. Riskesdas 2018. Ministry of Health RI. 2018;53(9):1689–1699.
- 444 2. Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. Biomed and  
445 Pharm. 2020;128(110314): 1-9.
- 446 3. Ladeska V, Elya B, Hanafi M, Kusmardi, Rohmat SS. Pharmacognostic Evaluation and  
447 Antioxidant Activities of *Tetracera indica* (Christm. and Panz.) Merr. Hayati.  
448 2024;31(5):836–853.

- 449 4. Romiti GF, Corica B, Raparelli V, Basili S, Cangemi R. The interplay between  
450 antioxidants and the immune system: A promising field, still looking for answers.  
451 *Nutrients*. 2020;12(6):10–13.
- 452 5. Li S, Pan J, Hu X, Zhang Y, Gong D, Zhang G. Kaempferol inhibits the activity of  
453 pancreatic lipase and its synergistic effect with Orlistat. *J Funct Foods*.  
454 2020;72(104041) : 1-11.
- 455 6. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute  
456 liver injury: Self controlled case series study in UK Clinical Practice Research Datalink.  
457 *BMJ (Online)*. 2013;346(7906):1–9.
- 458 5. Rahardhian MRR, Susilawati Y, Sumiwi A, Muktiwardoyo M, Muchtaridi M, Sumiwi  
459 SA. A Review Of Sungkai (*Peronema Canescens*): Traditional Usage, Phytoconstituent,  
460 And Pharmacological Activities. *Int J. App Pharm*. 2022;14(Special issue 5):15–23.
- 461 6. Chike-Ekwughe A, John-Africa LB, Adebayo AH, Ogunlana OO. Evaluation of the In  
462 vitro and In silico Pancreatic Lipase Inhibitory Activity of Ethanol Leaf Extract of  
463 *Tapinanthus cordifolius* and its Effect on Oral Glucose Tolerance in Mice. *Trop J Nat*  
464 *Prod Res*. 2024;8(8):8168–8175.
- 465 7. Rahardhian MRR, Susilawati Y, Musfiroh I, Febriyanti RM, Muchtaridi, Sumiwi SA. In  
466 Silico Study of Bioactive Compounds From Sungkai (*Peronema Canescens*) As  
467 Immunomodulator. *Int J. App Pharm*. 2022;14(Special Issue 4):135–141.
- 468 10. Indriastuti M, Astuti AF, Anna L Yusuf, Akbar F, Kurnia R R. Optimization of Formula  
469 Preparation of Effervescent Granules of Moringa Leaf Extract (*Moringa oleifera* L.).  
470 *Med Sains : JIK*. 2023;8(2):519–528.
- 471 11. Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD. Novel pyrimidoazepine analogs  
472 as serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands for the treatment of obesity. *Eur J*  
473 *Med Chem*. 2013;63:558–569.

- 474 12. Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers SP.  
475 TAAR1 agonists improve glycemic control, reduce body weight and modulate  
476 neurocircuits governing energy balance and feeding. *Mol Metab.* 2024;80 (101883): 1-  
477 14.
- 478 13. Suharsanti R, Wahyuono S, Yuniarti N, Astuti P. Molecular Docking of Lipase  
479 Inhibitory Activities , Pharmacokinetics and Toxicity Prediction of Chemical  
480 Constituents from *Curcuma aeruginosa* Roxb Rhizome. *Int J. Pharm Res and App.*  
481 2024;9(2):162–174.
- 482 14. Rahardhian MRR, Suharsanti R, Sugihartini N, Lukitaningsih E. In vitro assessment of  
483 total phenolic, total flavonoid and sunscreen activities of crude ethanolic extract of  
484 belimbing wuluh (*Averrhoa bilimbi*) fruits and leaves. *J. Glob Pharm Tech.*  
485 2019;11(4):308–313.
- 486 15. Syofyan, S, Almahdy, A, Wulandari, A, Alen, Y, Diliarosta, S, Kurniawan, H, Noverial,  
487 N, Putra, P.P, Dillasamola, D. Effects of Ethanol Extract of Sungkai (*Peronema*  
488 *canescens* Jack.) on Fertility of Female Wistar Mice (*Mus musculus* L.). *Trop J Nat*  
489 *Prod Res.* 2023;7(5):2863–2866.
- 490 16. Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Effect of Different  
491 Solvent on Total Phenolic, Total Flavonoid, and Sun Protection Factor of Belimbing  
492 Wuluh (*Averrhoa bilimbi* linn.) Fruits Fraction. *J. Glob Pharm Tech.* 2019;11(1):154–  
493 162.
- 494 17. Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Potency Of Belimbing  
495 Wuluh (*Averrhoa Bilimbi*) As Antioxidat And Tyrosinase Inhibitor For Skin Whitening  
496 Product. *J. Pharm Res.* 2019;8(4):151–154.
- 497 18. 2.Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomed*  
498 *and Pharm.* 2020;128(110314): 1-9.

- 499 19. Falodun A, Siraj R, Choudhary MI. GC-MS Insecticidal Leaf essential oil of *P. staudtii*  
500 Hutch and Dalz (Icacinaceae). Trop J. Pharm Res. 2009; 82:139-143.
- 501 20. Puspitasari YE, Alfikri MA, Sitanggang R, Tambunan JE, Hardoko H. In Silico  
502 Analysis of Phenolic Compounds from *Ceriops decandra* Griff. Leaves and Molecular  
503 Interaction as Anti Diabetes. Sci and Tech Ind. 2023;8(4):542–553.
- 504 21. Molyneux P. The Use of the Stable Free Radical Diphenylpicryl-hydrazyl (DPPH) for  
505 Estimating Antioxidant Activity. Songkla J. Sci and Tech. 2004, 26(2) : 211-219.
- 506 22. Alias N, Leow TC, Ali MSM, Tajudin AA, Salleh AB, Zaliha RN, Rahman RA. Anti-  
507 obesity Potential of Selected Tropical Plants via Pancreatic Lipase Inhibition. Adv Obes  
508 Weight Manag Control. 2017;6(4): 122-131.
- 509 23. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Free Radicals in  
510 Bio and Med. 2015
- 511 24. Fernández A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á,  
512 Esquivel-Chirino C. Inflammation, oxidative stress, and obesity. Int J Mol Sci.  
513 2011;12(5):3117–3132.
- 514 25. Suharsanti, Wahyuono S, Yuniarti N, Astuti P. Antioxidant Activity and Pancreatic  
515 Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions. J. Bio.  
516 2024;9(11):228–243.
- 517 26. Shah RB, Tawakkul MA, Khan MA. Comparative Evaluation of flow for  
518 pharmaceutical powders and granules. AAPS Pharm Sci Tech. 2008;9(1):250–8.
- 519 27. Rani KC, Parfati N, Muarofah D, Sacharia SN. Meniran (*Phyllanthus niruri* L.) Herbal  
520 Effervescent Granule Formulation with Variations of Suspending Agent Xanthan Gum,  
521 CMC-Na, and Combination CMC-Na-Microcrystalline Cellulose RC- 591. J. Sci  
522 Pharm.and Clin. 2020;7(1):39-51.


- 523 28. Aulton M. *Pharmaceutics: the Science of Dosage Form Design*. 2nd ed. Edinburgh:  
524 Churchill Livingstone; 2002.
- 525 29. Lee, R. E. *Effervescent Tablets : Key Facts About A Unique, Effective Dossage Form*.  
526 CSC Publishing; 2004.
- 527 30. Mutiah R, Briliana MSD, Ahmad ARA, Fauziyah B, Janaloka NA, Suryadinata A.  
528 *Network Pharmacology and Component Analysis Integrated Study to Uncovers the*  
529 *Molecular Mechanisms of *Lansium parasiticum* Bark Extract in Colon Cancer*  
530 *Treatment*. *Sci and Tech Ind*. 2024;9(2):314–324.
- 531 31. Okolie NP, Falodun A, Oluseyi D. Evaluation of the Antioxidant Activity of Root  
532 Extract of Pepper Fruit (*Dennetia Tripetala*), and It's Potential for the Inhibition of  
533 Lipid Peroxidation. *Afr J. of Trad Compl and Altern Med*. 2014;11(3):221–227.
- 534  
535  
536  
537  
538  
539  
540  
541



542

543 **Figure 1:** Research methods for *in vitro* and *in silico* analysis of antilipase, antioxidants, and  
 544 optimization of effervescent granules from PC.


545



546

547 **Figure 2:** Antioxidant activity of PC fractions measured by DPPH assay, ns = not Significant  
 548 ( $p > 0.05$ ), \*\*\* ( $p < 0.001$ ), QS (Quercetin standard), NHF (n-Hexane fraction, EAF (Ethyl acetate  
 549 fraction), EF (Ethanol fraction), IF (Insoluble fraction).

550



551

552 **Figure 3:** 3D structure of the pancreatic lipase enzyme (PDB ID 1LPB) showing an overlay of the  
 553 blue (before) and red (after) molecular docking of the native ligand.

554


555

556

557

558

559



560 **Figure 4:** Design Expert optimization (A) Formula 1 Solution (B) Formula 2 Solution

561

562

563

564

565

566


567

568

569

570

571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587



**Figure 5:** Formula optimization using Design expert vs test, ns = not Significant ( $p > 0,05$ ), \* ( $p < 0,05$ ), F1 DE (Formula 1 Design Expert), F2 DE (Formula 2 Design Expert), F1 Test (Formula 1 test), F2 Test (Formula 2 test)

**Table 1:** Formulation of Effervescent Granules from PC Extract.

Ingredient	Formula				
	A	B	C	D	E
PC Extract	10%	10%	10%	10%	10%
Tartaric Acid	12.72%	12.30%	13.58%	14%	13.15%
Citric Acid	1.58%	2%	0.72%	0.30%	1.15%
Na. Bicarbonate	14.30%	14.30%	14.30%	14.30%	14.30%
Sucrose	60.40%	60.40%	60.40%	60.40%	60.40%
PVP	1%	1%	1%	1%	1%

588

589 **Table 2:** Pancreatic antilipase activity of the PC fraction.

590	<b>Sample</b>	<b>% inhibition of <math>\pm</math>SD</b>	<b>Types of Antilipase ?</b>
591	Orlistat Standard	61.64 $\pm$ 9.11	Strong
592	N-hexane fraction	18.66 $\pm$ 5.21	Weak
593	Ethyl Acetate Fraction	67.65 $\pm$ 8.04	Strong
594	Ethanol Fraction	14.22 $\pm$ 4.69	Weak
595	Insoluble fraction	6.45 $\pm$ 1.13	Weak
596			
597			

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619 **Table 3:** Molecular docking scores and interactions of the identified compounds.

No	Structure Name	Binding Energy	Amino Acid Bonds
1	Orlistat	-6.62	Gly 76, Phe 77, Ile 78, Asp 79, Tyr 114, His 151, Ser 152, Leu 153, Ala 178, Glu 179, Pro 180, Ile 209, Phe 215, Arg 256, Ala 259, His 263, Leu 264
2	Quercetin	-8.28 (Run of 83)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, Ser B:152, Ala B:178, Glu B:179, Pro B:180, Ile B:209, Phe B:215, Gly B:216, Arg B:256, His B:263.
3	Dimethyl Tetracycline	-7.78 (Run of 14)	Gly B:76, Phe B:77, Ile B:78, Asp B:79, Tyr B:114, His B:151, Ser B:152, Leu B:153, Ala B:178, Pro B:180, Phe B:215, Arg B:256, Asp B:257, Ala B:259, Ala B:260, His B:263, Leu B:264.
4	2-methoxy-5H- indole[2,3- b]quinoxaline	-7.25 (Run of 77)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, Ser B:152, Leu B:153, Ala B:178, Pro B:180, Ile B:209, Phe B:215, His B:263, Leu B:264.
5	Trilaurin	-3.52 (Run of 7)	Ile B:78, Tyr B:114, His B:151, Ser B:152, Leu B:153, Ala B:178, Pro B:180, Ile B: 209, Leu B:213, Phe B:215, Trp B:252, Thr B:255, Arg B:256, Ala B:259, Ala B:260, His B:263, Leu B:264.

620

621

622

623

624

625

626

627

**Table 4:** Predicted Lipinski's Rule of Five for the Ligands.

No	Molecular Name	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar Voltage Activity (PSA)
1	Quercetin	302.24	1.99	5	7	122.11
2	Dimethyl Tetracycline	430.41	-0.55	6	9	176.06
3	2-methoxy-5H-indolo[2,3-b]quinoxaline	249.27	3.27	1	3	108.60
4	Trilaurin	639.02	11.75	0	6	278.43

628

629

**Table 5:** ADMET Prediction for Compounds from the Ethyl Acetate Fraction of PC

No	Molecular Name	Absorption	Distributi	Metabolism	Excretion	AMES	Hepato	Skin
		(CaCO <sub>2</sub> Permeability) (log Papp in 10 <sup>-6</sup> cm/sec)	on (VDss (human)) (log L/kg)	(CYP2D6) (YES/NO)	(Total clearance) (log ml/min/kg)	Toxicity (YES/NO)	toxicity	Sensitization
1	Orlistat	0.40	-1.02	No	1.68	No	Yes	No
2	Quercetin	-0.28	0.06	No	0.46	No	No	No
3	Dimethyl tetracycline	-0.01	0.61	No	0.35	No	No	No
4	2-methoxy-5H-indolo[2,3-b]quinoxaline	1.30	-0.01	No	0.77	Yes	Yes	No
5	Trilaurin	0.14	-0.82	No	2.23	No	No	No

630

631 **Table 6:** Flow rate, angle of repose, and bulk density of the effervescent granules from PC.

Formula	Flow	Angle of	Bulk	Tapped	Hausner	Carr's
	rate	repose	density	density	ratios	compressibility
			(g/ml)	(g/ml)		index (%)
A	18.66	25.05	0.52	0.56	1.07	6.25
B	20.43	25.85	0.53	0.55	1.04	4.26
C	20.79	27.16	0.53	0.56	1.07	6.38
D	20.63	24.09	0.50	0.56	1.14	11.98
E	18.74	26.03	0.49	0.53	1.06	5.99

632

633 **Table 7:** Results of the formula test from Design Expert Optimization.

Formula	Flow	Angle of	Bulk	Tapped	Hausner	Carr's
	rate	repose	density	density	ratios	compressibility
			(g/ml)	(g/ml)		index (%)
1	20.50	27.61	0.52	0.60	1.17	14.59
2	17.96	24.10	0.54	0.59	1.10	8.68

634

635

## BUKTI KORESPONDENSI

### Author's Reply to Editor and Reviewers Comments

**Journal name** : Tropical Journal of Natural Product Research

**Manuscript Title** : *In Vitro and In Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from Peronema canescens Jack.*

**Manuscript No** : TJNPR MH559AR

**Type of paper** : Research Article

**Authors Name** : Muhammad Ryan Radix Rahardhian, Nurchasanah, Yasmiwar Susilawati, Sri Adi Sumiwi, Dewi Ramonah, Chintiana Nindya Putri, Ririn Suharsanti

#### Reply to the reviewers' comments

Reviewer Number	Original comments of the reviewer	Reply by the author(s)	Changes done on page number and line number
1	Line 9 sungkai, change to Sungkai	The term "sungkai" on line 9 has been corrected to "Sungkai" as per the suggestion. We have ensured consistency in capitalization throughout the manuscript.	Page 1 line 19
1	Line 21 ADMET, describe admet	We have added a description of ADMET.	Page 2, line 31-32

		ADMET refers to the Absorption, Distribution, Metabolism, Excretion, and Toxicity properties of compounds, which are critical parameters in evaluating the pharmacokinetics and safety profile of potential drug candidates.	
1	Line 31 RISKESDAS, describe RISKESDAS	We have added a description of RISKESDAS. RISKESDAS refers to "Indonesia basic health research".	Page 2 line 45
1	Line 55-56 add reference	We have added an appropriate reference to support the statement on lines 55-56. The updated reference is now included in the revised manuscript and properly cited in the reference list.	Page 3, line 65-66
1	Line 63 add reference	We have added an appropriate reference to support the statement on lines 63. The updated reference is now included in the revised manuscript and properly cited in the reference list.	Page 3, line 75
1	Line 140 add reference	We have added an appropriate reference to support the statement on lines 140. The updated reference is now included in the revised manuscript and properly cited in the reference list.	Page 6, line 151
1	Every data change comma to dot and consistently 2 digits behind the dot	We have revised all numerical data in the manuscript to ensure consistency in formatting. All commas have been replaced with dots as decimal separators, and all numerical values are now	Page 24, table 1 Page 24, table 2 Page 24, table 3 Page 26, table 4 Page 26, table 5 Page 27, table 6

		presented with two digits after the decimal point.	Page 27, table 7
1	Add a closing statement that emphasizes the contribution of the research to scientific development or its applications.	We have added a closing statement in the conclusion about contribution of this research to scientific development and its potential applications. In vivo studies are also recommended to validate the efficacy and safety of these compounds in animal models and clinical settings. Furthermore, advanced formulations, such as nanocarrier systems, could be developed to enhance PC-based products' bioavailability and therapeutic potential.	Page 16, line 392-395
1	In line 359 Demethyltetracycline, 2-methoxy-5H-indolol [2,3-bquinoxaline rewrite to Demethyltetracycline, 2-methoxy-5H-indol [2,3]quinoxaline	We have revised Demethyltetracycline, 2-methoxy-5H-indol [2,3]quinoxaline	Page 27, table 6
2	The abstract word count is < 250. The authors should correct all grammatical, spellings and punctuation errors.	Thank you for the feedback. We have revised the abstract to meet the recommended word count of <250 words, and we have carefully corrected all grammatical, spelling, and punctuation errors. The abstract has been revised as suggested	Page 1 Line 19-37
2	The aim and objectives of the research are obvious. The authors should include a statement of research novelty. Authors should briefly discuss the relevance of the research methods to the research. All grammatical, spellings and punctuation errors should be corrected. The literature review should	Thank you for your valuable feedback. We have revised the manuscript based on your suggestions:  1. We have included a statement of the research novelty.	1. Page 4 line 97-100 2. Page 5 line 106-113 3. Page 1-18 4. Page 3 line 66

	<p>mostly be contextual. Use recent citations. Abbreviated words should be mentioned in full prior to abbreviations.</p>	<ol style="list-style-type: none"> <li>2. We have clarified the relevance of the research methods to the research.</li> <li>3. All grammatical, spelling, and punctuation errors have been corrected.</li> <li>4. The literature review has been updated to include recent and relevant citations, providing better context.</li> <li>5. Abbreviations are now fully defined before being abbreviated.</li> </ol>	<ol style="list-style-type: none"> <li>5. Page 1, line 12, 13, 16, 20</li> </ol>
2	<p>Include methods for the statistical analysis. Mention the software used in the statistical analysis alongside the manufacturer, version and release year. Include the number of replicate measurements. All chemicals and reagents used should be mentioned alongside the manufacturer, % purity, conc., grade and specificities. All equipment and instrument used should be mentioned alongside their model, manufacturer and country. Authors should specify instruments/equipment used for each experiment. All methods used should be validated with relevant citations. All grammatical, spellings and punctuation errors should be corrected. Authors should include the GPS location of the sample collection</p>	<p>Thank you for the constructive feedback. We have revised the manuscript as per your suggestions:</p> <ol style="list-style-type: none"> <li>1. We have included the statistical analysis methods, specifying the software used and relevant details.</li> <li>2. All chemicals and reagents have been listed alongside the manufacturer, purity, concentration, grade, and specificities.</li> <li>3. The instruments and equipment used for each experiment have been mentioned, along with their model, manufacturer, and country.</li> <li>4. We have added citations to validate the methods used in the</li> </ol>	<ol style="list-style-type: none"> <li>1. Page 9, line 209-214</li> <li>2. Page 5, 106-113</li> <li>3. Page 7 line 154-155</li> <li>4. Page 10 line 250, page 11 line 268</li> <li>5. Page 6, line 132</li> </ol>

		<p>study.</p> <p>5. The GPS location of the sample collection site has been included</p>	
2	<p>All results should be presented based on the journal guideline. Images should be of a very high quality/resolution (300 dpi) – some images were not clear and readable. Authors should forward all supplementary data (input and output files) associated with the research to the journal management for validations and authentications. Use footnotes were necessary to define terms. Crosscheck the methodologies to ensure that results obtained tally with methods used. The results of the IC50 (antioxidant assay) should be presented as graphs used in the estimation of the IC50. Authors should include the GCMS spectra obtained from the analysis. Authors shouldn't use commas as decimal points.</p>	<p>Thank you for your detailed feedback. We have addressed the comments as follows:</p> <ol style="list-style-type: none"> <li>1. We have revised the results section to align with the journal guidelines.</li> <li>2. We have ensured that all images meet the required resolution of 300 dpi and are clear and readable.</li> <li>3. Footnotes have been added where necessary to define terms.</li> <li>4. The IC50 results from the antioxidant assay are now presented as graphs, as requested.</li> <li>5. Thank you for your feedback. Due to the extensive nature of the GC-MS spectra data, we have included it as supplementary material, which has been submitted alongside the manuscript for review and validation</li> <li>6. We have corrected all instances of commas used as decimal points and replaced them with periods</li> </ol>	<ol style="list-style-type: none"> <li>1. Page 9, line 216-page 17 395</li> <li>2. Page 23, figure 3</li> <li>3. Page 22, Figure 2. Page 23 figure 5</li> <li>4. Page 13, Figure 5</li> <li>5. Page 4 line 96 Page 8 line 167</li> <li>6. Page 24, table 1 Page 24, table 2 Page 24, table 3 Page 26, table 4 Page 26, table 5 Page 27, table 6 Page 27, table 7</li> </ol>
2	<p>The discussions should be mostly statistically comparative. Authors should discuss mainly the</p>	<p>Thank you for your valuable feedback.</p>	<ol style="list-style-type: none"> <li>1. Page 22, Figure 2 Page</li> </ol>

	significant findings in details. Authors should use recent citations in discussing their findings. All grammatical, spellings and punctuation errors should be corrected	<ol style="list-style-type: none"> <li>1. Statistically Comparative Discussion</li> <li>2. Focus on Significant Findings</li> <li>3. Recent Citations for Discussion</li> <li>4. Grammatical, Spelling, and Punctuation Corrections</li> </ol>	<ol style="list-style-type: none"> <li>23 Figure 5.</li> <li>2. Page 11, Line 398-409</li> <li>3. Page 11, line 267-269</li> <li>4. Page 1-18</li> </ol>
2	Authors should capture the future prospects of the research.	Thank you for the suggestion. We have added a section discussing the future prospects of the research, highlighting potential applications, further research directions, and broader implications	Page 16, line 392-395
2	Authors should ensure that all the references follow the journal guideline. The number of cited references must tally with those at the references sections	Thank you for highlighting this issue. We have thoroughly reviewed and revised the manuscript to ensure that all references adhere to the journal's formatting guidelines. Additionally, we have cross-checked the in-text citations to ensure they tally with the references listed in the references section.	Page 21, line 622-24 line 721
2	All figures should be presented based on the journal guideline. All figures should be of a very high quality/resolution. Figures 3 and 4 captured were not discussed in the manuscript	Thank you for your constructive feedback. We have revised the manuscript to ensure that all figures comply with the journal guidelines and meet the required resolution of at least 300 dpi. Figures 3 and 4 have been discussed in the manuscript, and their relevance to the study has been clarified.	Page 23, Figure 3 Page 12, line 284 Page 16, line 367 Page 16, line 371
2	All tables should be presented based on the journal	Thank you for your valuable feedback.	Page 24, table 1

	guideline. Table captured was discussed in the manuscript.	We have revised the manuscript to ensure all tables comply with the journal's formatting guidelines. Additionally, all tables have been reviewed to confirm they are appropriately discussed and integrated into the manuscript.	Page 24, table 2 Page 24, table 3 Page 26, table 4 Page 26, table 5 Page 27, table 6 Page 27, table 7
2	Remove *	Thank you for the feedback. We have removed the asterisk (*) from the term 'pdbqt' in the manuscript to improve clarity and consistency	Page 8 line 192
2	in full prior to abbreviations	Thank you for your comment. We have revised the manuscript to include the full form of DPPH, TLC, GC-MC, p-NPB, and ADMET before its abbreviation to ensure clarity for the readers	Page 1, line 23-32
2	include reference – citation needed	Thank you for the comment. We have added the appropriate reference to support the statement about the types of antioxidants in the manuscript	Page 9, line 224
2	include reference – citation	Thank you for the suggestion. We have added the necessary reference to support the discussion on the types of anti-lipase in the manuscript	Page 11. Line 258
2	do not use commas as a decimal point rather use periods	Thank you for the feedback. We have revised the manuscript to use periods (.) as the decimal point instead of commas to align with international formatting standards	Page 24, table 1 Page 24, table 2 Page 24, table 3 Page 26, table 4 Page 26, table 5 Page 27, table 6 Page 27, table 7
2	Figure 1	Change to Figure 4	Page 20 line 375

2	all images should be clear and readable – at least 300dpi	All images presented in this manuscript have been reviewed and updated to ensure they meet a minimum resolution of 300 dpi for clarity and readability	Page 26, table 4
3	A brief conclusion should be added at the end of abstract.	A conclusion has been added at the end of the abstract :  <i>Peronema canescens</i> Jack. (PC) leaves has the potential as an antioxidant and antiobesity and can be developed into effervescent formula.	Page 2 Line 36-37
3	Many grammatical errors and typos appear in the text such as anti-lipase, anti-obesity, in vitro, in silico, etc. It is suggested that the authors revisit and improve the English quality of the manuscript.	has been corrected throughout the manuscript	has been corrected throughout the manuscript
3	In Figure 4, statistical analysis was applied to examine the granule characteristics. Which statistical method was used here? The statistical analysis should be mentioned in the Methods section in detail.	Data analysis has been added to the method : The data were expressed as the mean ± standard deviation (SD) of experiments in triplicate. This statistical analysis in this study was carried out with one way anova using a GraphPad Prism (version 9.5.1 (528), 2023. Graph Pad Inc. software San Diego, CA, USA). IC50 value represented the concentration of the test sample causing 50% inhibition in which value <0.05 was considered significant.	Page 16 Line 370-378
3	The IC <sub>50</sub> of ethanol fraction is higher than that of quercetin standard showing the better antioxidant activity of the standard as compared to the PC fraction. How did the authors explain this result?	There is a writing error regarding the results related to table 2, the author has corrected the sentence in the discussion section and added an explanation to the related results :  As indicated in Figure 2, quercetin as a	Page 9 Line 222-233

		<p>positive control had the highest antioxidant activity and the ethanol fraction exhibits stronger antioxidant activity than the other fraction samples, with the order being Ethanol fraction &gt; ethanol extract &gt; insoluble fraction &gt; ethyl acetate fraction &gt; n-hexane fraction. The OH group on quercetin can function as a hydrogen donor. This means that quercetin can donate hydrogen atoms to neutralize free radicals, thereby reducing the potential for oxidative damage to cells.</p>	
3	<p>What is the correlation of antioxidant activity and anti-lipase potency of the PC towards the anti-obesity as the primary claim of this study?</p>	<p>has been added to the discussion section of the relationship between antioxidants and anti-obesity :</p> <p>Obesity triggers inflammatory processes, lipogenesis excess, inhibit lipolysis, and increase adipocyte apoptosis. This matter increases the release of Reactive Oxygen Species (ROS) and will cause oxidative stress. Oxidative stress caused by obesity can result damage to cells and tissues and trigger the emergence of diseases degenerative. Antioxidants help neutralize radicals free and reduces the risk of complications from degenerative diseases. Therefore Supplementation with antioxidants will reduce the risk of disease complications associated with obesity and oxidative stress.</p>	<p>Page 12 Line 260-266</p>
3	<p>Ethanol fraction was revealed as the most potent anti-oxidant agent, while ethyl acetate showed the highest pancreatic anti-lipase activity. Why do these two assays</p>	<p>has been added to the discussion section:</p> <p>The ethanol fraction proved to be the most</p>	<p>Page 12 Line 267-275</p>

	<p>demonstrate different findings? Which type of fraction was finally used in the effervescent formula? And why? Authors are suggested to discuss it more profoundly in the Results and Discussion Section.</p>	<p>potent antioxidant agent, while ethyl acetate showed pancreatic anti-lipase activity highest. This is because there are differences in the compounds that guide these two activities. These results are in accordance with research on other materials that the ethyl acetate fraction has higher anti-obesity activity than the ethanol fraction, while the ethanol fraction has stronger antioxidant activity than the ethyl acetate fraction. When related to compound content, the ethanol fraction has higher total phenolic content and total flavonoid content than the ethyl acetate fraction. It is necessary to prove the levels of PC leaf extracts and fractions regarding the levels of compounds not only phenolics and flavonoids, but also other groups of compounds. So to support both activities an effervescent preparation will be made from PC leaves extract.</p>	
3	<p>Why is the optimized effervescent granule formula not continued with the tablet formulation?</p>	<p>has been added to the discussion section:</p> <p>Effervescent granules are preferred because they are easy to use, dissolve easily in water, taste better, and when compared to tablet preparations, effervescent granules reduce stomach irritation which sometimes occurs when tablet preparations are swallowed directly and reduce the risk of blockage in the esophagus because they are completely dissolved in liquid. before consumption.</p>	<p>Page 12 Line 275-280</p>

3	Authors need to enrich the Discussion with more relevant references	References have been added to support the results	Page 9, line 222-Page 17, line 395
3	Figure legends in Figure 3 are too small.	figure 3 has been enlarged and moved to the bottom	Page 23, Figure 3
Editorial comments	Cite two related published articles from TJNPR	<p>Thank you for the suggestion. We have added references to two related published articles from <i>TJNPR</i> to strengthen the background and context of our study</p> <ol style="list-style-type: none"> <li>1. Chike-Ekwughe A, John-Africa LB, Adebayo AH, Ogunlana OO. Evaluation of the In vitro and In silico Pancreatic Lipase Inhibitory Activity of Ethanol Leaf Extract of <i>Tapinanthus cordifolius</i> and its Effect on Oral Glucose Tolerance in Mice. <i>Trop J Nat Prod Res.</i> 2024;8(8):8168–8175.</li> <li>2. Syofyan, S, Almahdy, A, Wulandari, A, Alen, Y, Diliarosta, S, Kurniawan, H, Noverial, N, Putra, P.P, Dillasamola, D. Effects of Ethanol Extract of <i>Sungkai</i> (<i>Peronema canescens</i> Jack.) on Fertility of Female Wistar Mice (<i>Mus musculus</i> L.). <i>Trop J Nat</i></li> </ol>	<p>Page 19 line 460 Page 20 line 485 Page 21 line 498</p>

	<p>Cite related published article</p> <p>Adhere strictly to the Journal’s style for listing references. Abbreviate all journal names, and replace ‘et al’ with names of all contributing authors</p> <p>All journal titles should be abbreviated ex : Trop J Nat Prod Res</p> <p>The table format should be like table 1 (table 3)</p>	<p>Prod Res. 2023;7(5):2863–2866.</p> <p>3. Falodun A, Siraj R, Choudhary MI. GC-MS Insecticidal Leaf essential oil of <i>P. staudtii</i> Hutch and Dalz (Icacinaceae). Trop J. Pharm Res. 2009; 82:139-143.</p> <p>Okolie NP, Falodun A, Oluseyi D. Evaluation of the Antioxidant Activity of Root Extract of Pepper Fruit (<i>Dennetia Tripetala</i>), and It’s Potential for the Inhibition of Lipid Peroxidation. Afr J. of Trad Compl and Altern Med. 2014;11(3):221–227.</p> <p>We have abbreviated all journal titles, et al is not allowed in the references</p> <p>We have adapted table 3 to the format of table 1</p>	<p>Page 22 line 530</p> <p>Line 441-532</p> <p>Page 27 line 618</p>
--	--	--	---

--	--	--	--

**Note : Highlighted turquoise for changes to response reviewer.**

**In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack**Muhammad R. R. Rahardhian<sup>1</sup>, Nurchasanah<sup>1</sup>, Yasmiwar Susilawati<sup>2</sup>, Sri A. Sumiwi<sup>3</sup>, Dewi Ramonah<sup>1</sup>, Chintiana N. Putri<sup>4</sup>, Ririn Suharsanti<sup>1\*</sup><sup>1</sup>Department of Pharmaceutical Biology, Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, Indonesia.<sup>2</sup>Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.<sup>3</sup>Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.<sup>4</sup>Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Islam Sultan Agung, Semarang, Indonesia.

## ARTICLE INFO

## ABSTRACT

## Article history:

Received

Revised

Accepted

Published online \*\*\*\*\*

Obesity results from prolonged energy imbalance, with anti-obesity treatment targeting pancreatic lipase inhibition. *Peronema canescens* Jack. (PC) known as Sungkai, has traditionally been used to treat various ailments. This study aimed to assess PC antioxidant and antilipase activities and optimize effervescent granule formulations. Phytochemical screening and thin-layer chromatography (TLC) were performed, followed by antioxidant analysis using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and pancreatic antilipase activity, using the p-NPB substrate, were employed. The ethanol fraction of PC demonstrated potent antioxidant activity ( $IC_{50} = 47.27 \mu\text{g/mL}$ ), while the insoluble fraction showed the highest pancreatic antilipase activity (67.65%). Gas chromatography-mass spectrometry (GC-MS) identified active compounds, including dimethyl tetracycline, 2-methoxy-5H-indolo[2,3-b] quinoxaline, and trilaurin, with molecular docking study indicating dimethyl tetracycline was the most effective antilipase candidate, binding to the pancreatic receptor (PDB ID: 1LPB). This compound also met Lipinski's Rule of Five and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity), suggesting favorable pharmacokinetics and safety. Evaluation of effervescent granules included angle of repose, bulk density, and tapped density. Optimization of tartaric and citric acid concentration using Design Expert 13 yielding two optimal formulas: Formula 1 with 13.16% tartaric acid and 0.84% citric acid, and Formula 2 with 13.21% tartaric acid and 0.80% citric acid. PC leaves have the potential to be an antioxidant and anti-obesity and can be developed into effervescent formula.

**Copyright:** © 2025 Rahardhian *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Keywords:** *Peronema Canescens* Jack., Antioxidant, Effervescent granules, Molecular docking, Pancreatic antilipase.

## Introduction

The increasing prevalence of degenerative diseases in Indonesia, alongside infectious diseases, indicates changing health challenges, with obesity emerging as a major concern. RISKESDAS (Indonesia's basic health research) data reveal a rise in obesity rates from 14.8% in 2013 to 21% in 2018.<sup>1</sup> Factors that contribute to obesity encompass environmental factors, urban living, and eating patterns. Diets high in fats and sugars but low in fiber cause an energy imbalance, which, when combined with triglyceride buildup, this imbalance triggers oxidative stress and inflammatory responses within the body.<sup>2</sup> This ongoing inflammation, fat accumulation, and suppression of fat breakdown causes adipocyte apoptosis, producing Reactive Oxygen Species (ROS) that harm cells and tissues, raising the risk of degenerative diseases.<sup>3</sup> Antioxidants are essential for neutralizing ROS, helping to reduce the risk of degenerative diseases linked to oxidative stress.<sup>4</sup> In the context of medical treatments, FDA-approved drugs for obesity aim to either decrease calorie absorption or control appetite.

Central nervous system (CNS) suppressants, including lorcaserin, liraglutide, phentermine-topiramate, and naltrexone/bupropion, work by targeting appetite-regulating receptors such as 5HT<sub>2c</sub>, GLP-1, and TAAR-1. On the other hand, Orlistat acts as a lipase inhibitor, reducing the absorption of dietary fats by approximately 30%.<sup>5</sup> People in Indonesia prefer using herbal medicine due to its natural properties, which are perceived as safer and less likely to cause unwanted side effects. In general, herbal medicines are more affordable than synthetic drugs. They also contain a variety of plant-based ingredients. Herbal medicine is considered effective for targeting multiple health issues. Conversely, Orlistat is a therapeutic agent for obesity that reduces calorie absorption in the intestinal tract.<sup>5</sup> Nevertheless, the effectiveness of Orlistat is constrained by side effects such as gastrointestinal problems, including oily stools, flatulence, and rectal discharge.<sup>6</sup> These limitations highlight the importance of seeking complementary or alternative treatments, especially natural ones with fewer side effects and potential long-term benefits. Herbal medicine presents a promising alternative to synthetic drugs for managing obesity, thanks to its safety, availability, and ability to target multiple mechanisms. *Peronema canescens* Jack. (PC), locally known as Sungkai, has attracted attention for its potential therapeutic benefits. Traditionally utilized in Indonesian medicine, the leaves of PC contain secondary metabolites like phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and saponins, which have been reported to exhibit anti-inflammatory, antioxidant, antidiabetic, and immune-boosting properties.<sup>7</sup> The bioactive compounds in PC position it as a promising candidate for anti-obesity treatments, primarily by inhibiting

\*Corresponding author. Email: [ririnsuharsanti@gmail.com](mailto:ririnsuharsanti@gmail.com)  
Tel: +62 821 3692 3586

**Citation:** Rahardhian MRR, Nurchasanah, Susilawati Y, Sumiwi SA, Ramonah D, Putri CN, Suharsanti R. In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack. Trop J Nat Prod Res. 2025; 9(2):

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

pancreatic lipase, which helps reduce lipid absorption. Recent studies have highlighted the potential of plant-based compounds for pancreatic lipase inhibition, particularly in treating obesity.<sup>8</sup> For example, in silico modeling allows for structural predictions and identifying binding sites, enhancing target interaction in drug development.<sup>9</sup> Moreover, effervescent granules offer a convenient dosage form by combining acidic and alkaline compounds that release CO<sub>2</sub> upon dissolution. These granules provide high solubility, ease of use, and rapid absorption, making them an ideal delivery system for antioxidants and antilipase agents.<sup>10</sup> Given the therapeutic potential of PC, developing a granule formulation can enhance the accessibility and effectiveness of its bioactive components. While traditional treatments like GLP-1 receptor agonists have proven effective in managing obesity, they are especially beneficial for patients with comorbidities such as type 2 diabetes. Other plant-based studies indicate that appetite suppression may occur by activating the 5-HT<sub>2C</sub> receptor.<sup>11</sup> Additionally, TAAR1 agonists present the potential to address maladaptive eating behaviors associated with metabolic disorders.<sup>12</sup> Inhibitors targeting the lipase enzyme, such as those aimed at PDB proteins 1LPB and 5ZUN, further reinforce the potential of lipase inhibition as a therapeutic target for anti-obesity drugs.<sup>13</sup> The methods employed in this study, including phytochemical screening, DPPH antioxidant assay, pancreatic antilipase activity testing, and molecular docking, are specifically chosen to assess the bioactive compounds in PC and their potential for obesity treatment. These approaches are highly relevant as they combine experimental and computational techniques to identify promising antilipase candidates. This is the first study to comprehensively evaluate PC antioxidant and antilipase activities while optimizing effervescent granule formulations. The integration of in vitro and in silico approaches in this study provides a novel insight into the potential therapeutic uses of PC in combating obesity. This holistic approach highlights the potential of PC as a safe, accessible, and effective therapy for obesity.

## Materials and Methods

### Materials

Rotary evaporator (Heidolph-G3), Silica Gel F254 plates, UV lamps (254 nm and 366 nm, Evaco GL 220V 50Hz T8 15W), micropipettes (Socorex & Dragon Lab), vortex mixers, UV-Vis Spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation, Japan), ELISA reader (Synergy HTX, Agilent, USA), GC-MS (Shimadzu QP 2010 SE, Shimadzu Corporation, Japan). *Peronema canescens* Jack (PC), ethanol, n-hexane, ethyl acetate, FeCl<sub>3</sub>, MgSO<sub>4</sub>, hydrochloric-ethanolic acid mixture (1:1), hydrochloric acid, Liebermann-Burchard reagent, 2,2-diphenyl-1-picrylhydrazyl (DPPH, Sigma-Aldrich, USA, 97% purity, analytical grade) was used for antioxidant assays, quercetin, p.a. methanol, crude porcine pancreatic lipase (PPL), p-nitrophenyl butyrate (p-NPB, Sigma-Aldrich, USA, 98% purity,

analytical grade) was used for pancreatic antilipase activity, phosphate buffer (pH 7.2), DMSO, and orlistat standard.

### Hardware and Software

Some of the software used, including the receptors for the test, can be downloaded from the RCSB PDB website (<https://www.rcsb.org/>). The ligands used in the test are available for download from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). Test ligands and receptors were created using ChemDraw Professional 15.0, Chem3D 15.0, Biovia Discovery Studio 2021, Command Prompt, and AutoDock Tools 1.5.6. Docking visualizations were performed using Biovia Discovery Studio 2021. Lipinski's Rule of Five testing was conducted using the Lipinski rules available at (<http://www.scfbio-iitd.res.in/software/drugdesign/lipinski.jsp>). Pharmacokinetics and toxicology testing were performed using the pk-CSM website (<https://biosig.lab.uq.edu.au/pkcsml/>). Molecular docking simulations were conducted on a laptop (Acer Aspire A314-35, Laptop-ML0EUN2).


### Methods

The general research methods for the in vitro and in silico analysis of antilipase, antioxidants, and optimization of effervescent granules from PC are outlined in Figure 1.

### Sample preparation, extraction, and fractionation

The sample used in this study was *Peronema canescens*, Jack (PC), sourced from Kayutanam in Padang Pariaman District, West Sumatra, Latitude : 0°29'46.8312", Longitude : 100°20'7.638", Altitude: Located at an altitude of between 100 to 1000 meters above sea level. Harvested between May and July 2021 from trees measuring 6-7 meters in height. The maceration process was conducted for 3 days (3x24 hours), with occasional stirring and repeated solvent changes using 96% ethanol. The resulting macerate was then filtered and concentrated using a rotary vacuum evaporator, followed by thickening in a water bath at approximately 40°C.<sup>14-16</sup>

Twenty grams of the PC ethanol extract were placed in a beaker with a stir bar and magnetic stirrer. The fractionation process began by adding 100 mL of n-hexane, followed by stirring to separate the liquid from the insoluble extract. This step was repeated 5-6 times, adding 100 mL of n-hexane each time until a clear n-hexane fraction was obtained. Next, 100 mL of ethyl acetate was added to the insoluble n-hexane extract, and the fractionation was repeated until a distinct ethyl acetate fraction was obtained. Subsequently, 100 mL of ethanol solution was used to fractionate the insoluble ethyl acetate extract, repeating the process 5-6 times until a precise ethanol fraction was obtained. The remaining insoluble fraction, treated with ethanol, was designated as the insoluble fraction. The fractions were concentrated using a rotary vacuum evaporator, and the final thickening was performed in a water bath at approximately 50°C to yield a viscous fraction.<sup>14</sup>



**Figure 1:** Research methods for *in vitro* and *in silico* analysis of antilipase, antioxidants, and optimization of effervescent granules from PC.

#### Antioxidant Activity

The PC fraction was dissolved in methanol and prepared at 10, 20, 30, 40, 50, and 60  $\mu\text{g/mL}$ .<sup>17</sup> The antioxidant activity was determined by adding 1.0 mL of the PC fraction solution to a test tube containing 4.0 mL of 0.1 mM DPPH for each concentration. The mixture was homogenized using a vortex for 1 minute and allowed to stand for the designated time for each test solution. The absorbance of the solution was then measured wavelength at 516.0 nm using a UV-Vis spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation, Japan). The same procedure was followed to measure the absorbance of the quercetin standard series.

#### Pancreatic Antilipase Activity

The pancreatic antilipase inhibition activity of the n-hexane, ethyl acetate, ethanol, and insoluble fractions was assessed using 96-well plates and an ELISA reader (Synergy HTX, Agilent, USA). The enzyme stock concentration was approximately 0.1  $\mu\text{g/mL}$ , prepared by dissolving 1 mg of solid porcine pancreatic lipase (PPL) powder in 1 mL of buffer solution (a). The fraction was prepared at a concentration of 500  $\mu\text{g/mL}$  (b), and p-NPB was dissolved in 1% DMSO (c) and subsequently diluted with a 50 mM phosphate buffer (pH 7.2, 0.5%) to a final concentration of 2.5 mM in 100  $\mu\text{L}$  (d). Solutions (a), (b), and (d) were mixed and incubated at 37°C for 10 minutes. Each sample was tested in triplicate. Orlistat was used as a positive control, and 1% DMSO was the negative control without inhibitors. One unit of activity is defined as the reaction rate that generates 1  $\mu\text{mol}$  of p-nitrophenyl butyrate at 37°C. Lipase activity inhibition was expressed as the percentage reduction in activity when PPL was incubated with the test compound.<sup>18</sup>

#### Identification of compounds in the active fraction of PC using GC-MS.

GC-MS analysis was conducted at the integrated laboratory of Universitas Islam Indonesia. The active fraction, prepared at a concentration of 500  $\mu\text{g/mL}$ , was injected in a volume of 1.0  $\mu\text{L}$  for analysis using Gas Chromatography coupled with a Flame Ionization Detector (FID) and Mass Spectrometry (MS) (Shimadzu QP 2010 SE, Shimadzu Corporation, Japan). The mobile phase consisted of chloroform: ethanol mixture (1:1), and the analysis was performed using an Rtx-5 MS column (5% diphenyl / 95% dimethyl polysiloxane) with specifications of 0.25  $\mu\text{m}$  thickness, 30.0 m length, and 0.25 mm inner diameter. The instrument settings included an initial temperature

of 80°C, an injection temperature of 300°C, and an ion source temperature of 250°C. The oven temperature was gradually increased to 330°C at 6°C per minute. The column flow rate was set to 0.74 mL/min with a pressure of 42.3 kPa.<sup>19</sup>

#### Molecular Docking

The receptors used in this study were obtained from the Protein Data Bank in 3D structure format or were drawn using ChemDraw software. These receptors, which are protein macromolecules, were isolated from any irrelevant molecules along with the ligands. The isolation process was performed using Discovery Studio 2021, and the files were saved in pdb format. Optimization involved adding hydrogen atoms, merging nonpolar hydrogens, and calculating Gasteiger charges using AutoDockTools 1.5.6. The resulting file was saved in pdbt format. For ligand preparation, 2D and 3D structures of the selected ligands were created to determine their molecular structure using ChemDraw Pro 12.0 software. The ligands were then prepared using AutoDockTools 1.5.6, where the compound structures were corrected, and Gasteiger charges were added. The prepared ligands were saved and ready for docking.<sup>9,13</sup>

#### Evaluation of Drug Likelihood and ADMET

Assessing the drug-likeness of compounds is based on Lipinski's Rule of Five, which utilizes both experimental and computational approaches to evaluate solubility and permeability in drug discovery and development.<sup>20</sup> The Rule of Five suggests that poor absorption and permeability are likely when the molecular weight exceeds 500, the number of hydrogen bond acceptors is greater than 10, the number of hydrogen bond donors exceeds 5, and the calculated log P (ClogP) is higher than 5 (or MlogP > 4.15). ADMET predictions encompass absorption (CaCO<sub>2</sub> permeability), distribution (BBB permeability), metabolism (CYP2D6 substrate), excretion (total clearance), and toxicity (AMES toxicity).<sup>9</sup>

#### Effervescent formulation

The effervescent formula consists of five different formulations. Each ingredient is weighed and sifted through mesh 30. After sifting, the ingredients are added, extracted, and homogenized. The homogeneous mixture is gradually combined with 95% ethanol until granules are formed. The granules are then sifted through mesh 20/30 and dried. The effervescent formula containing PC extract is presented in Table 1.

**Table 1:** Formulation of Effervescent Granules from PC Extract.

Ingredient	Formula				
	A	B	C	D	E
PC Extract	10%	10%	10%	10%	10%
Tartaric Acid	12.72%	12.30%	13.58%	14%	13.15%
Citric Acid	1.58%	2%	0.72%	0.30%	1.15%
Na. Bicarbonate	14.30%	14.30%	14.30%	14.30%	14.30%
Sucrose	60.40%	60.40%	60.40%	60.40%	60.40%
PVP	1%	1%	1%	1%	1%


### Statistical analysis

The data were expressed as the mean  $\pm$  standard deviation (SD) of experiments in triplicate. This statistical analysis in this study was carried out with one-way anova using a GraphPad Prism (Version 9.5.1 (528), 2023. Graph Pad Inc. software San Diego, CA, USA). IC<sub>50</sub> value represented the concentration of the test sample causing 50% inhibition, in which the value  $<0.05$  was considered significant.

## Results and Discussion

### Antioxidant Activity (DPPH)

The antioxidant activity was determined using the DPPH method, with the results expressed as the Inhibition Concentration 50 (IC<sub>50</sub>). According to,<sup>21</sup> a compound is classified as a powerful antioxidant if its IC<sub>50</sub> is less than 50  $\mu\text{g/mL}$ , strong if IC<sub>50</sub> is less than 100  $\mu\text{g/mL}$ , medium if IC<sub>50</sub> is less than 150  $\mu\text{g/mL}$ , weak if IC<sub>50</sub> is less than 200  $\mu\text{g/mL}$ , and very weak if IC<sub>50</sub> is greater than 200  $\mu\text{g/mL}$ . The IC<sub>50</sub> values obtained in this study for the PC fractions are shown in Figure 2. Quercetin as a positive control had the highest antioxidant activity with



**Figure 2:** Antioxidant activity of PC fractions measured by DPPH assay, ns = not Significant ( $p>0,05$ ), \*\*\*( $p<0,001$ ), QS (Quercetin standard), NHF (n-Hexane fraction), EAF (Ethyl acetate fraction), EF (Ethanol fraction), IF (Insoluble fraction).

an IC<sub>50</sub> value of 23.77  $\mu\text{g/mL}$ , which is classified as very strong according to the criteria established by,<sup>21</sup> and the ethanol fraction with C50 of  $47.27 \pm 1.90 \mu\text{g/mL}$ , which is categorized as very strong exhibits stronger antioxidant activity than the other fraction. In contrast, the ethyl acetate fraction exhibited a much weaker antioxidant potential with an IC<sub>50</sub> of  $201.89 \pm 20.08 \mu\text{g/mL}$ , classified as very weak. The N-hexane fraction showed the highest IC<sub>50</sub> value at  $685.70 \pm 32.15 \mu\text{g/mL}$ , indicating very weak antioxidant activity. The insoluble fraction had an IC<sub>50</sub> value of  $86.09 \pm 7.94 \mu\text{g/mL}$ , falling under the strong category for antioxidant activity. with the order being Ethanol fraction > ethanol extract > insoluble fraction > ethyl acetate

fraction > n-hexane fraction. The OH group on quercetin can function as a hydrogen donor. Quercetin can donate hydrogen atoms to neutralize free radicals, reducing the potential for cell oxidative damage.<sup>21</sup> Polar molecules such as flavonoids, phenolics, and glycosides are known for their antioxidant properties. The Ethanol fraction, having the lowest IC<sub>50</sub> value, shows a significant difference, as denoted by four stars, when compared to the ethyl acetate and n-hexane fractions. Polar fractions, such as the ethanol and insoluble fractions, contain a higher number of substances capable of donating hydrogen atoms, leading to the formation of a reduced (nonradical) form, which is indicated by the loss of the purple color, as described in reference,<sup>21</sup> This process reduces 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals into a stable nonradical hydrazine derivative, resulting in a color change. The DPPH antioxidant activity of the PC fractions is presented in Figure 2.

### In vitro Pancreatic Antilipase Activity

The inhibition of pancreatic lipase involves the interaction between lipase enzymes and their substrates. This test uses PNPB (P-nitrophenyl butyrate) as the substrate and Porcine Pancreatic Lipase (PPL) as the enzyme. The inhibitory effect is assessed by measuring the hydrolysis of P-nitrophenyl butyrate to P-nitrophenol at a wavelength of 405 nm using an ELISA reader. Pancreatic lipase inhibition by PC was tested at a concentration of 200  $\mu\text{g/mL}$ , with PPL solution in phosphate buffer (pH 7.2) and PNPB solution. One unit of activity is defined as the reaction rate that produces 1  $\mu\text{mol}$  of p-nitrophenol in 10 minutes at 37°C. The inhibition of lipase activity is expressed as the percentage reduction in activity when PPL is incubated with the test compound. PPL was chosen as the enzyme model due to its similarities with human pancreatic lipase (HPL), exhibiting comparable kinetics and enzyme characteristics.<sup>22</sup> According to,<sup>18</sup> antilipase activity is robust when the inhibition percentage exceeds 50%. The results of the PC fraction at a concentration of 200  $\mu\text{g/mL}$  are shown in Table 2. Similar to our findings, a recent study demonstrated that flavonoid-rich plant extracts exhibit strong antioxidant and antilipase activities, making them potential candidates for anti-obesity therapy.<sup>5</sup>

**Table 2:** Pancreatic antilipase activity of the PC fraction


Sample	% inhibition of $\pm$ SD	Types of Antilipase <sup>2</sup>
Orlistat Standard	61.64 $\pm$ 9.11	Strong
N-hexane fraction	18.66 $\pm$ 5.21	Weak
Ethyl Acetate Fraction	67.65 $\pm$ 8.04	Strong
Ethanol Fraction	14.22 $\pm$ 4.69	Weak
Insoluble fraction	6.45 $\pm$ 1.13	Weak

Obesity triggers inflammatory processes in excess lipogenesis, inhibits lipolysis, and increases adipocyte apoptosis. This matter increases the release of Reactive Oxygen Species (ROS) and will cause oxidative stress. Oxidative stress caused by obesity can result in damage to cells

and tissues and trigger the emergence of degenerative diseases.<sup>23</sup> Antioxidants help neutralize radicals and reduce the risk of complications from degenerative diseases. Therefore, supplementation with antioxidants will reduce the risk of obesity-related complications and oxidative stress.<sup>24</sup> The ethanol fraction proved the most potent antioxidant agent, while ethyl acetate showed pancreatic antilipase activity. Differences in the compounds that guide these two activities. These results follow research on other materials that show that the ethyl acetate fraction has higher anti-obesity activity than the ethanol fraction. The ethanol fraction has stronger antioxidant activity than the ethyl acetate fraction. Regarding compound content, the ethanol fraction has higher total phenolic content and total flavonoid content than the ethyl acetate fraction.<sup>25</sup> It is necessary to prove the levels of PC leaf extracts and fractions regarding the levels of compounds, not only phenolics and flavonoids but also other groups of compounds. So, to support both activities, an effervescent preparation will be made from PC leaves extract. Effervescent granules are preferred because they are easy to use, dissolve easily in water, and taste better. Compared to tablet preparations, effervescent granules reduce stomach irritation, which sometimes occurs when tablet preparations are swallowed directly, and reduce the risk of blockage in the esophagus because they are completely dissolved in liquid before consumption.

#### *In silico Pancreatic Antilipase Activity*

Molecular docking validation is performed by redocking. The redocking results of the native ligands are shown in Figure 3. The blue structure represents the initial conformation of the enzyme-ligand complex before molecular docking. In contrast, the red structure shows the optimized docking pose of the native ligand after computational refinement. The close alignment between the pre- and post-docking structures, indicated by a root mean square deviation (RMSD) value below 2 Å, confirms the reliability and accuracy of the docking method used in this study.



**Figure 3:** 3D structure of the pancreatic lipase enzyme (PDB ID 1LPB) showing an overlay of the blue (before) and red (after) molecular docking of the native ligand.

The GC-MS identification revealed that the primary compound in the active fraction was Trilaurin, accounting for 54.83% of the area and a similarity index of 59%. The three compounds identified by GC-MS were then prepared for further *in silico* molecular docking tests. Molecular docking of the quercetin standard, Orlistat, and the three GC-MS compounds was performed to compare the compounds obtained from pancreatic antilipase testing with the standards known to exhibit pancreatic antilipase activity, as reported in previous studies. The results of the molecular docking are presented in Table 3.

The most promising compound is Dimethyl Tetracycline, which exhibits the lowest binding energy and inhibition coefficient values compared to the Orlistat standard. The Dimethyl Tetracycline has antilipase activity similar to Orlistat. In addition to the binding energy and inhibition coefficient, pancreatic antilipase activity is evaluated based on its interaction with the amino acid serine 152. After analyzing the GC-MS-identified compounds through *in silico* tests, any compounds that bind to amino acid residues can potentially serve as alternative ligands to replace Orlistat. The next step is to assess whether these compounds can be used as oral drugs by evaluating them according to Lipinski's Rule of Five, as shown in Table 4.

**Table 3:** Molecular docking scores and interactions of the identified compounds.

No	Structure Name	Binding Energy	Amino Acid Bonds
1	Orlistat	-6.62	Gly 76, Phe 77, Ile 78, Asp 79, Tyr 114, His 151, <b>Ser 152</b> , Leu 153, Ala 178, Glu 179, Pro 180, Ile 209, Phe 215, Arg 256, Ala 259, His 263, Leu 264
2	Quercetin	-8.28 (Run of 83)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Ala B:178, Glu B:179, Pro B:180, Ile B:209, Phe B:215, Gly B:216, Arg B:256, His B:263.
3	Dimethyl Tetracycline	-7.78 (Run of 14)	Gly B:76, Phe B:77, Ile B:78, Asp B:79, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Phe B:215, Arg B:256, Asp B:257, Ala B:259, Ala B:260, His B:263, Leu B:264.
4	2-methoxy-5H-indole[2,3-b]quinoxaline	-7.25 (Run of 77)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Phe B:215, His B:263, Leu B:264.
5	Trilaurin	-3.52 (Run of 7)	Ile B:78, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Leu B:213, Phe B:215, Trp B:252, Thr B:255, Arg B:256, Ala B:259, Ala B:260, His B:263, Leu B:264.

**Table 4:** Predicted Lipinski's Rule of Five for the Ligands.

No	Molecular Name	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar Activity (PSA)	Voltage
1	Quercetin	302.24	1.99	5	7	122.11	
2	Dimethyl Tetracycline	430.41	-0.55	6	9	176.06	
3	2-methoxy-5H-indolo[2,3-b]quinoxaline	249.27	3.27	1	3	108.60	
4	Trilaurin	639.02	11.75	0	6	278.43	

Table 4 indicates that the natural ligand candidates suitable for use are Quercetin, Dimethyl Tetracycline, and 2-methoxy-5H-indolo[2,3-b]quinoxaline. These compounds meet Lipinski's Rule of Five, with molecular weights under 500 Da, hydrogen bond donors not exceeding 5, hydrogen bond acceptors not exceeding 10, partition coefficients (log P) under 5, and polar surface areas (PSA) under 1025 Å<sup>2</sup>, making them suitable for oral administration. In addition to adhering to Lipinski's Rule, candidate compounds must also pass pharmacokinetic and toxicity assessments conducted using pkCSM software. The results of drug-likeness analysis, along with absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions, are presented in Table 5. A compound is considered to have blood-brain barrier (BBB) permeability if its log BB value in the distribution phase

is greater than 0.3. Molecules with a log BB value below 0.1 are not effectively distributed in the brain. CYP2D6 metabolic parameters predict whether cytochrome P450 will likely metabolize a given molecule. The total clearance (CL<sub>tot</sub>) parameter indicates excretion rates in log (ml/min/kg). Drug clearance primarily occurs through renal and hepatic clearance (kidney excretion) (liver metabolism and bile excretion). Ames toxicity testing is a commonly used method to evaluate the mutagenic potential of compounds through bacterial assays. Among the candidates, Dimethyl Tetracycline meets both Lipinski's rule of five and ADMET prediction criteria. The Evaluation of granule preparations includes tests for flow rate, angle of repose, bulk density, tapped density, Carr's compressibility index, and Hausner ratios.<sup>26</sup>

**Table 5:** ADMET Prediction for Compounds from the Ethyl Acetate Fraction of PC

No	Molecular Name	Absorption (CaCO <sub>2</sub> Permeability) (log P <sub>app</sub> in 10 <sup>-6</sup> cm/sec)	Distribution (VD <sub>ss</sub> (human)) (log L/kg)	Metabolism (CYP2D6) (YES/NO)	Excretion (Total clearance) (log ml/min/kg)	AMES Toxicity (YES/NO)	Hepatotoxicity	Skin Sensitization
1	Orlistat	0.40	-1.02	No	1.68	No	Yes	No
2	Quercetin	-0.28	0.06	No	0.46	No	No	No
3	Dimethyl tetracycline	-0.01	0.61	No	0.35	No	No	No
4	2-methoxy-5H-indolo[2,3-b]quinoxaline	1.30	-0.01	No	0.77	Yes	Yes	No
5	Trilaurin	0.14	-0.82	No	2.23	No	No	No

In this study, optimization using design experts focuses on flow rate, angle of repose, and Carr's index. Good flow characteristics are defined by the ability of particles to flow independently without clumping, influenced by gravitational force.<sup>27</sup> The flow rate test indicates that all the effervescent granules produced exhibit excellent flow, with a suitable flow time greater than 10 grams per second. The flow rate results of the effervescent granules for each formula are presented in Table 6. Based on the observations for Formula 3 and Formula 4 in Table 6, these formulas exhibit a faster flow time due to

a higher tartaric acid content than Formula 1 and Formula 2. Tartaric acid has a higher density than citric acid, which allows granules with a greater tartaric acid content to flow more rapidly because of the increased gravitational force.<sup>27</sup> The angle of repose is the stable angle formed between a pile of cone-shaped particles and a horizontal plane. If the angle is less than 30°, the material is considered to flow easily. Conversely, if the angle is 40° or greater, the material will likely be difficult to flow. The shape of the granules can influence the value of the angle of repose.<sup>28</sup>

**Table 6:** Flow rate, angle of repose, and bulk density of the effervescent granules from PC.

Formula	Flow rate	Angle of repose	Bulk density (g/ml)	Tapped density (g/ml)	Hausner ratios	Carr's compressibility index (%)
A	18.66	25.05	0.52	0.56	1.07	6.25
B	20.43	25.85	0.53	0.55	1.04	4.26

C	20.79	27.16	0.53	0.56	1.07	6.38
D	20.63	24.09	0.50	0.56	1.14	11.98
E	18.74	26.03	0.49	0.53	1.06	5.99

Table 6 presents the results of the stationary angle test for formulas 1-5, all of which are below 30°. A stationary angle of no more than 30° indicates excellent flow properties, meaning all the formulas demonstrate good flow behavior. The granules flow more quickly and easily with less friction and tensile force between them. Furthermore, smaller granule sizes increase cohesiveness, reducing the flow velocity and resulting in a higher stationary angle.<sup>29</sup> Determining bulk density includes measuring the actual weight, compressive weight, Hausner factor, and percent compressibility. The Hausner factor is used to compare the actual and compressive weights, helping to assess the flow or free-flowing properties of the powder. All seven formulas meet the qualification of having a Hausner factor of less than 1.25, indicating good flow characteristics. Granule compressibility refers to the ability of the granules to maintain compactness under pressure. Factors such as porosity, type density, particle shape, and moisture content can affect the flow properties of the granules. Good flow properties ensure easier molding of the granules and help maintain uniform weight. The results for the Hausner factor and compressibility are shown in Table 6. The percent compressibility results indicated that Carr's index ranged from 4.26% to 14.59%, which aligns with the literature stating that granules with a Carr's index value below 15% demonstrate good flowability.

The optimal formula using Design Expert is intended to generate the most efficient formula based on the response data from the prepared parameters. The response data, analyzed through ANOVA in Design

Expert, is processed to identify the optimal formula.<sup>10</sup> The ideal formula is the one with a desirability value closest to 1. Using the simplex lattice design method in the Design Expert software, the optimal formula was determined to have 65.81 mg of tartaric acid and 4.19 mg of citric acid, with a desirability value of 0.86. Before finalizing, the optimal formula requires verification. The results of design expert optimization formula 1 solution and formula 2 solution are shown in Figure 4, with the formula test results from the design expert optimization provided in Table 7. This study utilized a Design Expert to optimize the effervescent granule formulation containing PC extract Figure 4. This software allows integrated analysis to evaluate interactions between formulation variables and determine the optimal combination of ingredients used. The optimization of the effervescent granule formulation resulted in two optimal formulas. Formula 1: 13.16% tartaric acid and 0.84% citric acid. Formula 2: 13.21% tartaric acid and 0.80% citric acid. The desirability score for both formulas was 0.862, indicating a high optimization level. The flow rate and angle of repose parameters from the optimized formulas showed no significant differences compared to laboratory experimental results ( $p > 0.05$ ), suggesting the predictive model's accuracy in Figure 5. Based on the GraphPad Version 9.5.1 (528), 2023 statistical analysis Figure 5, the flow rate and angle of repose values from Formula 1 and Formula 2 in both the Design Expert optimization and the actual test results showed no significant difference, indicating that the optimization and laboratory test produced similar outcomes.





Figure 4: Design Expert optimization (A) Formula 1 Solution (B) Formula 2 Solution

## Design expert vs test formula effervescent



**Figure 5:** Formula optimization using Design expert vs test, ns = not Significant ( $p > 0.05$ ), \* ( $p < 0.05$ ), F1 DE (Formula 1 Design Expert), F2 DE (Formula 2 Design Expert), F1 Test (Formula 1 test), F2 Test (Formula 2 test).

**Table 7:** Results of the formula test from Design Expert Optimization.

Formula	Flow rate	Angle of repose	Bulk density (g/ml)	Tapped density (g/ml)	Hausner ratios	Carr's compressibility index (%)
1	20.50	27.61	0.52	0.60	1.17	14.59
2	17.96	24.10	0.54	0.59	1.10	8.68

However, Carr's index test revealed a discrepancy between the Design Expert optimization and the test results, as effervescent granules are highly sensitive to room temperature, which may have influenced the test outcomes. Additional research is needed to isolate compounds from PC based on the results of the *in silico* data. An integrated study of network pharmacology and component analysis should be conducted to explore the molecular mechanisms of PC extract in treating obesity.<sup>30</sup> *In silico* anti-obesity activity should be explored using additional receptor targets, as the anti-obesity mechanism extends beyond pancreatic lipase. Central nervous system mechanisms can be investigated, targeting receptors such as GLP-1 (liraglutide), 5-HT<sub>2c</sub> (lorcaserin), and TAAR-1 (phentermine). *In vivo*, testing is also recommended to validate the efficacy and safety of these compounds in animal models and clinical settings. Furthermore, advanced formulations, such as nanocarrier systems, could be developed to enhance PC-based products' bioavailability and therapeutic potential. Future studies should focus on the antioxidant properties of the sample using comprehensive methods.<sup>31</sup> These include determination of hydrogen peroxide scavenging capacity, determination of ferric reducing power, determination of nitric oxide (NO) scavenging activity, determination of ascorbic acid, determination of vitamin E, and assessment of lipid peroxidation inhibition. These assays will provide a deeper understanding of the antioxidant potential and the mechanisms by which the sample mitigates oxidative stress.

## Conclusion

The antioxidant activity of the PC fraction, evaluated using the DPPH method, revealed that the ethanol fraction exhibited significantly stronger antioxidant activity ( $IC_{50} = 47.27 \pm 1.90 \mu\text{g/mL}$ ) compared to the ethyl acetate fraction ( $IC_{50} = 201.89 \pm 20.08 \mu\text{g/mL}$ ,  $p < 0.05$ ). This difference highlights the greater presence of polar compounds, such as flavonoids and phenolics, in the ethanol fraction. Among the identified compounds, dimethyl tetracycline showed the lowest

binding energy (-7.78 kcal/mol) in molecular docking studies, suggesting its potential as a strong pancreatic lipase inhibitor. This was further supported by its adherence to Lipinski's Rule of Five, indicating good oral bioavailability. Formula optimization using the Design Expert software resulted in two formulae. The flow rate and angle of repose values from the design expert and the laboratory tests did not show significant differences, indicating that the optimization and experimental results aligned. However, differences were observed in the Carr's Index test between the design expert optimization and the lab results.

## Conflict of Interest

The authors declare no conflict of interest.

## Authors' Declaration

The authors affirm that the work presented in this article is original, and they accept full responsibility for any claims related to the article's content.

## Acknowledgments

Acknowledgment Hibah Penelitian Dan Pengabdian Kepada Masyarakat Akademik Pendidikan Tinggi Vokasi supports this work. Contract Number: 103/SPK/D.D4/PPK.01.APTV/III/2024. Derivative Contract Number 018/LL6/PPM-V/AL.04/2024.

## References

- Ministry of Health RI. Riskesdas 2018. Ministry of Health RI. 2018;53(9):1689–1699.
- Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomed and Pharm.* 2020;128(110314): 1-9.

3. Ladeska V, Elya B, Hanafi M, Kusmardi, Rohmat SS. Pharmacognostic Evaluation and Antioxidant Activities of *Tetracera indica* (Christm. and Panz.) Merr. Hayati. 2024;31(5):836–853.
4. Romiti GF, Corica B, Raparelli V, Basili S, Cangemi R. The interplay between antioxidants and the immune system: A promising field, still looking for answers. *Nutrients*. 2020;12(6):10–13.
5. Li S, Pan J, Hu X, Zhang Y, Gong D, Zhang G. Kaempferol inhibits the activity of pancreatic lipase and its synergistic effect with Orlistat. *J Funct Foods*. 2020;72(104041): 1-11.
6. Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: Self controlled case series study in UK Clinical Practice Research Datalink. *British Med J*. 2013;346(7906):1–9.
5. Rahardhian MRR, Susilawati Y, Sumiwi A, Muktiwardoyo M, Muchtaridi M, Sumiwi SA. A Review Of Sungkai (*Peronema Canescens*): Traditional Usage, Phytoconstituent, And Pharmacological Activities. *Int J. App Pharm*. 2022;14(Special issue 5):15–23.
6. Chike-Ekwughe A, John-Africa LB, Adebayo AH, Ogunlana OO. Evaluation of the In vitro and In silico Pancreatic Lipase Inhibitory Activity of Ethanol Leaf Extract of *Tapinanthus cordifolius* and its Effect on Oral Glucose Tolerance in Mice. *Trop J Nat Prod Res*. 2024;8(8):8168–8175.
7. Rahardhian MRR, Susilawati Y, Musfiroh I, Febriyanti RM, Muchtaridi, Sumiwi SA. In Silico Study of Bioactive Compounds From Sungkai (*Peronema Canescens*) As Immunomodulator. *Int J. App Pharm*. 2022;14(Special Issue 4):135–141.
10. Indriastuti M, Astuti AF, Anna L Yusuf, Akbar F, Kurnia R R. Optimization of Formula Preparation of Effervescent Granules of Moringa Leaf Extract (*Moringa oleifera* L.). *Med Sains : JIK*. 2023;8(2):519–528.
11. Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD. Novel pyrimidopyridazine analogs as serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands for the treatment of obesity. *Eur J Med Chem*. 2013;63:558–569.
12. Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers SP. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. *Mol Metab*. 2024;80(101883): 1-14.
13. Suharsanti R, Wahyuono S, Yuniarti N, Astuti P. Molecular Docking of Lipase Inhibitory Activities, Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa* Roxb Rhizome. *Int J. Pharm Res and App*. 2024;9(2):162–174.
14. Rahardhian MRR, Suharsanti R, Sugihartini N, Lukitaningsih E. In vitro assessment of total phenolic, total flavonoid and sunscreen activities of crude ethanolic extract of belimbing
28. Aulton M. *Pharmaceutics: the Science of Dosage Form Design*. 2nd ed. Edinburgh: Churchill Livingstone; 2002.
29. Lee, R. E. *Effervescent Tablets: Key Facts About A Unique, Effective Dossage Form*. CSC Publishing; 2004.
30. Mutiah R, Briliana MSD, Ahmad ARA, Fauziyah B, Janaloka NA, Suryadinata A. Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular wuluh (*Averrhoa bilimbi*) fruits and leaves. *J. Glob Pharm Tech*. 2019;11(4):308–313.
15. Syofyan, S, Almahdy, A, Wulandari, A, Alen, Y, Diliarosta, S, Kurniawan, H, Noverial, N, Putra, P.P, Dillasamola, D. Effects of Ethanol Extract of Sungkai (*Peronema canescens* Jack.) on Fertility of Female Wistar Mice (*Mus musculus* L.). *Trop J Nat Prod Res*. 2023;7(5):2863–2866.
16. Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Effect of Different Solvent on Total Phenolic, Total Flavonoid, and Sun Protection Factor of Belimbing Wuluh (*Averrhoa bilimbi* linn.) Fruits Fraction. *J. Glob Pharm Tech*. 2019;11(1):154–162.
17. Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Potency Of Belimbing Wuluh (*Averrhoa Bilimbi*) As Antioxidat And Tyrosinase Inhibitor For Skin Whitening Product. *J. Pharm Res*. 2019;8(4):151–154.
18. 2.Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomed and Pharm*. 2020;128(110314): 1-9.
19. Falodun A, Siraj R, Choudhary MI. GC-MS Insecticidal Leaf essential oil of *P. staudtii* Hutch and Dalz (Icacinaceae). *Trop J. Pharm Res*. 2009; 82:139-143.
20. Puspitasari YE, Alfikri MA, Sitanggang R, Tambunan JE, Hardoko H. In Silico Analysis of Phenolic Compounds from *Ceriops decandra* Griff. Leaves and Molecular Interaction as Anti Diabetes. *Sci and Tech Ind*. 2023;8(4):542–553.
21. Molyneux P. The Use of the Stable Free Radical Diphenylpicrylhydrazyl (DPPH) for Estimating Antioxidant Activity. *Songkla J. Sci and Tech*. 2004, 26(2) : 211-219.
22. Alias N, Leow TC, Ali MSM, Tajudin AA, Salleh AB, Zaliha RN, Rahman RA. Anti-obesity Potential of Selected Tropical Plants via Pancreatic Lipase Inhibition. *Adv Obes Weight Manag Control*. 2017;6(4): 122-131.
23. Halliwell B, Gutteridge JMC. *Free Radicals in Biology and Medicine*. Free Radicals in Bio and Med. 2015
24. Fernández A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González A, Esquivel-Chirino C. Inflammation, oxidative stress, and obesity. *Int J Mol Sci*. 2011;12(5):3117–3132.
25. Suharsanti, Wahyuono S, Yuniarti N, Astuti P. Antioxidant Activity and Pancreatic Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions. *J. Bio*. 2024;9(11):228–243.
26. Shah RB, Tawakkul MA, Khan MA. Comparative Evaluation of flow for pharmaceutical powders and granules. *AAPS Pharm Sci Tech*. 2008;9(1):250–258.
27. Rani KC, Parfati N, Muarofah D, Sacharia SN. Meniran (*Phyllanthus niruri* L.) Herbal Effervescent Granule Formulation with Variations of Suspending Agent Xanthan Gum, CMC-Na, and Combination CMC-Na-Microcrystalline Cellulose RC- 591. *J. Sci Pharm.and Clin*. 2020;7(1):39-51.
31. Okolie NP, Falodun A, Oluseyi D. Evaluation of the Antioxidant Activity of Root Extract of Pepper Fruit (*Denmetia Tripetala*), and It's Potential for the Inhibition of Lipid Peroxidation. *Afr J. of Trad Compl and Altern Med*. 2014;11(3):221–227.

***In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack***Muhammad R. R. Rahardhian<sup>1</sup>, Nurchasanah<sup>1</sup>, Yasmiwar Susilawati<sup>2</sup>, Sri A. Sumiwi<sup>3</sup>, Dewi Ramonah<sup>1</sup>, Chintiana N. Putri<sup>4</sup>, Ririn Suharsanti<sup>1\*</sup><sup>1</sup>Department of Pharmaceutical Biology, Sekolah Tinggi Ilmu Farmasi Yayasan Pharmasi Semarang, Indonesia.<sup>2</sup>Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.<sup>3</sup>Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia.<sup>4</sup>Department of Pharmaceutical Biology, Faculty of Pharmacy, Universitas Islam Sultan Agung, Semarang, Indonesia.

## ARTICLE INFO

## ABSTRACT

*Article history:*

Received 10 November 2024

Revised 06 December 2024

Accepted 28 December 2024

Published online 01 March 2024

**Copyright:** © 2025 Rahardhian *et al.* This is an open-access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Obesity results from prolonged energy imbalance, with anti-obesity treatment targeting pancreatic lipase inhibition. *Peronema canescens* Jack. (PC) known as Sungkai, has traditionally been used to treat various ailments. This study aimed to assess PC antioxidant and antilipase activities and optimize effervescent granule formulations. Phytochemical screening and thin-layer chromatography (TLC) were performed, followed by antioxidant analysis using 2,2-diphenyl-1-picrylhydrazyl (DPPH) and pancreatic antilipase activity, using the p-NPB substrate, were employed. The ethanol fraction of PC demonstrated potent antioxidant activity ( $IC_{50} = 47.27 \mu\text{g/mL}$ ), while the insoluble fraction showed the highest pancreatic antilipase activity (67.65%). Gas chromatography-mass spectrometry (GC-MS) identified active compounds, including dimethyl tetracycline, 2-methoxy-5H-indolo[2,3-b] quinoxaline, and trilaurin, with molecular docking study indicating dimethyl tetracycline was the most effective antilipase candidate, binding to the pancreatic receptor (PDB ID: 1LPB). This compound also met Lipinski's Rule of Five and ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity), suggesting favorable pharmacokinetics and safety. Evaluation of effervescent granules included angle of repose, bulk density, and tapped density. Optimization of tartaric and citric acid concentration using Design Expert 13 yielding two optimal formulas: Formula 1 with 13.16% tartaric acid and 0.84% citric acid, and Formula 2 with 13.21% tartaric acid and 0.80% citric acid. PC leaves have the potential to be an antioxidant and anti-obesity and can be developed into effervescent formula.

**Keywords:** *Peronema Canescens* Jack., Antioxidant, Effervescent granules, Molecular docking, Pancreatic antilipase.

**Introduction**

The increasing prevalence of degenerative diseases in Indonesia, alongside infectious diseases, indicates changing health challenges, with obesity emerging as a major concern. RISKESDAS (Indonesia's basic health research) data reveal a rise in obesity rates from 14.8% in 2013 to 21% in 2018.<sup>1</sup> Factors that contribute to obesity encompass environmental factors, urban living, and eating patterns. Diets high in fats and sugars but low in fiber cause an energy imbalance, which, when combined with triglyceride buildup, this imbalance triggers oxidative stress and inflammatory responses within the body.<sup>2</sup> This ongoing inflammation, fat accumulation, and suppression of fat breakdown causes adipocyte apoptosis, producing Reactive Oxygen Species (ROS) that harm cells and tissues, raising the risk of degenerative diseases.<sup>3</sup> Antioxidants are essential for neutralizing ROS, helping to reduce the risk of degenerative diseases linked to oxidative stress.<sup>4</sup> In the context of medical treatments, FDA-approved drugs for obesity aim to either decrease calorie absorption or control appetite.

Central nervous system (CNS) suppressants, including lorcaserin, liraglutide, phentermine-topiramate, and naltrexone/bupropion, work by targeting appetite-regulating receptors such as 5HT<sub>2c</sub>, GLP-1, and TAAR-1. On the other hand, Orlistat acts as a lipase inhibitor, reducing the absorption of dietary fats by approximately 30%.<sup>5</sup> People in Indonesia prefer using herbal medicine due to its natural properties, which are perceived as safer and less likely to cause unwanted side effects. In general, herbal medicines are more affordable than synthetic drugs. They also contain a variety of plant-based ingredients. Herbal medicine is considered effective for targeting multiple health issues. Conversely, Orlistat is a therapeutic agent for obesity that reduces calorie absorption in the intestinal tract.<sup>5</sup> Nevertheless, the effectiveness of Orlistat is constrained by side effects such as gastrointestinal problems, including oily stools, flatulence, and rectal discharge.<sup>6</sup> These limitations highlight the importance of seeking complementary or alternative treatments, especially natural ones with fewer side effects and potential long-term benefits. Herbal medicine presents a promising alternative to synthetic drugs for managing obesity, thanks to its safety, availability, and ability to target multiple mechanisms. *Peronema canescens* Jack. (PC), locally known as Sungkai, has attracted attention for its potential therapeutic benefits. Traditionally utilized in Indonesian medicine, the leaves of PC contain secondary metabolites like phenols, triterpenoids, flavonoids, tannins, alkaloids, steroids, and saponins, which have been reported to exhibit anti-inflammatory, antioxidant, antidiabetic, and immune-boosting properties.<sup>7</sup> The bioactive compounds in PC position it as a promising candidate for anti-obesity treatments, primarily by inhibiting pancreatic lipase, which helps reduce lipid absorption. Recent studies have highlighted the potential of plant-based compounds for pancreatic lipase inhibition, particularly in

\*Corresponding author. Email: [ririnsuharsanti@gmail.com](mailto:ririnsuharsanti@gmail.com)  
Tel: +62 821 3692 3586

**Citation:** Rahardhian MRR, Nurchasanah, Susilawati Y, Sumiwi SA, Ramonah D, Putri CN, Suharsanti R. In Vitro and in Silico Analysis of Antilipase, Antioxidant, and Optimization of Granule Effervescent from *Peronema canescens* Jack. Trop J Nat Prod Res. 2025; 9(2): 545 – 553 <https://doi.org/10.26538/tjnpr/v9i2.19>

Official Journal of Natural Product Research Group, Faculty of Pharmacy, University of Benin, Benin City, Nigeria

treating obesity.<sup>8</sup> For example, *in silico* modeling allows for structural predictions and identifying binding sites, enhancing target interaction in drug development.<sup>9</sup> Moreover, effervescent granules offer a convenient dosage form by combining acidic and alkaline compounds that release CO<sub>2</sub> upon dissolution. These granules provide high solubility, ease of use, and rapid absorption, making them an ideal delivery system for antioxidants and antilipase agents.<sup>10</sup> Given the therapeutic potential of PC, developing a granule formulation can enhance the accessibility and effectiveness of its bioactive components. While traditional treatments like GLP-1 receptor agonists have proven effective in managing obesity, they are especially beneficial for patients with comorbidities such as type 2 diabetes. Other plant-based studies indicate that appetite suppression may occur by activating the 5-HT<sub>2C</sub> receptor.<sup>11</sup> Additionally, TAAR1 agonists present the potential to address maladaptive eating behaviors associated with metabolic disorders.<sup>12</sup> Inhibitors targeting the lipase enzyme, such as those aimed at PDB proteins 1LPB and 5ZUN, further reinforce the potential of lipase inhibition as a therapeutic target for anti-obesity drugs.<sup>13</sup> The methods employed in this study, including phytochemical screening, DPPH antioxidant assay, pancreatic antilipase activity testing, and molecular docking, are specifically chosen to assess the bioactive compounds in PC and their potential for obesity treatment. These approaches are highly relevant as they combine experimental and computational techniques to identify promising antilipase candidates. This is the first study to comprehensively evaluate PC antioxidant and antilipase activities while optimizing effervescent granule formulations. The integration of *in vitro* and *in silico* approaches in this study provides a novel insight into the potential therapeutic uses of PC in combating obesity. This holistic approach highlights the potential of PC as a safe, accessible, and effective therapy for obesity.

## Materials and Methods

### Materials

Rotary evaporator (Heidolph-G3), Silica Gel F254 plates, UV lamps (254 nm and 366 nm, Evaco GL 220V 50Hz T8 15W), micropipettes (Socorex & Dragon Lab), vortex mixers, UV-Vis Spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation, Japan), ELISA reader (Synergy HTX, Agilent, USA), GC-MS (Shimadzu QP 2010 SE, Shimadzu Corporation, Japan). *Peronema canescens* Jack (PC), ethanol, n-hexane, ethyl acetate, FeCl<sub>3</sub>, MgSO<sub>4</sub>, hydrochloric-ethanolic acid mixture (1:1), hydrochloric acid, Liebermann-Burchard reagent, 2,2-diphenyl-1-picrylhydrazyl (DPPH, Sigma-Aldrich, USA, 97% purity, analytical grade) was used for antioxidant assays, quercetin, p.a. methanol, crude porcine pancreatic lipase (PPL), P-nitrophenyl butyrate (p-NPB, Sigma-Aldrich, USA, 98% purity, analytical grade) was used for pancreatic antilipase activity, phosphate buffer (pH 7.2), DMSO, and orlistat standard.

### Hardware and Software

Some of the software used, including the receptors for the test, can be downloaded from the RCSB PDB website (<https://www.rcsb.org/>). The ligands used in the test are available for download from the PubChem website (<https://pubchem.ncbi.nlm.nih.gov/>). Test ligands and receptors were created using ChemDraw Professional 15.0, Chem3D 15.0, Biovia Discovery Studio 2021, Command Prompt, and AutoDock Tools 1.5.6. Docking visualizations were performed using Biovia Discovery Studio 2021. Lipinski's Rule of Five testing was conducted using the Lipinski rules available at (<http://www.scfbio-itt.res.in/software/drugdesign/lipinski.jsp>). Pharmacokinetics and toxicology testing were performed using the pk-CSM website (<https://biosig.lab.uq.edu.au/pkcs/>). Molecular docking simulations were conducted on a laptop (Acer Aspire A314-35, Laptop-MLOEUN2).


### Methods

The general research methods for the *in vitro* and *in silico* analysis of antilipase, antioxidants, and optimization of effervescent granules from PC are outlined in Figure 1.

### Sample preparation, extraction, and fractionation

The sample used in this study was *Peronema canescens*, Jack (PC), sourced from Kayutanam in Padang Pariaman District, West Sumatra, Latitude : 0°29'46.8312", Longitude : 100°20'7.638", Altitude: Located at an altitude of between 100 to 1000 meters above sea level. Harvested between May and July 2021 from trees measuring 6-7 meters in height. The maceration process was conducted for 3 days (3x24 hours), with occasional stirring and repeated solvent changes using 96% ethanol. The resulting macerate was then filtered and concentrated using a rotary vacuum evaporator, followed by thickening in a water bath at approximately 40°C.<sup>14-16</sup>

Twenty grams of the PC ethanol extract were placed in a beaker with a stir bar and magnetic stirrer. The fractionation process began by adding 100 mL of n-hexane, followed by stirring to separate the liquid from the insoluble extract. This step was repeated 5-6 times, adding 100 mL of n-hexane each time until a clear n-hexane fraction was obtained. Next, 100 mL of ethyl acetate was added to the insoluble n-hexane extract, and the fractionation was repeated until a distinct ethyl acetate fraction was obtained. Subsequently, 100 mL of ethanol solution was used to fractionate the insoluble ethyl acetate extract, repeating the process 5-6 times until a precise ethanol fraction was obtained. The remaining insoluble fraction, treated with ethanol, was designated as the insoluble fraction. The fractions were concentrated using a rotary vacuum evaporator, and the final thickening was performed in a water bath at approximately 50°C to yield a viscous fraction.<sup>14</sup>



**Figure 1:** Research methods for *in vitro* and *in silico* analysis of antilipase, antioxidants, and optimization of effervescent granules from PC.

### Antioxidant Activity

The PC fraction was dissolved in methanol and prepared at 10, 20, 30, 40, 50, and 60 µg/mL.<sup>17</sup> The antioxidant activity was determined by adding 1.0 mL of the PC fraction solution to a test tube containing 4.0 mL of 0.1 mM DPPH for each concentration. The mixture was homogenized using a vortex for 1 minute and allowed to stand for the designated time for each test solution. The absorbance of the solution was then measured wavelength at 516.0 nm using a UV-Vis spectrophotometer (Shimadzu UV-1780, Shimadzu Corporation, Japan). The same procedure was followed to measure the absorbance of the quercetin standard series.

### Pancreatic Antilipase Activity

The pancreatic antilipase inhibition activity of the n-hexane, ethyl acetate, ethanol, and insoluble fractions was assessed using 96-well plates and an ELISA reader (Synergy HTX, Agilent, USA). The enzyme stock concentration was approximately 0.1 µg/mL, prepared by dissolving 1 mg of solid porcine pancreatic lipase (PPL) powder in 1 mL of buffer solution (a). The fraction was prepared at a concentration of 500 µg/mL (b), and p-NPB was dissolved in 1% DMSO (c) and subsequently diluted with a 50 mM phosphate buffer (pH 7.2, 0.5%) to a final concentration of 2.5 mM in 100 µL (d). Solutions (a), (b), and (d) were mixed and incubated at 37°C for 10 minutes. Each sample was tested in triplicate. Orlistat was used as a positive control, and 1% DMSO was the negative control without inhibitors. One unit of activity is defined as the reaction rate that generates 1 µmol of p-nitrophenyl butyrate at 37°C. Lipase activity inhibition was expressed as the percentage reduction in activity when PPL was incubated with the test compound.<sup>18</sup>

### Identification of compounds in the active fraction of PC using GC-MS.

GC-MS analysis was conducted at the integrated laboratory of Universitas Islam Indonesia. The active fraction, prepared at a concentration of 500 µg/mL, was injected in a volume of 1.0 µL for analysis using Gas Chromatography coupled with a Flame Ionization Detector (FID) and Mass Spectrometry (MS) (Shimadzu QP 2010 SE, Shimadzu Corporation, Japan). The mobile phase consisted of chloroform: ethanol mixture (1:1), and the analysis was performed using an Rtx-5 MS column (5% diphenyl / 95% dimethyl polysiloxane) with specifications of 0.25 µm thickness, 30.0 m length, and 0.25 mm inner diameter. The instrument settings included an initial temperature of 80°C, an injection temperature of 300°C, and an ion source

temperature of 250°C. The oven temperature was gradually increased to 330°C at 6°C per minute. The column flow rate was set to 0.74 mL/min with a pressure of 42.3 kPa.<sup>19</sup>

### Molecular Docking

The receptors used in this study were obtained from the Protein Data Bank in 3D structure format or were drawn using ChemDraw software. These receptors, which are protein macromolecules, were isolated from any irrelevant molecules along with the ligands. The isolation process was performed using Discovery Studio 2021, and the files were saved in pdb format. Optimization involved adding hydrogen atoms, merging nonpolar hydrogens, and calculating Gasteiger charges using AutodockTools 1.5.6. The resulting file was saved in pdbqt format. For ligand preparation, 2D and 3D structures of the selected ligands were created to determine their molecular structure using ChemDraw Pro 12.0 software. The ligands were then prepared using AutoDockTools 1.5.6, where the compound structures were corrected, and Gasteiger charges were added. The prepared ligands were saved and ready for docking.<sup>9,13</sup>

### Evaluation of Drug Likelihood and ADMET

Assessing the drug-likeness of compounds is based on Lipinski's Rule of Five, which utilizes both experimental and computational approaches to evaluate solubility and permeability in drug discovery and development.<sup>20</sup> The Rule of Five suggests that poor absorption and permeability are likely when the molecular weight exceeds 500, the number of hydrogen bond acceptors is greater than 10, the number of hydrogen bond donors exceeds 5, and the calculated log P (ClogP) is higher than 5 (or MlogP > 4.15). ADMET predictions encompass absorption (CaCO<sub>2</sub> permeability), distribution (BBB permeability), metabolism (CYP2D6 substrate), excretion (total clearance), and toxicity (AMES toxicity).<sup>9</sup>

### Effervescent formulation

The effervescent formula consists of five different formulations. Each ingredient is weighed and sifted through mesh 30. After sifting, the ingredients are added, extracted, and homogenized. The homogeneous mixture is gradually combined with 95% ethanol until granules are formed. The granules are then sifted through mesh 20/30 and dried. The effervescent formula containing PC extract is presented in Table 1.

**Table 1:** Formulation of Effervescent Granules from PC Extract.

Ingredient	Formula				
	A	B	C	D	E
PC Extract	10%	10%	10%	10%	10%
Tartaric Acid	12.72%	12.30%	13.58%	14%	13.15%
Citric Acid	1.58%	2%	0.72%	0.30%	1.15%
Na. Bicarbonate	14.30%	14.30%	14.30%	14.30%	14.30%
Sucrose	60.40%	60.40%	60.40%	60.40%	60.40%
PVP	1%	1%	1%	1%	1%


### Statistical analysis

The data were expressed as the mean ± standard deviation (SD) of experiments in triplicate. This statistical analysis in this study was carried out with one-way anova using a GraphPad Prism (Version 9.5.1 (528), 2023. Graph Pad Inc. software San Diego, CA, USA). IC<sub>50</sub> value represented the concentration of the test sample causing 50% inhibition, in which the value <0.05 was considered significant.

## Results and Discussion

### Antioxidant Activity (DPPH)

The antioxidant activity was determined using the DPPH method, with the results expressed as the Inhibition Concentration 50 (IC<sub>50</sub>). According to,<sup>21</sup> a compound is classified as a powerful antioxidant if its IC<sub>50</sub> is less than 50 µg/mL, strong if IC<sub>50</sub> is less than 100 µg/mL, medium if IC<sub>50</sub> is less than 150 µg/mL, weak if IC<sub>50</sub> is less than 200 µg/mL, and very weak if IC<sub>50</sub> is greater than 200 µg/mL. The IC<sub>50</sub> values obtained in this study for the PC fractions are shown in Figure 2. Quercetin as a positive control had the highest antioxidant activity with



**Figure 2:** Antioxidant activity of PC fractions measured by DPPH assay, ns = not Significant ( $p>0,05$ ), \*\*\*( $p<0,001$ ), QS (Quercetin standard), NHF (n-Hexane fraction, EAF (Ethyl acetate fraction), EF (Ethanol fraction), IF (Insoluble fraction).

an IC<sub>50</sub> value of 23.77  $\mu\text{g/mL}$ , which is classified as very strong according to the criteria established by,<sup>21</sup> and the ethanol fraction with C50 of  $47.27 \pm 1.90 \mu\text{g/mL}$ , which is categorized as very strong exhibits stronger antioxidant activity than the other fraction. In contrast, the ethyl acetate fraction exhibited a much weaker antioxidant potential with an IC<sub>50</sub> of  $201.89 \pm 20.08 \mu\text{g/mL}$ , classified as very weak. The N-hexane fraction showed the highest IC<sub>50</sub> value at  $685.70 \pm 32.15 \mu\text{g/mL}$ , indicating very weak antioxidant activity. The insoluble fraction had an IC<sub>50</sub> value of  $86.09 \pm 7.94 \mu\text{g/mL}$ , falling under the strong category for antioxidant activity. with the order being Ethanol fraction > ethanol extract > insoluble fraction > ethyl acetate fraction > n-hexane fraction. The OH group on quercetin can function as a hydrogen donor. Quercetin can donate hydrogen atoms to neutralize free radicals, reducing the potential for cell oxidative damage.<sup>21</sup> Polar molecules such as flavonoids, phenolics, and glycosides are known for their antioxidant properties. The Ethanol fraction, having the lowest IC<sub>50</sub> value, shows a significant difference, as denoted by four stars, when compared to the ethyl acetate and n-hexane fractions. Polar fractions, such as the ethanol and insoluble fractions, contain a higher number of substances capable of donating hydrogen atoms, leading to the formation of a reduced (nonradical) form, which is indicated by the loss of the purple color, as described in reference.<sup>21</sup> This process reduces 2,2-diphenyl-1-picrylhydrazyl (DPPH) radicals into a stable nonradical hydrazine derivative, resulting in a color change. The DPPH antioxidant activity of the PC fractions is presented in Figure 2.

#### *In vitro* Pancreatic Antilipase Activity

The inhibition of pancreatic lipase involves the interaction between lipase enzymes and their substrates. This test uses PNPB (P-nitrophenyl butyrate) as the substrate and Porcine Pancreatic Lipase (PPL) as the enzyme. The inhibitory effect is assessed by measuring the hydrolysis of P-nitrophenyl butyrate to P-nitrophenol at a wavelength of 405 nm using an ELISA reader. Pancreatic lipase inhibition by PC was tested at a concentration of 200  $\mu\text{g/mL}$ , with PPL solution in phosphate buffer (pH 7.2) and PNPB solution. One unit of activity is defined as the reaction rate that produces 1  $\mu\text{mol}$  of p-nitrophenol in 10 minutes at 37°C. The inhibition of lipase activity is expressed as the percentage reduction in activity when PPL is incubated with the test compound. PPL was chosen as the enzyme model due to its similarities with human pancreatic lipase (HPL), exhibiting comparable kinetics and enzyme characteristics.<sup>22</sup> According to,<sup>18</sup> antilipase activity is robust when the inhibition percentage exceeds 50%. The results of the PC fraction at a concentration of 200  $\mu\text{g/mL}$  are shown in Table 2. Similar to our findings, a recent study demonstrated that flavonoid-rich plant extracts

exhibit strong antioxidant and antilipase activities, making them potential candidates for anti-obesity therapy.<sup>5</sup>


**Table 2:** Pancreatic antilipase activity of the PC fraction

Sample	% inhibition of $\pm\text{SD}$	Types of Antilipase <sup>2</sup>
Orlistat Standard	61.64 $\pm$ 9.11	Strong
N-hexane fraction	18.66 $\pm$ 5.21	Weak
Ethyl Acetate Fraction	67.65 $\pm$ 8.04	Strong
Ethanol Fraction	14.22 $\pm$ 4.69	Weak
Insoluble fraction	6.45 $\pm$ 1.13	Weak

Obesity triggers inflammatory processes in excess lipogenesis, inhibits lipolysis, and increases adipocyte apoptosis. This matter increases the release of Reactive Oxygen Species (ROS) and will cause oxidative stress. Oxidative stress caused by obesity can result in damage to cells and tissues and trigger the emergence of degenerative diseases.<sup>23</sup> Antioxidants help neutralize radicals and reduce the risk of complications from degenerative diseases. Therefore, supplementation with antioxidants will reduce the risk of obesity-related complications and oxidative stress.<sup>24</sup> The ethanol fraction proved the most potent antioxidant agent, while ethyl acetate showed pancreatic antilipase activity. Differences in the compounds that guide these two activities. These results follow research on other materials that show that the ethyl acetate fraction has higher anti-obesity activity than the ethanol fraction. The ethanol fraction has stronger antioxidant activity than the ethyl acetate fraction. Regarding compound content, the ethanol fraction has higher total phenolic content and total flavonoid content than the ethyl acetate fraction.<sup>25</sup> It is necessary to prove the levels of PC leaf extracts and fractions regarding the levels of compounds, not only phenolics and flavonoids but also other groups of compounds. So, to support both activities, an effervescent preparation will be made from PC leaves extract. Effervescent granules are preferred because they are easy to use, dissolve easily in water, and taste better. Compared to tablet preparations, effervescent granules reduce stomach irritation, which sometimes occurs when tablet preparations are swallowed directly, and reduce the risk of blockage in the esophagus because they are completely dissolved in liquid before consumption.

#### *In silico* Pancreatic Antilipase Activity

Molecular docking validation is performed by redocking. The redocking results of the native ligands are shown in Figure 3. The blue structure represents the initial conformation of the enzyme-ligand complex before molecular docking. In contrast, the red structure shows the optimized docking pose of the native ligand after computational refinement. The close alignment between the pre-and post-docking structures, indicated by a root mean square deviation (RMSD) value below 2 Å, confirms the reliability and accuracy of the docking method used in this study.



**Figure 3:** 3D structure of the pancreatic lipase enzyme (PDB ID 1LPB) showing an overlay of the blue (before) and red (after) molecular docking of the native ligand.

The GC-MS identification revealed that the primary compound in the active fraction was Trilaurin, accounting for 54.83% of the area and a similarity index of 59%. The three compounds identified by GC-MS were then prepared for further in silico molecular docking tests. Molecular docking of the quercetin standard, Orlistat, and the three GC-MS compounds was performed to compare the compounds obtained from pancreatic antilipase testing with the standards known to exhibit pancreatic antilipase activity, as reported in previous studies. The results of the molecular docking are presented in Table 3.

The most promising compound is Dimethyl Tetracycline, which exhibits the lowest binding energy and inhibition coefficient values

compared to the Orlistat standard. The Dimethyl Tetracycline has antilipase activity similar to Orlistat. In addition to the binding energy and inhibition coefficient, pancreatic antilipase activity is evaluated based on its interaction with the amino acid serine 152. After analyzing the GC-MS-identified compounds through in silico tests, any compounds that bind to amino acid residues can potentially serve as alternative ligands to replace Orlistat. The next step is to assess whether these compounds can be used as oral drugs by evaluating them according to Lipinski's Rule of Five, as shown in Table 4.

**Table 3:** Molecular docking scores and interactions of the identified compounds.

No	Structure Name	Binding Energy	Amino Acid Bonds
1	Orlistat	-6.62	Gly 76, Phe 77, Ile 78, Asp 79, Tyr 114, His 151, <b>Ser 152</b> , Leu 153, Ala 178, Glu 179, Pro 180, Ile 209, Phe 215, Arg 256, Ala 259, His 263, Leu 264
2	Quercetin	-8.28 (Run of 83)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Ala B:178, Glu B:179, Pro B:180, Ile B:209, Phe B:215, Gly B:216, Arg B:256, His B:263.
3	Dimethyl Tetracycline	-7.78 (Run of 14)	Gly B:76, Phe B:77, Ile B:78, Asp B:79, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Phe B:215, Arg B:256, Asp B:257, Ala B:259, Ala B:260, His B:263, Leu B:264.
4	2-methoxy-5H-indole[2,3-b]quinoxaline	-7.25 (Run of 77)	His B:75, Gly B:76, Phe B:77, Ile B:78, Asp B:79, Trp B:85, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Phe B:215, His B:263, Leu B:264.
5	Trilaurin	-3.52 (Run of 7)	Ile B:78, Tyr B:114, His B:151, <b>Ser B:152</b> , Leu B:153, Ala B:178, Pro B:180, Ile B:209, Leu B:213, Phe B:215, Trp B:252, Thr B:255, Arg B:256, Ala B:259, Ala B:260, His B:263, Leu B:264.

**Table 4:** Predicted Lipinski's Rule of Five for the Ligands.

No	Molecular Name	Molecular Weight	Log P	Hydrogen Bond Donor (HBD)	Hydrogen Bond Acceptor (HBA)	Polar Activity (PSA)	Voltage
1	Quercetin	302.24	1.99	5	7	122.11	
2	Dimethyl Tetracycline	430.41	-0.55	6	9	176.06	
3	2-methoxy-5H-indolo[2,3-b]quinoxaline	249.27	3.27	1	3	108.60	
4	Trilaurin	639.02	11.75	0	6	278.43	

Table 4 indicates that the natural ligand candidates suitable for use are Quercetin, Dimethyl Tetracycline, and 2-methoxy-5H-indolo[2,3-b]quinoxaline. These compounds meet Lipinski's Rule of Five, with molecular weights under 500 Da, hydrogen bond donors not exceeding 5, hydrogen bond acceptors not exceeding 10, partition coefficients (log P) under 5, and polar surface areas (PSA) under 1025 Å<sup>2</sup>, making them suitable for oral administration. In addition to adhering to Lipinski's Rule, candidate compounds must also pass pharmacokinetic and toxicity assessments conducted using pkCSM software. The results of drug-likeness analysis, along with absorption, distribution, metabolism, excretion, and toxicity (ADMET) predictions, are presented in Table 5. A compound is considered to have blood-brain barrier (BBB) permeability if its log BB value in the distribution phase is greater than

0.3. Molecules with a log BB value below 0.1 are not effectively distributed in the brain. CYP2D6 metabolic parameters predict whether cytochrome P450 will likely metabolize a given molecule. The total clearance (CL<sub>tot</sub>) parameter indicates excretion rates in log (ml/min/kg). Drug clearance primarily occurs through renal and hepatic clearance (kidney excretion) (liver metabolism and bile excretion). Ames toxicity testing is a commonly used method to evaluate the mutagenic potential of compounds through bacterial assays. Among the candidates, Dimethyl Tetracycline meets both Lipinski's rule of five and ADMET prediction criteria.

The Evaluation of granule preparations includes tests for flow rate, angle of repose, bulk density, tapped density, Carr's compressibility index, and Hausner ratios.<sup>26</sup>

**Table 5:** ADMET Prediction for Compounds from the Ethyl Acetate Fraction of PC

No	Molecular Name	Absorption (CaCO <sub>2</sub> Permeability) (log Papp in 10-6 cm/sec)	Distribution (VDss (human)) (log L/kg)	Metabolism (CYP2D6) (YES/NO)	Excretion (Total clearance) (log ml/min/kg)	AMES Toxicity (YES/NO)	Hepatoto xicity	Skin Sensitization
1	Orlistat	0.40	-1.02	No	1.68	No	Yes	No
2	Quercetin	-0.28	0.06	No	0.46	No	No	No
3	Dimethyl tetracycline	-0.01	0.61	No	0.35	No	No	No
4	2-methoxy- 5H- indolo[2,3- b]quinoxaline	1.30	-0.01	No	0.77	Yes	Yes	No
5	Trilaurin	0.14	-0.82	No	2.23	No	No	No

In this study, optimization using design experts focuses on flow rate, angle of repose, and Carr's index. Good flow characteristics are defined by the ability of particles to flow independently without clumping, influenced by gravitational force.<sup>27</sup> The flow rate test indicates that all the effervescent granules produced exhibit excellent flow, with a suitable flow time greater than 10 grams per second. The flow rate results of the effervescent granules for each formula are presented in Table 6. Based on the observations for Formula 3 and Formula 4 in Table 6, these formulas exhibit a faster flow time due to a higher tartaric


acid content than Formula 1 and Formula 2. Tartaric acid has a higher density than citric acid, which allows granules with a greater tartaric acid content to flow more rapidly because of the increased gravitational force.<sup>27</sup> The angle of repose is the stable angle formed between a pile of cone-shaped particles and a horizontal plane. If the angle is less than 30°, the material is considered to flow easily. Conversely, if the angle is 40° or greater, the material will likely be difficult to flow. The shape of the granules can influence the value of the angle of repose.<sup>28</sup>

**Table 6:** Flow rate, angle of repose, and bulk density of the effervescent granules from PC.

Formula	Flow rate	Angle of repose	Bulk density (g/ml)	Tapped density (g/ml)	Hausner ratios	Carr's compressibility index (%)
A	18.66	25.05	0.52	0.56	1.07	6.25
B	20.43	25.85	0.53	0.55	1.04	4.26
C	20.79	27.16	0.53	0.56	1.07	6.38
D	20.63	24.09	0.50	0.56	1.14	11.98
E	18.74	26.03	0.49	0.53	1.06	5.99


Table 6 presents the results of the stationary angle test for formulas 1-5, all of which are below 30°. A stationary angle of no more than 30° indicates excellent flow properties, meaning all the formulas demonstrate good flow behavior. The granules flow more quickly and easily with less friction and tensile force between them. Furthermore, smaller granule sizes increase cohesiveness, reducing the flow velocity and resulting in a higher stationary angle.<sup>29</sup> Determining bulk density includes measuring the actual weight, compressive weight, Hausner factor, and percent compressibility. The Hausner factor is used to compare the actual and compressive weights, helping to assess the flow or free-flowing properties of the powder. All seven formulas meet the qualification of having a Hausner factor of less than 1.25, indicating good flow characteristics. Granule compressibility refers to the ability of the granules to maintain compactness under pressure. Factors such as porosity, type density, particle shape, and moisture content can affect the flow properties of the granules. Good flow properties ensure easier molding of the granules and help maintain uniform weight. The results for the Hausner factor and compressibility are shown in Table 6. The percent compressibility results indicated that Carr's index ranged from 4.26% to 14.59%, which aligns with the literature stating that granules with a Carr's index value below 15% demonstrate good flowability. The optimal formula using Design Expert is intended to generate the most efficient formula based on the response data from the prepared parameters. The response data, analyzed through ANOVA in Design

Expert, is processed to identify the optimal formula.<sup>10</sup> The ideal formula is the one with a desirability value closest to 1. Using the simplex lattice design method in the Design Expert software, the optimal formula was determined to have 65.81 mg of tartaric acid and 4.19 mg of citric acid, with a desirability value of 0.86. Before finalizing, the optimal formula requires verification. The results of design expert optimization formula 1 solution and formula 2 solution are shown in Figure 4, with the formula test results from the design expert optimization provided in Table 7. This study utilized a Design Expert to optimize the effervescent granule formulation containing PC extract Figure 4. This software allows integrated analysis to evaluate interactions between formulation variables and determine the optimal combination of ingredients used. The optimization of the effervescent granule formulation resulted in two optimal formulas. Formula 1: 13.16% tartaric acid and 0.84% citric acid. Formula 2: 13.21% tartaric acid and 0.80% citric acid. The desirability score for both formulas was 0.862, indicating a high optimization level. The flow rate and angle of repose parameters from the optimized formulas showed no significant differences compared to laboratory experimental results ( $p > 0.05$ ), suggesting the predictive model's accuracy in Figure 5. Based on the GraphPad Version 9.5.1 (528), 2023 statistical analysis Figure 5, the flow rate and angle of repose values from Formula 1 and Formula 2 in both the Design Expert optimization and the actual test results showed no significant difference, indicating that the optimization and laboratory test produced similar outcomes.



**Figure 4:** Design Expert optimization (A) Formula 1 Solution (B) Formula 2 Solution

### Design expert vs test formula effervescent



**Figure 5:** Formula optimization using Design expert vs test, ns = not Significant ( $p > 0.05$ ), \* ( $p < 0.05$ ), F1 DE (Formula 1 Design Expert), F2 DE (Formula 2 Design Expert), F1 Test (Formula 1 test), F2 Test (Formula 2 test).

**Table 7:** Results of the formula test from Design Expert Optimization.

Formula	Flow rate	Angle of repose	Bulk density (g/ml)	Tapped density (g/ml)	Hausner ratios	Carr's compressibility index (%)
1	20.50	27.61	0.52	0.60	1.17	14.59
2	17.96	24.10	0.54	0.59	1.10	8.68

However, Carr's index test revealed a discrepancy between the Design Expert optimization and the test results, as effervescent granules are highly sensitive to room temperature, which may have influenced the test outcomes. Additional research is needed to isolate compounds from PC based on the results of the *in silico* data. An integrated study of network pharmacology and component analysis should be conducted to explore the molecular mechanisms of PC extract in treating obesity.<sup>30</sup> *In silico* anti-obesity activity should be explored using additional receptor targets, as the anti-obesity mechanism extends beyond pancreatic lipase. Central nervous system mechanisms can be investigated, targeting receptors such as GLP-1 (liraglutide), 5-HT<sub>2c</sub> (lorcaserin), and TAAR-1 (phentermine). *In vivo*, testing is also recommended to validate the efficacy and safety of these compounds in animal models and clinical settings. Furthermore, advanced

formulations, such as nanocarrier systems, could be developed to enhance PC-based products' bioavailability and therapeutic potential. Future studies should focus on the antioxidant properties of the sample using comprehensive methods.<sup>31</sup> These include determination of hydrogen peroxide scavenging capacity, determination of ferric reducing power, determination of nitric oxide (NO) scavenging activity, determination of ascorbic acid, determination of vitamin e, and assessment of lipid peroxidation inhibition. These assays will provide a deeper understanding of the antioxidant potential and the mechanisms by which the sample mitigates oxidative stress.

## Conclusion

The antioxidant activity of the PC fraction, evaluated using the DPPH method, revealed that the ethanol fraction exhibited significantly stronger antioxidant activity ( $IC_{50} = 47.27 \pm 1.90 \mu\text{g/mL}$ ) compared to the ethyl acetate fraction ( $IC_{50} = 201.89 \pm 20.08 \mu\text{g/mL}$ ,  $p < 0.05$ ). This difference highlights the greater presence of polar compounds, such as flavonoids and phenolics, in the ethanol fraction. Among the identified compounds, dimethyl tetracycline showed the lowest binding energy ( $-7.78 \text{ kcal/mol}$ ) in molecular docking studies, suggesting its potential as a strong pancreatic lipase inhibitor. This was further supported by its adherence to Lipinski's Rule of Five, indicating good oral bioavailability. Formula optimization using the Design Expert software resulted in two formulas. The flow rate and angle of repose values from the design expert and the laboratory tests did not show significant differences, indicating that the optimization and experimental results aligned. However, differences were observed in the Carr's Index test between the design expert optimization and the lab results.

## Conflict of Interest

The authors declare no conflict of interest.

## Authors' Declaration

The authors affirm that the work presented in this article is original, and they accept full responsibility for any claims related to the article's content.

## Acknowledgments

Acknowledgment Hibah Penelitian Dan Pengabdian Kepada Masyarakat Akademik Pendidikan Tinggi Vokasi supports this work. Contract Number: 103/SPK/D.D4/PPK.01.APTV/III/2024. Derivative Contract Number 018 /LL6/PPM-V/AL.04/2024.

## References

- Ministry of Health RI. Riskesdas 2018. Ministry of Health RI. 2018;53(9):1689–1699.
- Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomed and Pharm.* 2020;128(110314): 1-9.
- Ladeska V, Elya B, Hanafi M, Kusmardi, Rohmat SS. Pharmacognostic Evaluation and Antioxidant Activities of *Tetraceara indica* (Christm. and Panz.) Merr. *Hayati.* 2024;31(5):836–853.
- Romiti GF, Corica B, Raparelli V, Basili S, Cangemi R. The interplay between antioxidants and the immune system: A promising field, still looking for answers. *Nutrients.* 2020;12(6):10–13.
- Li S, Pan J, Hu X, Zhang Y, Gong D, Zhang G. Kaempferol inhibits the activity of pancreatic lipase and its synergistic effect with Orlistat. *J Funct Foods.* 2020;72(104041) : 1-11.
- Douglas IJ, Langham J, Bhaskaran K, Brauer R, Smeeth L. Orlistat and the risk of acute liver injury: Self controlled case series study in UK Clinical Practice Research Datalink. *British Med J.* 2013;346(7906):1–9.
- Rahardhian MRR, Susilawati Y, Sumiwi A, Muktiwardoyo M, Muchtaridi M, Sumiwi SA. A Review Of Sungkai (*Peronema Canescens*): Traditional Usage, Phytoconstituent, And Pharmacological Activities. *Int J. App Pharm.* 2022;14(Special issue 5):15–23.
- Chike-Ekwughe A, John-Africa LB, Adebayo AH, Ogunlana OO. Evaluation of the In vitro and In silico Pancreatic Lipase Inhibitory Activity of Ethanol Leaf Extract of *Tapinanthus cordifolius* and its Effect on Oral Glucose Tolerance in Mice. *Trop J Nat Prod Res.* 2024;8(8):8168–8175.
- Rahardhian MRR, Susilawati Y, Musfiroh I, Febriyanti RM, Muchtaridi, Sumiwi SA. In Silico Study of Bioactive Compounds From Sungkai (*Peronema Canescens*) As Immunomodulator. *Int J. App Pharm.* 2022;14(Special Issue 4):135–141.
- Indriastuti M, Astuti AF, Anna L Yusuf, Akbar F, Kurnia R R. Optimization of Formula Preparation of Effervescent Granules of Moringa Leaf Extract (*Moringa oleifera* L.). *Med Sains : JIK.* 2023;8(2):519–528.
- Yang HY, Tae J, Seo YW, Kim YJ, Im HY, Choi GD. Novel pyrimidoazepine analogs as serotonin 5-HT<sub>2A</sub> and 5-HT<sub>2C</sub> receptor ligands for the treatment of obesity. *Eur J Med Chem.* 2013;63:558–569.
- Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers SP. TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding. *Mol Metab.* 2024;80(101883): 1-14.
- Suharsanti R, Wahyuono S, Yuniarti N, Astuti P. Molecular Docking of Lipase Inhibitory Activities , Pharmacokinetics and Toxicity Prediction of Chemical Constituents from *Curcuma aeruginosa* Roxb Rhizome. *Int J. Pharm Res and App.* 2024;9(2):162–174.
- Rahardhian MRR, Suharsanti R, Sugihartini N, Lukitaningsih E. In vitro assessment of total phenolic, total flavonoid and sunscreen activities of crude ethanolic extract of belimbing wuluh (*Averrhoa bilimbi*) fruits and leaves. *J. Glob Pharm Tech.* 2019;11(4):308–313.
- Syofyan, S, Almahdy, A, Wulandari, A, Alen, Y, Diliarosta, S, Kurniawan, H, Noverial, N, Putra, P.P, Dillasamola, D. Effects of Ethanol Extract of Sungkai (*Peronema canescens* Jack.) on Fertility of Female Wistar Mice (*Mus musculus* L.). *Trop J Nat Prod Res.* 2023;7(5):2863–2866.
- Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Effect of Different Solvent on Total Phenolic, Total Flavonoid, and Sun Protection Factor of Belimbing Wuluh (*Averrhoa bilimbi* linn.) Fruits Fraction. *J. Glob Pharm Tech.* 2019;11(1):154–162.
- Suharsanti R, Sugihartini N, Lukitaningsih E, Rahardhian MRR. Potency Of Belimbing Wuluh (*Averrhoa Bilimbi*) As Antioxidat And Tyrosinase Inhibitor For Skin Whitening Product. *J. Pharm Res.* 2019;8(4):151–154.
- Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. *Biomed and Pharm.* 2020;128(110314): 1-9.
- Falodun A, Siraj R, Choudhary MI. GC-MS Insecticidal Leaf essential oil of *P. staudtii* Hutch and Dalz (Icacinaeae). *Trop J. Pharm Res.* 2009; 82:139-143.
- Puspitasari YE, Alfikri MA, Sitanggang R, Tambunan JE, Hardoko H. In Silico Analysis of Phenolic Compounds from *Ceriops decandra* Griff. Leaves and Molecular Interaction as Anti Diabetes. *Sci and Tech Ind.* 2023;8(4):542–553.
- Molyneux P. The Use of the Stable Free Radical Diphenylpicrylhydrazyl (DPPH) for Estimating Antioxidant Activity. *Songkla J. Sci and Tech.* 2004, 26(2) : 211-219.
- Alias N, Leow TC, Ali MSM, Tajudin AA, Salleh AB, Zaliha RN, Rahman RA. Anti-obesity Potential of Selected Tropical Plants via Pancreatic Lipase Inhibition. *Adv Obes Weight Manag Control.* 2017;6(4): 122-131.
- Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. *Free Radicals in Bio and Med.* 2015
- Fernández A, Madrigal-Santillán E, Bautista M, Esquivel-Soto J, Morales-González Á, Esquivel-Chirino C. Inflammation, oxidative stress, and obesity. *Int J Mol Sci.* 2011;12(5):3117–3132.
- Suharsanti, Wahyuono S, Yuniarti N, Astuti P. Antioxidant Activity and Pancreatic Lipase Inhibition of *Curcuma aeruginosa* Roxb Rhizome Fractions. *J. Bio.* 2024;9(11):228–243.
- Shah RB, Tawakkul MA, Khan MA. Comparative Evaluation of flow for pharmaceutical powders and granules. *AAPS Pharm Sci Tech.* 2008;9(1):250–258.
- Rani KC, Parfati N, Muarofah D, Sacharia SN. Meniran (*Phyllanthus niruri* L.) Herbal Effervescent Granule Formulation with Variations of Suspending Agent Xanthan Gum, CMC-Na, and Combination CMC-Na-Microcrystalline Cellulose RC- 591. *J. Sci Pharm. and Clin.* 2020;7(1):39-51. Aulton M. *Pharmaceutics:*

- the Science of Dosage Form Design. 2nd ed. Edinburgh: Churchill Livingstone; 2002.
29. Lee, R. E. Effervescent Tablets : Key Facts About A Unique, Effective Dossage Form. CSC Publishing; 2004.
  30. Mutiah R, Briliana MSD, Ahmad ARA, Fauziyah B, Janaloka NA, Suryadinata A. Network Pharmacology and Component Analysis Integrated Study to Uncovers the Molecular Mechanisms of *Lansium parasiticum* Bark Extract in Colon Cancer Treatment. Sci and Tech Ind. 2024;9(2):314–324.
  31. Okolie NP, Falodun A, Oluseyi D. Evaluation of the Antioxidant Activity of Root Extract of Pepper Fruit (*Denmetia Tripetala*), and It's Potential for the Inhibition of Lipid Peroxidation. Afr J. of Trad Compl and Altern Med. 2014;11(3):221–227.